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Abstract  
Cancer is one of the most common diseases worldwide and one of the leading 
causes of death globally each year. Current mortality rates are high despite the 
many treatment options, leading many researchers to investigate new more 
effective cancer treatments. Currently the majority of patients receive 
chemotherapy as a part of their treatment and the most common drugs are 
platinum based cisplatin, oxaliplatin and carboplatin. These drugs covalently bind to 
DNA subsequently causing apoptosis. Although effective at killing cancerous cells 
these drugs are non-specific and also destroy non target cells. Their non-specificity 
results in a variety of negative side effects, many of them so severe that patients 
terminate treatment early or move to a lower than optimal dosage. Resistance is 
another area of concern for these drugs, with both intrinsic and acquired resistance 
resulting in poor prognosis for patients. 
New complexes proposed for anticancer treatments hope to mitigate these 
issues by utilising different mechanisms of action. Polyaromatic platinum complexes 
are an example of a class of promising new complexes that have a different 
mechanism of action than the traditional platinum drugs. These complexes have the 
general formula [Pt(PL)(AL)]
2+ incorporating polyromantic ligands (PL) with a 
coordinated ancillary ligand (AL), they have achieved GI50 results up to 1000 times 
better than cisplatin. These polyaromatic complexes can be oxidised to platinum(IV) 
which  may allow oral administration, improved extracellular stability and fine 
tuning of the pharmacokinetics through modification of the axial ligands. 
In this work the method for the synthesis of a series of novel platinum(IV) 
polyaromatic complexes was developed and these complexes were characterised 
using ESIMS, UV spectroscopy, CD spectroscopy, SRCD spectroscopy, microanalysis, 
NMR and HPLC. These complexes were synthesised via the coordination of halides 
Cl, Br and I in the axial positions producing the di-halogenated platinum(IV) 
complexes desired. The effectiveness of substitution in the axial position by various 
ligands was assessed, as well as the cytotoxicity of the resulting compounds in cell 
lines. It was revealed that these compounds allow the development of new 
synthetic methods which were previously closed to these complexes, allowing the 
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synthesis of targeted complexes that have the potential to improve prognosis. The 
developed method is much less time consuming than the current oxidation 
methods, reducing time spent on synthesising intermediates which will maximise 
outcomes for further synthesis. The GI50’s revealed that these complexes are of 
comparable cytotoxicity to the platinum(II) complexes and are more cytotoxic than 
dihydroxido platinum(IV) complexes of the same type. 
Further development of these complexes was achieved through the linkage of 
targeting and cytotoxic ligands. These ligands were provided by collaborators and 
will undergo biological testing in their respective laboratories. DCF, a cytotoxic 
ligand, was bound in both axial positions through an ethylene diamine linker. The 
synthesis was confirmed by NMR, providing proof of concept for the attachment of 
such ligands, further diversifying the skillset of the research group. The PSMA 
targeting ligand DCL was bound using a succinate linker to one of the axial ligands. 
This synthesis provided proof of concept for the synthesis of asymmetric 
compounds with large targeting ligands; whose pharmacokinetics can be further 
adjusted through derivatisation of the remaining axial ligand. The synthesis of more 
novel asymmetric complexes was developed, platinum compounds with both a 
hydroxido and acetardo ligand. The asymmetric design of these compounds will 
allow further asymmetric derivatisation of the Pt(IV) which may be advantageous in 
the design and synthesis of multi action drugs. 
The use of flow chemistry to streamline the synthesis of these compounds 
was also trailed. Although the resulting protocol was successful, being the first 
reported use of flow chemistry for the synthesis of an inorganic complex; yields 
were not improved to the ~90% typically achieved in batch chemistry. As such this 
method of synthesis was not pursued in the synthesis of platinum(II) starting 
materials in our research group; instead working as a proof of concept in the use of 
flow chemistry in the synthesis of such complexes. 
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DCFen 2-Aminoethyldiclofenacamide 
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Chapter 1 Introduction 
1.1 Cancer  
Cancer is one of the leading causes of death worldwide with 
approximately 8 million deaths occurring each year.1 In Australia approximately 
470 per 100,000 people are predicted to be diagnosed with cancer in 2017 with 
a mortality rate of 161 per 100,000 people.2 This takes a large toll on the quality 
of Australian lives and hospitals, with just under 40% of deaths being attributed 
to cancer.2-4 Cancer is characterised by the rapid uncontrolled proliferation of 
abnormal cells which can metastasise to different sites in the body. These 
growths result in obstruction of normal tissue function, eventually causing 
death.5  These abnormal cells are the result of mutation of deoxyribonucleic 
acid (DNA), occurring due to mutagens or during normal cell division. There are 
many different types of cancers; some are more easily prevented or cured 
when diagnosed early such as skin cancer, while others have high mortality 
rates.4 For example, brain cancer patients only have a 22% chance of surviving 
the first five years after diagnosis.6, 7  
1.2 Cancer treatments 
Although changes in lifestyle and diet can reduce the occurrence of some 
cancers, over 70% cannot be prevented and thus treatment is needed.1 There 
are currently several treatment options for most types of cancer; however, 
many of them have severe side effects and low success rates. For example brain 
cancer is treated with a combination of surgery, radiotherapy, chemotherapy or 
steroid therapy, and yet the low survival rates persist.7 Chemotherapy is the 
most common form of cancer therapy with just over 60% of patients receiving 
it as their primary form of treatment.4, 8 Of these patients, many  are treated 
with platinum based drugs such as cisplatin or oxaliplatin in combination with 
other organic anticancer agents or physical techniques such as radiotherapy or 
sugery.4, 9 Most “traditional” platinum anticancer drugs have the basic formula 
cis-[PtX2(NHR2)2], in which R = organic ligand and X = leaving group. The main 
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challenge of these treatments is low specificity for cancer cells, which results in 
lower than optimal dosage to mitigate negative side effects. The risk of 
resistance to the treatment developing is heightened when a suboptimal 
dosage is used.4 There are many researchers focusing on developing improved 
strategies for cancer to solve these problems.  
1.2.1 Cisplatin 
Cis-diamminedichloroplatinum(II) (cisplatin) was first identified by Barnett 
Rosenberg in 1965 as the compound that prevented cell division of Escherichia 
coli.10 He hypothesized that cisplatin and other platinum complexes would also 
be able to prevent the division of cancerous cells thus resulting in the death of 
the tumours. In 1978 it gained FDA approval and it is now one of the most 
widely used anticancer drugs.4, 11 Cisplatin is composed of a square planar 
platinum(II) coordinated to two chloride ligands and two ammine ligands 
(Figure 1.2.1). Its mechanism of action requires that the chloride ligands leave, 
allowing the platinum to bind covalently to DNA;12 however, it has many other 
intracellular targets such as RNA, thiols, cytoskeletal microfilaments and 
phospholipids.13, 14 When cisplatin binds, it alters the shape of the DNA by 
unwinding, bending or forming crosslinks within the strand; these changes 
prevent transcription and trigger apoptosis.11 Cisplatin can be absorbed by cells 
though both active and passive pathways.15 This interaction occurs in both 
cancerous and normal cells, although uptake of cisplatin is greater in rapidly 
dividing cells.4 This includes cancerous cells as well as epithelial and hair cells, 
resulting in deterioration of the skin and hair loss.16  
 
 
 
Figure 1.2.1: The chemical structure of the platinum(II) compound Cisplatin. 
Cisplatin is highly effective against some forms of cancer; for example, the 
cure rate for testicular cancer is 95%. Cisplatin is also very effective against 
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lung, ovarian head and neck cancer.4 Despite this success, there are many 
disadvantages to the use of cisplatin as an anticancer drug. Cisplatin is 
susceptible to acquired resistance by cancer cells, in most cases only one 
treatment schedule can be completed before resistance occurs; thus, if a follow 
up treatment is required a different drug must be used.17 There are several 
mechanism by which resistance can occur, including upregulation of cisplatin 
binding proteins and peptides which deactivate cisplatin, reduced retention 
time within the cell, and upregulation of the natural repair mechanisms for 
DNA.18, 19 There are also several cancers that are inherently resistant to cisplatin 
treatments.17, 18, 20 The high toxicity of cisplatin is dose limiting, reducing the 
likelihood of curing the disease. Cisplatin is administered intravenously, which 
is complicated by its low solubility in aqueous solution and inflammation at the 
injection site.21 There are many side effects, including nausea and low white 
blood cell counts, which leaves the patient susceptible to disease.4, 22 Cisplatin 
is also toxic to the kidneys and can cause hearing loss.23 Researchers aspire to 
create more potent platinum complexes with increased cytotoxicity that target 
cancer cells more effectively and will result in a better prognosis.  
1.2.2  Carboplatin and oxaliplatin 
Diammine[1,1-cyclobutanedicarboxylato(2-)]-O,O′-platinum(II) 
(carboplatin) (Figure 1.2.2) gained FDA approval following a collaboration 
between Johnson Matthey and the Institute of Cancer Research in London, 
when it was tested to see if a more stable leaving group would reduce the 
toxicity of the drug without reducing its anticancer activity.4 They were 
successful, with nephrotoxicity and neurotoxicity of carboplatin greatly reduced 
compared with cisplatin; this allowed it to be administered at two hundred 
times the dose of cisplatin (2000 mg/dose).24 However, carboplatin has similar 
side effects to cisplatin, with greater than 30% of patients experiencing hair 
loss, taste changes, nausea and vomiting, weakness and blood test 
abnormalities (low magnesium).25 Despite a higher administrative  dose of 
carboplatin, the rate of DNA adduct formation is approximately ten times 
slower, resulting in treatment success rates that are essentially the same as 
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that of cisplatin.26, 27 Like cisplatin, carboplatin is susceptible to acquired 
resistance by cancer cells and is also cross-resistant, because it  works via the 
same mechanism of action as cisplatin and induces what can be considered the 
same type of DNA crosslinks.4, 20, 25, 26 
 
 
 
Figure 1.2.2: The chemical structures of the platinum(II) (Pt(II)) compounds 
carboplatin and oxaliplatin. 
[(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II) 
(Oxaliplatin) (Figure 1.2.2) was discovered in 1979 and approved internationally 
in 2009.4 It was used predominantly as a treatment for colorectal cancer.4 
Oxaliplatin has similar anticancer activity to cisplatin, although it works via a 
slightly different mechanism; this limits the chance of cross resistance to 
cisplatin and carboplatin.20, 24 Oxaliplatin has many of the same side effects as 
cisplatin, and can also cause temporary nerve damage and loss of breath, but it 
is still widely used due to its lack of cross resistance and effectiveness against 
bowel and colorectal cancer, for which cisplatin has limited effectiveness.28 
1.3 Unconventional Pt drugs 
By developing treatments with a different mechanism of action to 
cisplatin and its analogues we are potentially able to overcome both intrinsic 
and acquired resistance.29 In fact, it has been suggested that the only way to 
improve the oncology of cancer treatments is to develop compounds whose 
structure and mechanism of action are significantly different to that of 
cisplatin.29-31 These compounds are often referred to as non-classical or 
unconventional metal complexes and do not follow the same design “rules” as 
classical anticancer compounds. For example, it had been proposed that 
potential anticancer compounds should have no charge, and yet many non-
classical metal complexes with proven anticancer activity are charged.18, 32, 33 
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1.3.1 Polyaromatic platinum(II) complexes 
One form of unconventional platinum complexes with a different 
mechanism of action to cisplatin are polyaromatic platinum complexes (PPCs) 
which have the general formula [Pt(PL)(AL)]
2+. The design of these complexes 
incorporates polyromantic ligands (PL) with a coordinated ancillary ligand (AL) 
(Figure 1.3.1). Unlike cisplatin, this type of complex is substitutionally inert, 
thus it cannot covalently bind to DNA. Although no longer thought to be the 
mechanism of action they do bind to DNA through non-covalent intercalation 
where the PL inserts between the base pairs of DNA.34 This interaction does not 
form adducts with DNA although the interactions can both stretch or bend the 
helix (Figure 1.3.1). Intercalation is stabilised by hydrogen bonding and 
electrostatic interactions between the negative charge on the DNA phosphate 
backbone and the net positive charge of the PPC.35 Although it was 
hypothesised that intercalation was responsible for the cytotoxicity of PPCs, it 
was subsequently demonstrated that enantiomeric pairs have bound to DNA 
with similar affinity despite large differences in cytotoxicity.35 The mechanism 
of cytotoxicity is now proposed to be a result of interactions with other cellular 
mechanisms.34, 36 Complexes of this type have been reported to be significantly 
more potent than cisplatin in all cancer cell lines tested,34 indicating the 
potential of these unconventional platinum complexes as a viable cancer 
treatment option.32 In particular, the complex [(5,6-dimethyl-1,10-
phenanthroline)(1S,2S-diaminocyclohexane)platinum(II)] dichloride (56MESS, 
Figure 1.3.2) is over 100 times more cytotoxic than cisplatin to several cancer 
cells (Table 1.3.1.1). Improved cytotoxicity reduces the dosage required, 
treatment time and the reduces the chance of acquired resistance.37 Despite 
encouraging in vitro activity, in vivo studies demonstrated low specificity and 
high toxicity in non-target organs similarly to cisplatin.38 Subsequent studies are 
developing new methods to increase specificity and reduce toxicity. 
19 
 
 
Table 1.3.1.1: Cytotoxicity of complexes of the type [Pt(PL)(AL)]2+ 
and [Pt(PL)(AL)(OH)2]2+ compared to cisplatin, oxaliplatin and carboplatin. 
 
Complex 
MCF-7 
Breast 
n=3-4 
A2780 
Ovarian 
n=3-4 
H460 
Lung 
n=3-4 
A431 
Skin 
n=3-4 
Du145 
Prostate 
n=3-4 
MIA 
Pancreas 
n=3-4 
ADDP 
 Ovarian 
n=3-4 
PHENSSDACH 0.53 ± 0.15 0.27 ± 0.029 0.48 ± 0.15 0.87 ± 0.28 0.081 ± 0.050 0.80 ± 0.65 0.24 ± 0.038 
56MESSDACH 0.050 ± 0.020 0.030 ± 0.004 0.037 ± 0.009 0.051 ± 0.021 0.007 ± 0.002 0.015 ± 0.002 0.032 ± 0.007 
56MESSDACH(OH)2 0.14 ± 0.000 0.063 ± 0.016 0.053 ± 0.010 0.10 ± 0.015 0.009 ± 0.003 0.027 ± 0.002 0.075 ± 0.019 
cisplatin 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 7.5 ± 1.3 1.2 ± 0.1 
oxaliplatin 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 1.4 ± 0.1 
carboplatin >50 9.2 ± 2.9 14 ± 1.0 24.3 ± 2.2 14.7 ± 1.2 >50 14.3 ± 0.7 
 
 
 
 
  
Figure 1.3.2 General structure of polyaromatic platinum(II)complexes. 
*indicates a stereocentre, either S or R. 
1.3.2 Platinum(IV) complexes 
The oxidization of PPCs from Pt(II) to Pt(IV) enables two additional ligands 
to be bound to Pt, thus offering new design features to be explored.39 Many 
different ligands have been assessed, several of which show increased targeting 
of cancer cells and comparable activity to cisplatin.34, 40, 41 Platinum(IV) 
complexes are hypothesised to act as prodrugs, i.e. they are inert in vivo until 
they are absorbed by the target cells and are reduced to the active platinum(II) 
form (Figure 1.3.3).42 The in vitro intercellular inertness is thought to minimise 
unwanted interactions with nucleophiles in the human blood serum; thus 
reducing side effects, increasing cellular dosage and, enhancing 
bioavailability.43 This mechanism has been proven by the completion of phase 
three clinical trials by satraplatin; however, it was not approved for 
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chemotherapy worldwide due to not significantly improving the patients 
survival compared to drugs currently in the clinic.44 The cytotoxicity of the Pt(II) 
complex correlates with that of the Pt(IV), i.e. the Pt(IV) complex should reduce 
to Pt(II) in vitro and produce the same cytotoxic effect.39 There have been 
several different lines of inquiry as to which ligands would produce maximal 
efficacy. These include ligands that: change the overall lipophilicity or charge of 
the PC, increase the size of the complex to utilize the enhanced permeability 
and the retention (EPR) effect, have anticancer activity of their own or contain 
known targeting groups. 34, 40, 41 
Figure 3.3.3: Intra- and extracellular reduction of Pt(IV), resulting in the loss of 
the axial ligands, producing a Pt(II) compound, showing potential mechanisms 
of action.41, 45 (X= axial ligand) 
1.3.3 Advantages of platinum(IV) complexes with targeting 
Vectors. 
Platinum(IV) prodrugs have the potential to deliver drugs specifically to 
tumour cells, which should limit unwanted side-effects and reduce the quantity 
of drug required for effective treatment.43 Targeting may be accomplished 
through either active or passive methods.46-48 Passive targeting makes use of 
the disorganised vasculature and poor lymphatic drainage of cancer tissue.47-
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51,46, 52, 53 Macromolecules that range in size from 100 – 1200 nm are able to 
passively cross the cancer endothelium via the fenestrations, while normal cells 
have pore sizes smaller than 2 nm.49 Additionally, removal of these molecules 
from cancer cells is impeded by poor lymphatic drainage. This phenomenon is 
termed the enhanced permeability and retention (EPR) effect (Figure 3.3.4).54 
 
Figure 3.3.4: Enhanced permeability and retention (EPR) effect: A) Small drug 
size results in the diffusion of the unconjugated drug into both the healthy and 
tumour tissue. B) Larger drug size results in the diffusion of the conjugated drug 
into tumour tissue only.  
Active targeting requires specific interactions between the prodrug and 
cancer cell; for example, receptors that are over-expressed on the surface of 
cancer cells have potential as cellular targets.46, 48, 50, 55 Active targeting then 
requires that the prodrug contains a targeting vector for that specific cellular 
receptor.46, 48, 50 However, the receptor must be overexpressed relative to 
normal cells,56 should be recycled frequently,57 and it must be in an accessible 
location such as the surface of cells.58 Based on these principles, several 
prospective targets have been identified, including: folate receptor (FR); 
glucose transporter 1; prostate-specific membrane antigen (PSMA); and 
epidermal growth factor receptor.58-61 Folic acid for example is an excellent 
candidate for a targeting ligand due to the overexpression of FR, the ease at 
which it may be derivatised, its high specificity and affinity, resistance to 
denaturing and low immunogenicity.58, 62-66 FRs are also largely absent from 
healthy tissue, reducing the likelihood of unwanted side effects while being 
= Healthy 
Tissue 
= Unconjugated 
Drug 
= Conjugated 
Drug 
[A] [B
] 
=Tumor Tissue 
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present in several different cancer types.58, 65-67 PSMA is also a good target for 
cancer treatment, as it is a trans-membrane protein overexpressed by 
essentially all prostate cancer cells. The expression of PSMA is increased in fast 
growing, poorly differentiated, intrinsically resistant, and metastatic cancers. 
PSMA is also expressed in gliomas (most common primary brain tumours) and 
several other solid tumours including those found in the pancreas, kidney and 
lung. There is also evidence that PSMA is overexpressed in the vascular 
endothelium, and targeting this structure may “starve” the cancer and 
consequently kill it.68 Although some normal tissue (apart from in prostate 
cells) express PSMA, it is in relatively small amounts in cells not accessible 
through the vasculature, or are within the kidneys where they are potentially 
protected by the glomerulus (which would stop larger molecules passing). 
Treatments targeted to PSMA are hypothesised to: selectively target prostate 
cancers or vessels perfusing to cancer calls, accumulate significantly, reducing 
the risk of acquired resistance, and spare non target tissue in which PSMA is not 
expressed. A Lu-PSMA complex was recently awarded best image of the year by 
Society of Nuclear Medicine and Molecular Imaging, for a demonstration of 
exceptional responsiveness in patients with metastatic prostate cancer. This 
Phase II clinical trial drug demonstrated the viability of PSMA targeted 
therapies.69  N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-lysine (DCL) is a part 
of a series of PSMA targeting ligands consisting of a urea base with attached 
amino acids, in this case lysine and glutamic acid.70 DCL has been proven as a 
selective targeting agent as both a radio-imaging tool and as a delivery ligand 
for a non-platinum anticancer agent.70-72 Binding DCL to Pt drugs is 
hypothesised to result in the active intake of the Pt-DCL complex in cells over 
expressing PSMA. The carboxylic acid groups make crossing lipophilic cell 
membranes of healthy tissue difficult, thus targeting cancer cells and reducing 
the risk of side effects.68 DCL is therefore an excellent candidate to bind o Pt(IV) 
prodrugs to increase the specificity of their cytotoxic action. 
1.3.4 Advantages of Pt(IV) complexes with bio-active ligands. 
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Pt(IV) derivatives of active Pt(II) complexes with bio-active ligands present 
a new method to further refine and enhance the suitability of Pt drugs as 
anticancer agent. As discussed above Pt(IV) analogues are considered pro-drugs 
as they are activated by reduction within cells. The hypothesis behind the use 
of bio-active ligands is that upon reduction of the Pt prodrug the axial ligands 
are released within cells and these ligands can be utilised to further enhance 
they cytotoxicity of the drug. The literature has many examples of ligands that 
are known antiproliferative agents, enzyme inhibitors/enhancers, cytotoxic 
agents or exhibit biological activity that works alongside Pt drugs or that help to 
overcome resistance to Pt drugs.73-78 Because these bioactive ligands have the 
potential to affect a variety of cellular mechanisms, their cytotoxic activity 
cannot be attributed to just one pathway; hence it would be more accurate to 
call them multi-action rather than dual action drugs.77 
Nonsteroidal anti-inflammatory drugs (NASIDs) have been shown to inhibit the 
cyclooxygenase enzyme system which consequently leads to reduced tumour 
growth and angiogenesis.79-84 The anticancer effect of these compounds is 
achieved only at high concentrations and thus they have limited 
pharmacological activity.84 However, these compounds attached to a Pt(IV) 
prodrug may achieve a high intracellular concentration without a high dosage. 
This hypothesis has been confirmed in the literature; a study in which NASIDs 
were bound to cisplatin and its derivatives found that NSAID cellular 
concentration was high enough to change the reaction of the cell to the Pt(II) 
drug, promoting apoptosis.85, 86 An example of one such NASID is 2-[2,6-
dichlorophenylamino]phenyl acetate (DCF) which has proven anticancer activity 
and has also been bound to cisplatin by  Brabec et al.87 Their study 
demonstrates that cisplatin bound DCF is cytotoxic against cancer cell lines, and 
is more potent than cisplatin alone against cisplatin resistant cell lines. The DCF 
was bound to cisplatin in place of the chloride ions, forming a square planar 
Pt(II) complex (Figure 1.3.4.1). The DCF ligands are still cleaved intracellularly as 
per the normal cisplatin mechanism, allowing the cisplatin to bind to the DNA 
while the DCF affects multiple cellular pathways. Unlike most NSAIDs, DCF is 
not cyclooxygenase enzyme dependant; it instead works through mitochondrial 
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interaction, inhibiting glycolysis and lactate transport. DCF also modulates the 
phases of the cell cycle, enabling damaged cells to traverse the S phase. Thus 
DCF is a good candidate for further experimentation with different Pt 
anticancer agents and potentially new linkers. 
 
 
Figure 1.3.4.1: Examples of DCL complexes; complex 1: cis-[PtCl2(DCF)2(NH)], 
complex 2: cis-[Pt(DCF)2(NH3)2] and complex 3: [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)(2-Aminoethyldiclofenacamide)2]2+. 
1.3.5 Advantages of asymmetric Pt(IV) complexes. 
 
Asymmetric Pt(IV) complexes allow for further fine tuning of the 
pharmacokinetics of a cytotoxic Pt(II) drug. Asymmetric complexes may be 
advantageous in one of two ways. Firstly, using two different cytotoxic axial 
ligands in a multi-action prodrug means a greater amount of different 
mechanisms of action per complex relative to one with two of the same axial 
ligand. Secondly, the use of two different axial ligands can profoundly affect the 
reduction potential of  a platinum(IV) complex. The reduction potential is 
important because the activation of Pt(IV) prodrugs relies on the intracellular 
reduction of the complex, which is modulated by the nature of the axial ligands. 
The axial ligands must have a reduction potential high enough that it is 
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chemically inert extracellularly, providing the aforementioned advantages of 
Pt(IV) drugs such as being orally active. The reduction potential must also be 
low enough that it can be reduced once inside the cell, initiating its cytotoxic 
action.77  
When it comes to the reduction potential of Pt(IV) analogues, there are 
several variables that must be accounted for to elucidate any correlation 
between cytotoxicity and reduction potential. The reactivity of Pt(IV) is 
enhanced in the presence of intracellular reducing agents, ascorbic acid,88 
glutathione89 and protein sulfhydryl.90 Pt(IV) complexes may bind differently to 
DNA depending on these reaction conditions and the nature of the axial 
ligands.91 When the equatorial ligands are kept approximately the same and 
the axial ligands are varied a correlation between the electronegativity of the 
axial ligands and the speed of reduction is revealed. In general the more 
electronegative the ligands, the more destabilised the Pt(IV) state, resulting in 
faster reduction.91 In general this translates to hydroxyl ligands axial ligands 
reducing the slowest followed by acetate chloride and fluroacetate. Rate of 
reduction is also dependant on the bulkiness of the axial ligands, with more 
bulky ligands reducing faster than smaller ligands. In this case the bulkiness of 
the equatorial ligands also contributes to the speed of reduction. The bulky 
ligands destabilise the octahedral Pt(IV) structure resulting is faster reduction 
to the more stable square planar structure.91 Everything else equal, cytotoxicity 
and reduction have a positive correlation, and thus the rate of reduction is an 
important consideration in the design of Pt(IV) pro-drugs. This conclusion leads 
to the understanding that in some cases binding two bioactive or targeting 
ligands may negatively affect the reduction rate and thus negatively affect the 
prodrugs cytotoxicity. It may therefore be essential for the efficiency of the 
drug to have two different axial ligands, one to enhance the efficiency of the 
cytotoxic mechanism and the other to ensure the timely reduction of the 
prodrug to release said cytotoxic agents.77 
Asymmetric ligands also offer a large library of potential prodrugs, where 
bioactive and targeting ligands can be mixed and matched to find the most 
efficient prodrug. This avenue also leads to dinuclear Pt(IV) compounds, which 
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combine two different Pt(II) analogues. For example, a dinuclear Pt(IV) 
compound was synthesised comprising of 56MESS and cisplatin joined by a 
linker, with two different cytotoxic agents covalently bound to each Pt centre; 
phenylbutyrate (PhB) and dichloroacetate (DCA) (Figure 1.3.5.1).92 This 
“quadruple action” complex was shown to have DNA binding, mitochondrial 
action as well as inhibition of histone deacetylase inhibitor, and it is suggested 
to have further action through the multiple possible cellular processes of each 
component i.e. the bioactive ligands and PCs way work via more than one 
mechanism. The combined mechanisms resulted in the GI50 being higher than 
that of any of the individual components, and the complex is active in cisplatin 
resistant cells.92 These complexes have shown good activity in KRAS mutated 
cells, which is exciting as KRAS mutated cancers have been previously described 
as “undrugable”.93 The KRAS gene is responsible for the activation of number of 
signalling molecules that affect cell differentiation, growth, chemotaxis and 
apoptosis.94  It is a part of the RAS class of oncogenes meaning that their 
mutations are likely to become cancerous. KRAS mutations are the most 
common mutation to cause cancer, and occur in particularly high rates in some 
of the most deadly cancers, 97.7% of pancreatic ductal adenocarcinomas, 
44.7% of colorectal adenocarcinomas and 30.9% of lung adenocarcinomas.93 
the multi-action dinuclear complexes mentioned above were tested against 
several lines of aggressive KRAS mutated cells and showed promising activity, 
significantly higher than that of cisplatin.92 
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Figure 1.3.5.1: An example of an asymmetric dineclear anticancer agent made 
up of 56MESS, cisplatin, PhB and DCA.92 
1.4 New synthetic procedures: continuous flow chemistry 
Continuous flow chemistry refers to reactions that occur in a stream 
rather than in a batch as used in traditional synthesis chemistry. This usually 
involves pumping solutions through tubes containing reagents or catalysts 
bound to a solid phase. The stream can flow under pressure or at temperature 
and can be run with minimal supervision for extended periods of time. As 
exemplified in Figure 1.4.1 continuous flow chemistry set ups can include a 
multitude of parameters and intermediates which unlike in batch are 
undertaken as a part of a continuous system rather than purifying 
intermediates after each reaction as typically seen in batch chemistry. 
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Figure 1.4.1: An example of a flow chemistry set up, where reactants A and B 
are combined under condition a to create the intermediate C before 
undergoing condition b and the addition of D to finally produce the final 
product E. 
Continuous flow chemistry has many advantages over batch chemistry: it 
allows for more precise control of variables such as temperature and pressure, 
more efficient use of reagents and solvents, as well as reduction of reaction and 
purification time.95 This leads to reduced cost of production as well as creating 
a safer work space, as the reaction is contained and minimal handling is 
necessary.96 Continuous flow chemistry can also increase the sustainability of 
the synthesis by reducing waste and increasing the reproducibility of the 
results.97 The current synthesis of 56MESS and analogues using batch chemistry 
is relatively time consuming with an average time for 2 days with an average 
yield of ~80% (Figure 2.4.1). Developing a continuous flow protocol for the 
synthesis of these PCs would reduce the amount of time and resources used 
during synthesis and purification. The development of such a protocol would be 
particularly significant as there are currently no reported applications of flow 
chemistry in the field of inorganic syntheses. 
Figure 1.4.2: Reaction scheme for the batch chemistry method (top) and the 
flow chemistry method (bottom).  
A 
E 
B 
D 
Condition a Condition b 
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1.5 Project Aims 
• To produce a new protocol for the synthesis of [Pt(PL)(AL)]2+ type 
complexes, that is more efficient than the current method. Continuous 
flow chemistry will be investigated to meet this aim which may 
produce novel findings in the use of flow chemistry for inorganic 
synthesis protocols. 
Pt(IV) polyaromatic complexes are producing promising preliminary in vivo 
results.34 Further development of these compounds would be significantly 
assisted if their synthesis were to be automated using flow chemistry protocol. 
Another exciting aspect of the development of such a protocol is the novelty of 
using what is currently a technique used for purely organic chemistry and apply 
it to an inorganic synthesis. The main aim of this aspect of the project is to 
develop a synthesis that is straightforward and less time consuming than the 
batch synthesis while achieving the same if not better yields. This will be done 
by developing the flow protocol using much of the same strategy for 
optimisation of any other flow system, focusing on each reaction variable in 
turn until optimal results are achieved. Thus the aim is; to produce a new 
protocol for the synthesis of [Pt(PL)(AL)]
2+ type complexes, where (PL) is an 
analogue of 1,10-phenanthroline (phen) and (AL) is diaminocyclohexane (dach), 
that is more efficient than the current method. 
 
• To effectively oxidise Pt(II) complexes with halides Cl, Br, and I on the 
axial positions to produce [Pt(PL)(AL)(X2)]2+. The resulting compounds 
will be characterised and their biological activity determined. 
The coordination of halides (X) in the axial positions of the platinum(IV) 
complex (c,c,t-[Pt(5,6-dimethyl-1,10-phenanthroline(56Me2phen))(SS-
dach)(X)2]
2+) will be investigated as a part of this project. It has been previously 
observed that reduction to platinum(II) occurs faster when the axial ligand is 
chlorine rather than oxygen, and thus it is hypothesized that the other halides 
will similarly affect the reduction rate and the pharmacology of these 
complexes.9 To explore their effect on cytotoxicity and pharmacokinetics, a 
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series of compounds with axially coordinated Cl, Br or I will be synthesised. 
They will be utilised as an intermediate to more efficiently coordinate other 
ligands onto the axial positions that can be targeting factors or have anticancer 
properties themselves. Using the resulting complexes, the effectiveness of 
substitution in the axial position by various ligands will be assessed, as well as 
the cytotoxicity of the resulting compounds in cell lines. The main aim of the 
synthesis of [Pt(AL)(PL)(X)2] complexes is to identify a more efficient method of 
substitution onto the axial positions, which could be incredibly useful for 
attaching targeting groups such as folic acid and glucose.98 The protocol used 
will be a modification of a previously described method which has already 
proven successful.99  
 
• To develop a method for the synthesis of asymmetric compounds of 
the type [Pt(PL)(AL)(OH)(C2H3O2)]2+. 
The third aim of the project is to develop a method for the synthesis of 
asymmetric Pt(IV) compounds which will offer further diversification of the 
platinum compounds able the be synthesised. These Pt(IV) compounds will 
incorporate acetate and hydroxido ligands to produce compounds of the type  
[Pt(PL)(AL)(OH)(C2H3O2)]
2+. The asymmetric design of these compounds will 
allow further asymmetric derivatisation of the Pt(IV) which may be 
advantageous in the design and synthesis of multi action drugs.  
 
• To investigate the substitution of targeting vectors onto 
[Pt(PL)(AL)(X2)]2+ as a potential method for more efficient cancer cell 
selectivity. 
The third aim of the project is to develop a method for the synthesis of 
asymmetric Pt(IV) compounds which will offer further diversification of the 
platinum compounds able the be synthesised. These Pt(IV) compounds will 
incorporate acetate and hydroxido ligands to produce compounds of the type  
[Pt(PL)(AL)(OH)(C2H3O2)]
2+. The asymmetric design of these compounds will 
allow further asymmetric derivatisation of the Pt(IV) which may be 
advantageous in the design and synthesis of multi action drugs.  
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• To collaborate with other research labs, producing complexes that 
have the potential to increase targeting. 
The fourth aim of this project is to bind targeting ligands provided by 
international and local collaborators to PPCs of the type [Pt(PL)(AL)(OH)2]2+ to 
determine their effectiveness. The synthesis of these compounds will further 
diversify the synthetic methods available to the research team at WSU, 
expanding the number and type of compounds able to be synthesised. These 
complexes have the potential to increase the viability of 56MESS (and 
analogues) as a drug, targeting specific types of cancers and reducing its 
systemic toxicity. As these targeting ligands will be developed with 
international and local collaborators; this project also serves to strengthen our 
position in the research field and our connections with these valuable 
collaborators. 
 
• To prepare manuscripts for publication: 1) Modifying the 
Pharmacokinetics of Platinum(IV) Complexes via Halogenation at axial 
positions and, 2/3) Substitution of Targeting Vectors Pt(IV) 
compounds. 
The first paper will be a synthesis and characterisation paper in which nine 
novel complexes will be synthesises, characterised using a combination of 
HPLC, NMR, ESI-MS, CD, SRCD microanalysis and biological testing. These 
complexes should have some interesting activity in cancer cell lines and have 
characterisation data different to other complexes of the same type which will 
be a point of interest for the paper. The second and third papers will be in 
collaboration with other researches who have provided ligands which I will 
attach to our labs complexes. These complexes will be novel and are 
hypothesised to have improved activity and pharmacokinetics. 
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Chapter 2 Materials and Methodology 
2.1 Materials 
Reagents were used as received unless otherwise specified. All solvents 
used were of analytical grade or higher. Potassium tetrachloroplatinate 
(K2PtCl4) was purchased from Precious Metals Online. Acetone, acetic acid, 
acetonitrile, dichloromethane (DCM), diethyl ether, ethyl acetate, hexane, 
hydrochloric acid, silver acetate, silver nitrate, N-iodosucinamide, N-
chlorosucinamide, N-bromosucinamine, and sodium chloride were obtained 
from Sigma-Aldrich. Hydrogen peroxide was obtained from VWR. Methanol was 
obtained from Honeywell. DCL was purchased from Tokyo Chemical Industry 
and DCL was synthesised by B. Pages.100 Deuterated solvents d7-
Dimethylformamide (99.5%), d6-dimethylsulphoxide (99.9%), deuterium oxide 
(99.9%) and deuterated acetonitrile (99.8%) were purchased from Cambridge 
Isotope Laboratories. Acetone (≥99.5%) was purchased from Biolab. 
 
2.2 Instrumentation 
1H NMR experiments were performed on a Bruker Avance 400 MHz NMR 
spectrometer. Using this instrument 13C NMR experiments were performed at 
101 MHz and 195Pt NMR at 86 MHz. All compounds were dissolved in one of the 
following: D2O, d7-DMF, d3- CD3CN, d2-CD2Cl2 or d6-DMSO. The temperature in 
the probe was maintained at 25 °C. Spectra are referenced to the residual 
deuterated solvent peak. The following abbreviations apply to spin multiplicity: 
s (singlet), d (doublet), dd (doublet of doublets) t (triplet), q (quartet) and m 
(multiplet). 
UV spectra were recorded on a Cary 1E spectrophotometer at room 
temperature in the 200–400 nm range, using a 10 mm quartz cell. All samples 
were automatically corrected for solvent baseline. Titration of a stock solution 
into a known volume of solvent allowed the calculation of the extinction 
coefficient, a measure of the absorbance at a given wavelength per mass 
density. 
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CD spectra were obtained using a Jasco-810 spectropolarimeter at room 
temperature. The instrument was left to equilibrate for 30 minutes prior to use. 
Spectra were obtained in a 10 mm quartz cell, and were measured from 400–
200 nm with a data pitch of 1 nm, bandwidth of 1 nm and response time of 1 
second. For each spectrum, 40 accumulations were collected and a water 
baseline was subtracted 
Electrospray ionisation mass spectrometry (ESIMS) experiments, in the 
positive mode, were performed using a Waters TQ-MS triple quadrupole mass 
spectrometer. Sample solutions were made up to 0.5 mM in H2O and flowed at 
0.1 mL/min. A desolvation temperature of 300 oC, desolvation flow rate 
(nitrogen) of 500 L/hr remained consistent whilst the cone voltage and capillary 
voltage were varied for each sample in order to adjust for fragmentation. 
Spectra were collected over varied m/z ranges depending on the target mass. 
Samples were purified using the Reveleris® X2 flash chromatography 
system fitted with a Reveleris® reverse phase C18 4 g column. The column was 
equilibrated to 3% MeOH in water for 2.4 min at 8 mL/min, and the samples 
run for 9 minutes with the UV detector sensitivity on high and detecting at 230, 
254 and 280 nm. Samples between 20 and 100 mg were prepared in ~1-2 mL 
H2O injected and eluted with a flow rate of 8 mL/min. The column was eluted 
with 3% MeOH for 6 minutes then MeOH was increased to 100% over 1 minute, 
kept steady for 1 minute before returning to 3% over another minute. Only one 
product peak was detected and this was collected in 10 mL fractions. 
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2.3 Synthesis 
2.3.1 Synthesis of [Pt(1S,2S-diaminocyclohexane)Cl2]2+ 
 
 
The synthesis of Pt(1S,2S-diaminocyclohexane)Cl2  and Pt(1R,2R-
diaminocyclohexane)Cl2  was achieved using the published method.101  
Potassium tetrachloroplatinate (307.5 mg: 7.41 mmol: 1 equiv.) was dissolved 
in 30 mL of deionized water and filtered using a 45 micrometre syringe filter. 
Then either 1S,2S-diaminocyclohexane (SS-dach) or 1R,2R-diaminocyclohexane 
(RR-dach) (350.2 mg; 3.05 mmol ;1.1 equiv.) was added to the solution which 
was then sealed and cooled to 4 oC for approximately 48 hrs, at which point the 
solution turned an opaque pale orange and a yellow precipitate had formed. 
The solution was then filtered and washed three times with 3 mL aliquots of 
deionized water. The pure product was then dried in a desiccator for several 
days. [Pt(SS-dach)Cl2], yield 254.7 mg, 90.0 %: 1H NMR (400 MHz,d6-DMSO) δ 
5.56 (d, J = 8.2Hz, 1H), 5.03 (s, 1H), 2.08 (s, 1H), 1.85 (d, 1H,  J = 12.6 Hz,) 1.44 
(d, 1H , J = 8.4 Hz), 1.24 (s, 1H), 0.96 (t, 1H, J = 9.7 Hz). Pt(RR-dach)Cl2, yield 
254.7 mg, 90.0 %: 1H NMR (400 MHz,d6-DMSO) δ 5.56 (d, 1H, J = 8.2Hz), 5.03 (s, 
1H), 2.08 (s, 1H), 1.85 (d, 1H, J = 12.6 Hz), 1.44 (d, 1H, J = 8.4 Hz), 1.24 (s, 1H), 
0.96 (t, 1H, J = 9.7 Hz). 
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2.3.2 Synthesis of [Pt(1,10phenanthroline)(1S,2S-
diaminocyclohexane)]2+ (Batch) 
The batch synthesis of [Pt(phen)(SS-dach)]2+  (PHENSS) was achieved 
using the published method.101 [Pt(SS-dach)Cl2] (307.5 mg; 85.4 mmol: 1 equiv.) 
and phen (164.5 mg : 91.3 mmol: 1.1 equiv.) were refluxed for 24 hrs, resulting 
in the solution transforming from an opaque pale yellow to a clear yellow-
orange solution. The volume was then reduced to allow purification via a Vac 
20cc (5 g) C18 Sep-Pak© column connected to a pump apparatus with UV 
detector (Bio-Rad, EM-1 Econo™ UV Monitor). The column was activated with 
methanol (20 mL) and then flushed with water (~40 mL) until the UV 
absorbance equilibrated.  The purified solution was then reduced under 
vacuum and freeze dried. Yield 393.6 mg, 86.5 %. 1H  NMR (400 MHz, D2O) δ 
8.88 (m, 4H, CH), 8.13 (s, 2H, CH), 7.98 (dd, 2H, CH, J = 8.36, 8.50 Hz), 2.70 (m, 
2H, CH), 2.20 (d, 2H, CH, J = 10.97), 1.62(m, 2H, CH), 1.46 (m, 2H, CH), 1.23 (m, 
2H, CH). 
 
2.3.3 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)]2+ (Flow) 
 
The flow synthesis of PHENSS was developed and optimized to be as 
follows. [Pt(SS-dach)Cl2]2+ (118.0 mg; 47.35 mmol: 1.1 equiv.) and phen (78.8 
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mg : 43.72 mmol: 1.equiv.) were heated in  a 10 x 100 mm Omnifit column to 
140 oC under 100 PSI. The reaction ran for 1.5 hrs at 0.05 mL/min. The crude 
product was purified via a Vac 20cc (5 g) C18 Sep-Pak© column as per the 
methods in the batch synthesis. The purified solution was then freeze dried in a 
minimal volume of deionized water (~2 mL). Yield 91.1 mg, 49.6%. 1H NMR (400 
MHz, D2O) δ 8.92 (m, 4H: CH), 8.11 (s, 2H: CH), 7.98 (dd, 2H: CH, J = 8.3, 5.4 Hz), 
2.70 (dd, 2H: CH, J = 12.2, 8.3 Hz), 2.21 (d, 2H: CH, J = 12.7 Hz,), 1.83 (s, 6H: 
CH3), 1.65 (d, 2H: CH, J = 8.9 Hz), 1.46 (d,2H: CH, J = 8.6 Hz), 1.13 (m, 2H: CH). 
 
2.3.4 Synthesis of Pt(II) complexes of the type [Pt(PL)(AL)] 2+ 
 
Pt(II) complexes of the type [Pt(PL)(AL)] 2+ was achieved using the method 
described in B.Pages et al 2014.101  PL (1 equiv) and AL (1.1 equiv) were refluxed 
for 48 hrs, resulting in the solution transforming from an opaque pale yellow to 
a clear yellow orange. The volume was then reduced to allow purification via a 
Vac 2Occ (5 g) C18 Sep-Pak© column connected to a pump apparatus with UV 
detector (Bio-Rad, EM-1 Econo™ UV Monitor). The column was activated with 
methanol (20 mL) and then flushed with water (~40 mL) until the UV 
absorbance equilibrated.. The purified solution was then freeze dried in a 
minimal volume of deionized water (~2 mL) to produce a pale yellow solid. 
This method was utilised to synthesise; [Pt(56Me2phen)(SS-dach)]2+ 
(56MESS), [Pt(56Me2phen)(RR-dach)]2+ (56MERR), [Pt(phen)(SS-dach)]2+ 
(PHENSS), [Pt(phen)(RR-dach)]2+(PHENRR), [Pt(5-methyl-1,10-
phenanthroline(5Mephen))(SS-dach)]2+ (5MESS), [Pt(5Mephen)(RR-dach)]2+ 
(5MERR), [Pt(4-methyl-1,10-phenanthroline(4Mephen))(SS-dach)]2+ (4MESS), 
[Pt(4Mephen)(RR-dach)]2+(4MERR), [Pt(4,4′-Dimethyl-2,2′-dipyridyl(44BPY))(SS-
dach)]2+(44BPYSS), and [Pt(44BPY)(RR-dach)]2+(44BPYRR). Yields and NMR data 
are displayed in Table 2.3.4.1 
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Table 2.3.4.1 Summary of NMR data of Pt(II) complexes of the type [Pt(PL)(AL)]2+ complexes, showing chemical shift (ppm) 
with integration, multiplicity and coupling constants. Experiments were performed in D2O, so amine resonances were not 
observed due to proton exchange.  
   Complex   
Label PHENSS PHENRR 56MESS 56MERR 5MESS 5MERR 4MESS 4MERR 44BPYSS 44BPYRR 
H4 8.87 
(d, 2H: CH,k J= 
5.35 Hz) 
8.88 
(d, 2H: CH,k  = 
5.58 Hz) 
8.78 
(d, 1H: CH, J= 
5.32Hz) 
8.78 
(d, 1H: CH, J= 
4.87  Hz) 
8.66 
(d, 1H: CH, J= 
8.29 Hz) 
8.69 
(d, 1H: CH, J= 
8.44 Hz) 
- - - - 
H7 - - - - 8.5 
(d, 1H: CH, J= 
8.90 Hz) 
8.89 
(d, 1H: CH, J= 
8.63 Hz) 
8.86 
(d, 1H: CH, J= 
5.34 Hz) 
8.87 
(d, 1H: CH, J= 
5.48 Hz) 
- - 
H3 7.97 
(dd, 2H: CH, J= 
8.37, 8.46 Hz) 
7.98  
(dd, 2H: CH, J= 
8.44, 8.47 Hz) 
7.94 
(dd, 1H: CH, 
J=8.48, 8.37 Hz) 
7.95 
(dd, 1H: CH, 
J=8.71, 8.58 Hz) 
7.92 
(dd, 1H: CH, J= 
7.98, 8.29 Hz) 
7.92 
(dd, 1H: CH, J= 
5.57, 8.32Hz) 
7.80 
(d, 1H: CH, J= 
5.64 Hz) 
7.81 
(d, 1H: CH, J= 
5.65 Hz) 
8.11 
(s, 2H: CH) 
8.13 
(s, 2H: CH) 
H8 - - - - 7.97 
(dd, 1H: CH, J= 
8.34, 8.44 Hz) 
7.98 
(dd, 1H: CH, J= 
5.57, 8.44 Hz) 
7.95 
(dd, 1H: CH, J= 
8.34, 8.26 Hz) 
 
7.95 
(dd, 1H: CH, J= 
8.54, 8.26 Hz) 
 
- - 
H2 8.48 
 (d, 2H: CH, J= 
8.50 Hz) 
8.86 
 (d, 2H: CH, J= 
8.28 Hz) 
8.90 
(d, 1H: CH, J= 
8.76  Hz) 
8.89 
(d, 1H: CH, J= 
8.72Hz) 
8.77 
(d, 1H: CH, J= 
5.36 Hz) 
8.78 
(d, 1H: CH, J= 
5.72Hz) 
8.84 
(d, 1H: CH, J= 
8.93 Hz) 
8.84 
(d,  H: CH, J= 
8.54 Hz) 
- - 
H9 - - - - 8.83 
(d, 1H: CH, J= 
5.04 Hz) 
8.85 
(d, 1H: CH, J= 
5.49 Hz) 
8.67 
(d, 1H: CH, J= 
5.55 Hz) 
8.68 
(d, 1H: CH, J= 
5.82Hz) 
- - 
H5 8.07  
(s,2H; CH) 
8.11  
(s,2H; CH) 
- - - - 8.18 
(d, 1H: CH, J= 
9.26 Hz) 
8.19 
(d, 1H: CH, J= 
9.29 Hz) 
7.49 
(d, 1H: CH, J= 
6.12Hz) 
7.48 
(d, 1H: CH, J= 
5.51Hz) 
H6 - - - - 7.73 
(s,1H; CH) 
8.09 
(s,1H; CH) 
8.07 
(d, 1H: CH, J= 
9.26 Hz) 
8.08 
(d, 1H: CH, J= 
8.22Hz) 
8.29 
(d, 1H: CH, J= 
5.51Hz) 
8.28 
(d, 1H: CH, J= 
5.90 Hz) 
CH3 - - 2.64 
(s, 6H; CH3) 
2.63 
(s, 6H; CH3) 
2.72 
(s, 3H; CH3) 
2.85 
(s, 3H; CH3) 
2.85 
(s, 3H; CH3) 
2.86 
(s, 3H; CH3) 
2.49 
(s, 6H; CH3) 
2.49 
(s, 6H; CH3) 
H1’/2’ 2.71 
 (m, 2H; CH2) 
2.70 
(m, 2H; CH2) 
2.70 
(m, 2H;  CH2) 
2.70 
(m, 2H;  CH2) 
2.70 
(m, 2H;  CH2) 
3.35 
(m, 2H;  CH2) 
2.69 
(m, 2H;  CH2) 
2.69 
(m, 2H;  CH2) 
2.59 
(m, 2H;  CH2) 
2.59 
(m, 2H;  CH2) 
H3’/6’ 2.21 
(d, 2H; CH2, 
J=14.86 Hz) 
2.20  
(d, 2H; CH2, 
J=13.37 Hz) 
2.21 
(d, 2H;  CH2 J= 
12.57 Hz) 
2.21 
(d, 2H;  CH2 J= 
12.57 Hz) 
2.21 
(d, 2H;  CH2 J= 
13.44 Hz) 
2.36 
(d, 2H;  CH2 J= 
12.09 Hz) 
2.20 
(d, 2H;  CH2 J= 
13.18 Hz) 
2.19 
(d, 2H;  CH2 J= 
13.18 Hz) 
2.14 
(d, 2H;  CH2 J= 
13.00 Hz) 
 
2.14 
(d, 2H;  CH2 J= 
13.00 Hz) 
 
H4’/5’ 1.46 
 (m, 2H;  CH2) 
1.65 
 (m, 2H;  CH2) 
1.65 
(m, 2H;  CH2) 
1.1.66 
(m, 2H;  CH2) 
1.65 
(m, 2H;  CH2) 
1.72 
(m, 2H;  CH2) 
1.61 
(m, 2H;  CH2) 
1.64 
(m, 2H;  CH2) 
1.61 
(m, 2H;  CH2) 
1.61 
(m, 2H;  CH2) 
H3’/6’ 1.65 
(m, 2H;  CH2) 
1.46 
(m, 2H;  CH2) 
1.46 
(d, 2H;  CH2 J= 
12.49 Hz) 
1.45 
(d, 2H;  CH2 J= 
12.03 Hz) 
1.47 
(d, 2H;  CH2 J= 
10.90 Hz) 
1.66 
(d, 2H;  CH2 J= 
10.90 Hz) 
1.45 
(m, 2H;  CH2) 
1.44 
(m, 2H;  CH2) 
1.39 
(m, 2H;  CH2) 
1.39 
(m, 2H;  CH2) 
H4’/5’ 1.23 
 (m, 2H;  CH2) 
1.23 
 (m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.23 
(m, 2H; CH2) 
1.30 
(m, 2H;  CH2) 
1.22 
(m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.19 
(m, 2H;  CH2) 
1.19 
(m, 2H;  CH2) 
1H/195Pt
 8.96/-2823.4 8.97/-2823.6 9.66/-2759.2 9.05/-2753.7 8.92/-2757.8 8.94/-2757.9 9.64/-3189.2 9.59/-3120.5 8.36/-2811.8 8.36/-2814.4 
%Yield
 
90 89 90 85 87 88 78 81 75 76 
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2.3.5 Synthesis of complexes of the type [Pt(PL)(AL)] X2]2+ 
 
The synthesis of [Pt(AL)(PL)X2]2+   (where X = Cl Br or I, PL = Phen, 56Me2phen or 
5Mephen and AL = SS-dach) was achieved using the following method. The Pt(II) 
complex (1 equiv) and N-halogensuccinimide (2.4 equiv) were combined and left to 
react in a 9 mL solution of 1:1:1H2O: EtOH: 1 M HCl. After approximately 2 hr the 
reaction was stopped by evaporation under vacuum. To purify the product, the 
reaction was redissolved in water and eluted through a Vac 2Occ (5 g) C18 Sep-Pak© 
column connected to a pump apparatus with UV detector (Bio-Rad, EM-1 Econo™ UV 
Monitor). The column was activated with methanol (20 mL) and then flushed with 
water (~40 mL) until the UV absorbance equilibrated.  The first and last band of three 
to elute were identified as impurities whilst the second band contained the major 
product. The compound was further purified using toluene in a soxhlet apparatus. If 
impurities remained after this process, the sample was further purified using the 
Reveleris® X2 flash chromatography system fitted with a Reveleris® reverse phase C18 4 
g column and eluted with MeOH and H2O (see Section 2.2 Instrumentation for details). 
[Pt(phen)(SS-dach)Cl2]2+ (PHENSSCl2),  [Pt(phen)(SS-dach)Br2]2 (PHENSSBr2), 
[Pt(phen)(SS-dach)I2]2+ (PHENSSI2), [Pt(56Me2phen)(SS-dach)Cl2]2+ (56MESSCl2),  
[Pt(56Me2phen)(SS-dach)Br2]2+ (56MESSBr2),  [Pt(56Me2phen)(SS-dach)I2]2+  (56MESSI2), 
[Pt(5Mephen)(SS-dach)Cl2]2+ (5MESSCl2),   [Pt(5Mephen)(SS-dach)Br2]2+ (5MESSBr2), and 
[Pt(5Mephen)(SS-dach)I2]2 (5MESSI2), were all synthesised using this method.  
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Table 2.3.5.1: Summary of NMR data of complexes of the type [Pt(AL)(PL)X2]2, showing chemical shift (ppm) with integration, 
multiplicity and coupling constants. Experiments were performed in D2O, so amine resonances were not observed due to 
proton exchange.  
   Complex No. 
Label PHENSSCl2 PHENSSBR2 PHENSSI2 5MESSCl2 5MESSBR2 5MESSI2 56MESSCl2 56MESSBR2 56MESSI2 
H4 9.07 
(d, 2H: CH,k J= 
8.31Hz) 
9.03 
(d, 2H: CH, J= 
8.17  Hz) 
9.04 
(d, 2H: CH, J= 
8.43 Hz) 
8.90 
(d, 1H: CH, J= 
8.28 Hz) 
8.89 
(d, 1H: CH, J= 
8.50 Hz) 
8.91 
(d, 1H: CH, J= 
8.44 Hz) 
9.14 
(d, 1H: CH, J= 
8.42  Hz) 
9.13 
(d, 1H: CH, J= 
8.65 Hz) 
9.07 
(d, 1H: CH, J= 
8.58 Hz) 
H7 - - - 9.13 
(d, 1H: CH, J= 
8.37 Hz) 
9.11 
(d, 1H: CH, J= 
8.50 Hz) 
9.14 
(d, 1H: CH, J= 
8.72Hz) 
- - - 
H3 8.27 
(dd, 2H: CH, J= 
5.52, 8.35 Hz) 
8.26 
(dd, 2H: CH, J=  
5.47, 8.17 Hz) 
8.27 
(dd, 2H: CH, J= 
5.41, 8.22Hz) 
8.20 
(dd, 1H: CH, J= 
5.57, 8.32Hz) 
8.17 
(dd, 1H: CH, J= 
5.83, 7.85 Hz) 
8.20 
(dd, 1H: CH, J= 
5.26, 8.21Hz) 
8.24 
(dd, 1H: CH, 
J=5.48, 8.56 
Hz) 
8.21 
(dd, 1H: CH, J= 
5.55, 8.55 Hz) 
8.20 
(dd, 1H: CH, J= 
5.56, 8.56 Hz) 
H8 - - - 8.29 
(dd, 1H: CH, J= 
5.57, 8.44 Hz) 
8.25 
(dd, 1H: CH, J= 
5.60, 8.56 Hz) 
8.29 
(dd, 1H: CH, J= 
2.44, 5.62Hz) 
- - - 
H2 9.09 
(d, 2H: CH, J= 
5.56 Hz) 
9.07 
(d, 2H: CH, J=  
5.56 Hz) 
9.11 
(d, 2H: CH, J= 
5.55 Hz) 
9.01 
(d, 1H: CH, J= 
5.32Hz) 
8.97 
(d, 1H: CH, J= 
5.33 Hz) 
9.00 
(d, 1H: CH, J= 
5.58 Hz) 
9.02 
(d, 1H: CH, J= 
5.42Hz) 
8.99 
(d, 1H: CH, J= 
5.43 Hz) 
9.00 
(d, 1H: CH, J= 
5.47 Hz) 
H9 - - - 9.10 
(d, 1H: CH, J= 
5.49 Hz) 
9.05 
(d, 1H: CH, J= 
5.42Hz) 
9.09 
(d, 1H: CH, J= 
5.58 Hz) 
- - - 
H5 8.33 
(s,2H; CH) 
8.33 
(s,2H; CH) 
8.31  
(s,2H; CH) 
- - - - - - 
H6 - - - 8.09 
(s,1H; CH) 
8.12 
(s,1H; CH) 
8.12 
(s,1H; CH) 
- - - 
CH3 - - - 2.85 
(s, 3H; CH3) 
2.89 
(s, 3H; CH3) 
2.86 
(s, 3H; CH3) 
2.77 
(s, 6H; CH3) 
2.79 
(s, 6H; CH3) 
2.67 
(s, 6H; CH3) 
H1’/2’ 3.35  
(m, 2H; CH2) 
3.39 
(m, 2H;  CH2) 
3.35 
(m, 2H;  CH2) 
3.35 
(m, 2H;  CH2) 
3.33 
(m, 2H;  CH2) 
3.34 
(m, 2H;  CH2) 
3.33 
(m, 2H;  CH2) 
3.35 
(m, 2H;  CH2) 
3.30 
(m, 2H;  CH2) 
H3’/6’ 2.35  
(d, 2H; CH2, 
J=15.56 Hz) 
3.34 
(d, 2H;  CH2 
J=11.00 Hz) 
2.36 
(d, 2H;  CH2 J= 
12.13 Hz) 
2.36 
(d, 2H;  CH2 J= 
12.09 Hz) 
2.32 
(d, 2H;  CH2 J= 
11.55 Hz) 
2.36 
(d, 2H;  CH2 J= 
12.05 Hz) 
2.36 
(d, 2H;  CH2 J= 
12.57 Hz) 
2.33 
(d, 2H;  CH2 J= 
11.53 Hz) 
2.33 
(d, 2H;  CH2 J= 
12.08 Hz) 
H4’/5’ 1.72 
(m, 2H;  CH2) 
1.69 
(m, 4 H;  CH2) 
1.73 
(m, 2H;  CH2) 
1.72 
(m, 2H;  CH2) 
1.67 
(m, 4 H;  CH2) 
1.72 
(m, 2H;  CH2) 
1.72 
(m, 2H;  CH2) 
1.67 
(m, 4 H;  CH2) 
1.62 
(m, 2H;  CH2) 
H3’/6’ 1.66 
(d, 2H;  CH2 
J=10.92Hz) 
- 1.66 
(d, 2H;  CH2 
J=10.40 Hz) 
1.66 
(d, 2H;  CH2 J= 
10.90 Hz) 
- 1.66 
(d, 2H;  CH2 J= 
11.02Hz) 
1.66 
(d, 2H;  CH2 J= 
10.71Hz) 
- 1.69 
(d, 2H;  CH2 J= 
9.50 Hz) 
H4’/5’ 1.30 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.29 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.26(m, 2H;  
CH2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
1H/195Pt 9.19/-645.8 9.12/-964.3 9.02/-635.2 9.1/ -643.1 9.10/ -649.7 9.17/ -640.7 9.15/-653.5 9.1/ -969 9.09/ -648 
Yield % 30.4 21.2 16.3 52.9 19.9 9.16 34.7 45.9  10.9 
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Table 2.3.5.2: Summary of the characterisation data of complexes of the type [Pt(PL)(AL)(X)2]
2+ 
  
 
Molecular Formula 
 ESI-MS (m/z) Microanalysis 
Calc. (Found) 
 
UV / λmax (nm) 
(ε/mol-1.dm3.cm-1)  
× 102 
 
CD / λmax  (nm) 
(Θ)  
× 10-8 
 Yield [M-Cl]+ Calc. 
(Found) Complex (%) N C H 
PHENSSCl2 C18H22Cl2N4Pt 30.4 279.54(280.03) 8.40 (8.40) 33.40 (33.36) 3.93 (37.47) 278 (579), 208 (243) 268(3.85), 216(-25.5), 183(-1.08) 
PHENSSBr2 C18H22Br2N4Pt 21.2 323.49(323.35) 7.41 (7.45) 28.59 (28.85) 3.47 (3.39) 277 (310), 207 (168) 279(7.14),226(-20.2),183(-1.04) 
PHENSSI2 C18H22I2N4Pt 16.3 371.48(372.10) 8.53 (8.55) 32.17 (32.76) 3.68 (3.72) 277(375), 208 (159) 270(3.19), 217(-24.3),181(-1.38) 
5MESSCl2 C19H24Cl2N4Pt 52.9 286.55(285.54) 7.81 (7.72) 31.81 (31.94) 4.50 (4.27) 283 (189), 210 (80) 255(0.93),215(-3.60), 185(-0.45) 
5MESSBr2 C19H24Br2N4Pt 19.9 330.50(332.99) 6.51 (6.41) 26.53 (26.83) 3.68 (3.57) 282 (165), 228 (113) 282 (-0.12), 229(-6.80), 185(-2.31) 
5MESSI2 C19H24I2N4Pt 9.16 378.48(377.81) NA NA NA 282 (337), 209 (154) 282(2.19), 217(-23.9), 304(-1.18) 
56MESSCl2 C20H26Cl2N4Pt 34.7 293.56(294.07) 7.66 (7.52) 32.84 (32.71) 4.69 (4.61) 289 (238), 211(102) 290(4.66), 255(8.56), 214(-3.94) 
56MESSBr2 C20H26Br2N4Pt 45.9 337.51(337.07) 7.14 (6.98) 30.63 (30.26) 3.86 (3.70) 289 (227), 210 (121) 292(6.10), 224(-20.8) 
56MESSI2 C20H26I2N4Pt 10.9 385.49(385.89) 7.91 (7.43) 32.55 (32.53) 4.33 (4.51) 289 (281), 211 (119) 209(-6.29), 251(1.63) 
 
 
Table 2.3.5.3: Summary of cytotoxicity results in GI50 = Concentration (µM) that inhibits cell growth by 50%* 
Complex HT29 
Colon 
n=3-4 
U87 
Glioblastoma 
n=3-4 
MCF-7 
Breast 
n=3-4 
A2780 
Ovarian 
n=3-4 
H460 
Lung 
n=3-4 
A431 
Skin 
n=3-4 
Du145 
Prostate 
n=3-4 
BE2-C 
Neuroblasto
ma 
n=3-4 
SJ-G2 
Glioblastoma 
n=3-4 
MIA 
Pancreas 
n=3-4 
MCF10A 
Breast 
(Normal) 
n=3-4 
ADDP 
Ovarian 
n=3-4 
PHENSSCl2 0.11 ± 0.028 0.81 ± 0.15 0.46 ± 0.069 0.23 ± 0.0058 0.33 ± 0.0088 0.44 ± 0.045 0.11 ± 0.033 0.44 ± 0.050 0.34 ± 0.063 0.21 ± 0.029 0.30 ± 0.0033 0.23 ± 0.026 
PHENSSBr2 0.16 ± 0.015 0.82 ± 0.090 0.53 ± 0.10 0.27 ± 0.023 0.36 ± 0.029 0.68 ± 0.023 0.18 ± 0.010 0.52 ± 0.025 0.42 ± 0.071 0.25 ± 0.010 0.36 ± 0.032 0.28 ± 0.017 
PHENSSI2 0.10 ± 0.0033 0.70 ± 0.055 0.46 ± 0.10 0.24 ± 0.059 0.32 ± 0.031 0.44 ± 0.021 0.11 ± 0.0033 0.37 ± 0.00000 0.31 ± 0.031 0.20 ± 0.013 0.29 ± 0.032 0.25 ± 0.020 
5MESSCl2 0.032 ± 0.0036 0.23 ± 0.033 0.22 ± 0.13 0.25 ± 0.18 0.089 ± 0.018 0.13 ± 0.028 0.023 ± 0.0030 0.25 ± 0.060 0.18 ± 0.034 0.044 ± 0.0045 0.094 ± 0.024 0.056 ± 0.0032 
5MESSBr2 0.035 ± 0.0058 0.20 ± 0.029 0.087 ± 0.032 0.044 ± 0.012 0.070 ± 0.0091 0.11 ± 0.015 0.025 ± 0.0053 0.20 ± 0.010 0.16 ± 0.044 0.037 ± 0.0046 0.062 ± 0.0083 0.048 ± 0.0046 
5MESSI2 0.032 ± 0.0035 0.22 ± 0.030 0.091 ± 0.026 0.046 ± 0.010 0.065 ± 0.0061 0.10 ± 0.0123 0.027 ± 0.0027 0.20 ± 0.00000 0.16 ± 0.040 0.032 ± 0.0022 0.061 ± 0.0082 0.044 ± 0.0058 
56MESSCl2 0.025 ± 0.0020 0.12 ± 0.018 0.060 ± 0.010 0.037 ± 0.0067 0.048 ± 0.012 0.062 ± 0.013 0.012 ± 0.0017 0.12 ± 0.00000 0.092 ± 0.039 0.028 ± 0.0021 0.044 ± 0.0062 0.036 ± 0.0041 
56MESSBr2 0.021 ± 0.0023 0.090 ± 0.012 0.11 ± 0.056 0.035 ± 0.013 0.032 ± 0.0020 0.061 ± 0.011 0.011 ± 0.0031 0.34 ± 0.18 0.074 ± 0.033 0.024 ± 0.0026 0.034 ± 0.0038 0.033 ± 0.0023 
56MESSI2 0.019 ± 0.0032 0.074 ± 0.014 0.033 ± 0.0068 0.032 ± 0.017 0.027 ± 0.0032 0.037 ± 0.0054 0.025 ± 0.017 0.087 ± 0.063 0.067 ± 0.028 0.022 ± 0.0022 0.030 ± 0.0039 0.027 ± 0.0007 
 
*Incubated for 72 hr
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2.3.6 Synthesis of Pt(IV) complexes of the type [Pt(PL)(AL)(OH)2]2+ 
 
 
Pt(II) complex (1 equiv) was dissolved in the minimum amount of water and silver 
nitrate (2 equiv) was added. The solution was stirred in the dark overnight, and then 
filtered to produce the Pt(II) nitrate salt. This product was then dissolved in water (5.8 
mL) and heated to 70 °C on a water bath. 30% hydrogen peroxide solution (10 equiv 
peroxide) was added and the solution stirred for 2H in the dark at 70 °C. Still in the 
dark, the reaction solution was immediately frozen and lyophilised. Purification was 
achieved through a Sep-Pak® (20 cc, 5 g) C-18 column connected to a pump apparatus 
with UV detector (Bio-Rad, EM-1 Econo™ UV Monitor). The column was activated with 
methanol (20 mL) and then flushed with water (~40 mL) until the UV absorbance 
equilibrated. The crude lyophilised platinum(IV) product was dissolved in the minimum 
amount of water, loaded onto the column, and eluted with water at a flow rate of 1 
mL/min. Once absorbance began to increase, the first 2-3 mL to elute were collected 
and discarded. The rest of the product was collected together as a colourless band. The 
product solution was reduced to approx. 1-2 mL and was purified through the Sep-Pak® 
process twice more. The product solution was reduced to approx. 3-5 mL and 
lyophilised to produce a white solid. This method was utilised to synthesise; 
[Pt(56Me2phen)(SS-dach)(OH)2]2+ (56MESS(OH)2), [Pt(56Me2phen)(RR-dach)(OH)2]2+ 
(56MERR(OH)2), [Pt(phen)(SS-dach)(OH)2]2+ (PHENSS(OH)2), [Pt(phen)(RR-dach)(OH)2]2+ 
(PHENRR(OH)2), [Pt(5Mephen)(SS-dach)(OH)2]2+ (5MESS(OH)2), [Pt(5Mephen)(RR-
dach)(OH)2]2+ (5MERR(OH)2), [Pt(4Mephen)(SS-dach)(OH)2]2+ (4MESS(OH)2), 
[Pt(4Mephen)(RR-dach)(OH)2]2+ (4MERR(OH)2), [Pt(44BPY)(SS-dach)(OH)2]2+ 
(44BPYSS(OH)2), and [Pt(44BPY)(RR-dach)(OH)2]2+ (44BPYRR(OH)2). Yields and NMR data 
are displayed in Table 2.3.8.1 
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Table 2.3.6.1. Summary of NMR data of dihydroxido complexes, showing chemical shift (ppm) with integration, multiplicity 
and coupling constants. Experiments were performed in D2O, so amine resonances were not observed due to proton 
exchange.  
   Complex   
Label PHENSS(OH)2 PHENRR(OH)2 56MESS(OH)2 56MERR(OH)2 5MESS(OH)2 5MERR(OH)2 4MESS(OH)2 4MERR(OH)2 44BPYSS(OH)2 44BPYRR(OH)2 
H4 9.09 
(d, 2H: CH,k J= 
5.46 Hz) 
9.09 
(d, 2H: CH,k 
J= 6.12Hz) 
9.20 
(d, 1H: CH, J= 
8.67 Hz) 
9.21 
(d, 1H: CH, J= 
8.39  Hz) 
8.96 
(d, 1H: CH, 
J= 8.75 Hz) 
8.96 
(d, 1H: CH, J= 
8.20 Hz) 
- - - - 
H7 - - - - 9.17 
(d, 1H: CH, 
J= 8.37 Hz) 
9.18 
(d, 1H: CH, J= 
8.31Hz) 
9.20 
(d, 1H: CH, J= 
5.65 Hz) 
8.87 
(d, 1H: CH, J= 
5.48 Hz) 
- - 
H3 8.27 
(dd, 2H: CH, J= 
8.19, 8.44 Hz) 
8.27  
(dd, 2H: CH, 
J= 8.53, 8.65 
Hz) 
8.24 
(dd, 1H: CH, 
J=8.50, 8.63 
Hz) 
8.24 
(dd, 1H: CH, 
J=8.20, 8.56 
Hz) 
8.20 
(dd, 1H: CH, 
J= 8.31, 8.54 
Hz) 
8.20 
(dd, 1H: CH, 
J= 8.34, 8.35 
Hz) 
8.10 
(d, 1H: CH, J= 
5.64 Hz) 
7.81 
(d, 1H: CH, J= 
5.82Hz) 
8.12 
(s, 2H: CH) 
8.12 
(s, 2H: CH) 
H8 - - - - 8.28 
(dd, 1H: CH, 
J= 8.60, 8.65 
Hz) 
8.29 
(dd, 1H: CH, 
J= 8.70, 8.65 
Hz) 
8.25 
(dd, 1H: CH, 
J= 8.50, 8.34 
Hz) 
7.95 
(dd, 1H: CH, 
J= 8.54, 8.26 
Hz) 
- - 
H2 9.22 
 (d, 2H: CH, J= 
8.32Hz) 
9.23 
 (d, 2H: CH, J= 
5.49 Hz) 
9.12 
(d, 1H: CH, J= 
5.71Hz) 
9.13 
(d, 1H: CH, J= 
5.53 Hz) 
9.20  
(d, 1H: CH, 
J= 5.65 Hz) 
9.13 
(d, 1H: CH, J= 
5.61Hz) 
9.08 
(d, 1H: CH, J= 
8.24 Hz) 
8.84 
(d, 1H: CH, J= 
8.54 Hz) 
- - 
H9 - - - - 9.12 
(d, 1H: CH, 
J= 5.62Hz) 
9.20 
(d, 1H: CH, J= 
5.73 Hz) 
9.02 
(d, 1H: CH, J= 
5.92Hz) 
9.02 
(d, 1H: CH, J= 
5.82Hz) 
- - 
H5 8.35 
(s,2H; CH) 
8.35 
(s,2H; CH) 
- - - - 8.46 
(d, 1H: CH, J= 
9.13 Hz) 
8.19 
(d, 1H: CH, J= 
9.29 Hz) 
7.48 
(d, 1H: CH, J= 
5.89 Hz) 
7.48 
(d, 1H: CH, J= 
5.79 Hz) 
H6 - - - - 8.16 
(s,1H; CH) 
8.16 
(s,1H; CH) 
8.35 
(d, 1H: CH, J= 
9.13 Hz) 
8.08 
(d, 1H: CH, J= 
8.22Hz) 
8.28 
(d, 1H: CH, J= 
6.01Hz) 
8.28 
(d, 1H: CH, J= 
5.79 Hz) 
CH3 - - 2.85 
(s, 6H; CH3) 
2.84 
(s, 6H; CH3) 
2.91 
(s, 3H; CH3) 
2.90 
(s, 3H; CH3) 
3.08 
(s, 3H; CH3) 
2.86 
(s, 3H; CH3) 
2.49 
(s, 6H; CH3) 
2.50 
(s, 6H; CH3) 
H1’/2’ 3.18 
 (m, 2H; CH2) 
3.19 
 (m, 2H; CH2) 
3.17 
(m, 2H;  CH2) 
3.15 
(m, 2H;  CH2) 
3.17 
(m, 2H;  CH2) 
3.18 
(m, 2H;  CH2) 
3.17 
(m, 2H;  CH2) 
2.69 
(m, 2H;  CH2) 
2.58 
(m, 2H;  CH2) 
2.58 
(m, 2H;  CH2) 
H3’/6’ 2.39  
(d, 2H; CH2, 
J=11.07 Hz) 
3.39  
(d, 2H; CH2, 
J=12.26 Hz) 
2.38 
(d, 2H;  CH2 
J= 10.99 Hz) 
2.37 
(d, 2H;  CH2 J= 
12.45 Hz) 
2.38 
(d, 2H;  CH2 
J= 11.11Hz) 
2.38 
(d, 2H;  CH2 
J= 10.75 Hz) 
2.38 
(d, 2H;  CH2 
J= 11.53 Hz) 
2.19 
(d, 2H;  CH2 
J= 13.18 Hz) 
2.13 
(d, 2H;  CH2 J= 
13.24 Hz) 
2.13 
(d, 2H;  CH2 J= 
13.00 Hz) 
H4’/5’ 1.69 
 (m, 4 H;  CH2) 
1.69 
 (m, 4 H;  CH2) 
1.72 
(m, 4 H;  CH2) 
1.68 
(m, 4 H;  CH2) 
1.69 
(m, 4 H;  
CH2) 
1.68 
(m, 4 H;  CH2) 
1.68 
(m, 4 H;  CH2) 
1.64 
(m, 4 H;  CH2) 
1.61 
(m, 2H;  CH2) 
1.60 
(m, 2H;  CH2) 
H3’/6’ - - - - - - - - 1.38 
(m, 2H;  CH2) 
1.37 
(m, 2H;  CH2) 
H4’/5’ 1.31 
 (m, 2H;  CH2) 
1.31 
 (m, 2H;  CH2) 
1.31 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.31 
(m, 2H; CH2) 
1.31 
(m, 2H;  CH2) 
1.30 
(m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.18 
(m, 2H;  CH2) 
1.18 
(m, 2H;  CH2) 
1H/195Pt 9.78/428.8 965/429.6 9.68/426.5 9.34/430.1 9.43/429.6 9.45/428.9 9.05/428.5 9.12/432.4 8.69/434.1 8.56/433.6 
%Yield 87 85 87 72 85 88 74 79 74 73 
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2.3.7 Synthesis of Pt(IV) complexes of the type [Pt(PL)(AL)(OH)(C2H3O2)]2+ 
 
 
The Pt(II) complex (1 equiv) was dissolved in water (20 mL) and silver acetate (2 
equiv) was added. The solution was stirred in the dark overnight, and then filtered to 
produce the Pt(II) acetate salt. This complex (1 equiv) was dissolved in acetic acid (1.5 
mL). 30% hydrogen peroxide solution (3.5 equiv of peroxide) was added and the 
solution stirred in the dark for 48 h. The solution was precipitated in diethyl ether 
(~100 mL) and cooled to ~4 °C for 16 h, at which point the product had redissolved in 
an immiscible solution which was separated and reduced to a minimal volume. 
This method was utilised to synthesise; [Pt(56Me2phen)(SS-dach)(OH)(C2H3O2)]2+ 
(56MESS(OH)(OAc)), [Pt(56Me2phen)(RR-dach)(OH)(C2H3O2)]]2+ (56MERR(OH)(OAc)), 
[Pt(phen)(SS-dach)(OH)(C2H3O2)]2+ (PHENSS(OH)(OAc)), [Pt(phen)(RR-
dach)(OH)(C2H3O2)]2+ (PHENRR(OH)(OAc)), [Pt(5Mephen)(SS-dach)(OH)(C2H3O2)]2+ 
(5MESS(OH)(OAc)), [Pt(5Mephen)(RR-dach)(OH)(C2H3O2)]2+ (5MERR(OH)(OAc)), 
[Pt(4Mephen)(SS-dach)(OH)(C2H3O2)]2+ (4MESS(OH)(OAc)), [Pt(4Mephen)(RR-
dach)(OH)(C2H3O2)]2+ (4MERR(OH)(OAc)), [Pt(44BPY)(SS-dach)(OH)(C2H3O2)]2+ 
(44BPYSS(OH)(OAc)), and [Pt(44BPY)(RR-dach)(OH)(C2H3O2)]2+ (44BPYRR(OH)(OAc)). 
Yields and NMR data are displayed in Table 2.3.10.1 
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Table 2.3.7.1. Summary of NMR data of Asymmetric (OH)(OAc) complexes, showing chemical shift (ppm) with integration, 
multiplicity and coupling constants. Experiments were performed in D2O, so amine resonances were not observed due to 
proton exchange.  
   Complex  
Label PHENSS(OH)(OAc) PHENRR(OH)(OAc) 56MESS(OH)(OAc) 56MERR(OH)(OAc) 5MESS(OH)(OAc) 5MERR(OH)(OAc) 4MESS(OH)(OAc) 4MERR(OH)(OAc) 44BPYSS(OH)(OAc) 44BPYRR(OH)(OAc) 
H4 9.24 
(d, 2H: CH,k J= 
6.12Hz) 
9.25 
(d, 2H: CH,k J= 
6.67 Hz) 
8.73 
(m, 4H: CH) 
9.16 
(d, 1H: CH, J= 
8.52  Hz) 
8.75 
(d, 1H: CH, J= 
8.19 Hz) 
8.90 
(d, 1H: CH, J= 
8.28 Hz) 
- - - - 
H7 - - - - 9.13 
(d, 1H: CH, J= 
8.37 Hz) 
8.79 
(d, 1H: CH, J= 
4.81Hz) 
9.04 
(d, 1H: CH, J= 
5.65 Hz) 
8.82 
(d, 1H: CH, J= 
5.24 Hz) 
- - 
H3 8.24  
(dd, 2H: CH, J= 
8.16, 8.34 Hz) 
8.25  
(dd, 2H: CH, J= 
5.87, 7.35 Hz) 
7.89 
(dd, 2H: CH, 
J=13.63, 11.46 
Hz) 
8.20 
(dd, 1H: CH, 
J=8.80, 8.93 Hz) 
7.89 
(dd, 1H: CH, J= 
8.66, 8.64 Hz) 
8.75  
(dd, 1H: CH, J= 
5.57, 8.32Hz) 
7.71 
(d, 1H: CH, J= 
5.64 Hz) 
7.75 
(d, 1H: CH, J= 
5.82Hz) 
8.09 
(s, 2H: CH) 
8.41 
(s, 2H: CH) 
H8 - - - 7.89 
(dd, 1H: CH, 
J=8.38, 8.52Hz) 
8.20 
(dd, 1H: CH, J= 
8.69, 8.83 Hz) 
8.29 
(dd, 1H: CH, J= 
5.57, 8.44 Hz) 
7.91 
(dd, 1H: CH, J= 
8.50, 8.34 Hz) 
7.91 
(dd, 1H: CH, J= 
8.47, 8.22Hz) 
- - 
H2 9.06 
 (d, 2H: CH,k J= 
5.57 Hz) 
9.05 
 (d, 2H: CH,k J= 
6.34 Hz) 
- 8.74 
(d, 1H: CH, J= 
5.24 Hz) 
7.95 
(d, 1H: CH, J= 
5.32Hz) 
7.91 
(d, 1H: CH, J= 
5.32Hz) 
8.82 
(d, 1H: CH, J= 
8.24 Hz) 
8.78 
(d, 1H: CH, J= 
8.65 Hz) 
- - 
H9 - - - - 8.72 
(d, 1H: CH, J= 
5.49 Hz) 
8.72 
(d, 1H: CH, J= 
5.49 Hz) 
8.75 
(d, 1H: CH, J= 
5.92Hz) 
8.64 
(d, 1H: CH, J= 
5.82Hz) 
- - 
H5 8.31  
(s,2H; CH) 
8.31  
(s,2H; CH) 
- - - - 8.61 
(d, 1H: CH, J= 
9.13 Hz) 
8.09 
(d, 1H: CH, J= 
5.85 Hz) 
7.75 
(d, 1H: CH, J= 
6.16 Hz) 
7.74 
(d, 1H: CH, J= 
5.67 Hz) 
H6 - - - - 7.67 
(s,1H; CH) 
7.60 
(s,1H; CH) 
8.03 
(d, 1H: CH, J= 
9.13 Hz) 
8.00 
(d, 1H: CH, J= 
6.06 Hz) 
8.60 
(d, 1H: CH, J= 
6.01Hz) 
8.60 
(d, 1H: CH, J= 
6.15 Hz) 
CH3 - - 1.86 
(s, 6H; CH3) 
1.85 
(s, 6H; CH3) 
2.45 
(s, 3H; CH3) 
2.36 
(s, 3H; CH3) 
1.86 
(s, 3H; CH3) 
1.86 
(s, 3H; CH3) 
2.26 
(s, 6H; CH3) 
2.45 
(s, 6H; CH3) 
H1’/2’ 3.18 
 (m, 2H; CH2) 
3.18 
 (m, 2H; CH2) 
2.70 
(m, 2H;  CH2) 
2.70 
(m, 2H;  CH2) 
2.69 
(m, 2H;  CH2) 
2.70 
(m, 2H;  CH2) 
2.68 
(m, 2H;  CH2) 
2.69 
(m, 2H;  CH2) 
3.06 
(m, 2H;  CH2) 
2.57 
(m, 2H;  CH2) 
H3’/6’ 3.38  
(d, 2H; CH2, 
J=10.64 Hz) 
3.38  
(d, 2H; CH2, 
J=15.56 Hz) 
2.21 
(d, 2H;  CH2 J= 
12.08 Hz) 
2.21 
(d, 2H;  CH2 J= 
12.02Hz) 
2.21 
(d, 2H;  CH2 J= 
12.09 Hz) 
2.20 
(d, 2H;  CH2 J= 
12.31Hz) 
2.19 
(d, 2H;  CH2 J= 
11.53 Hz) 
2.19 
(d, 2H;  CH2 J= 
13.18 Hz) 
2.30 
(d, 2H;  CH2 J= 
11.41Hz) 
2.11 
(d, 2H;  CH2 J= 
13.39 Hz) 
H4’/5’ 1.69 
 (m, 2H;  CH2) 
1.69 
 (m, 2H;  CH2) 
1.66 
(m, 2H;  CH2) 
1.66 
(m, 2H;  CH2) 
1.66 
(m, 2H;  CH2) 
1.65 
(m, 2H;  CH2) 
1.66 
(m, 2H;  CH2) 
1.65 
(m, 2H;  CH2) 
1.62 
(m, 2H;  CH2) 
1.62 
(m, 2H;  CH2) 
H3’/6’ - - 1.47 
(m, 2H;  CH2 ) 
1.48 
(m, 2H;  CH2 ) 
1.47 
(m, 2H;  CH2) 
1.45 
(m, 2H;  CH2) 
1.45 
(m, 2H;  CH2) 
1.45 
(m, 2H;  CH2) 
1.37 
(m, 2H;  CH2) 
1.37 
(m, 2H;  CH2) 
H4’/5’ 1.29 
 (m, 2H;  CH2) 
1.29 
 (m, 2H;  CH2) 
1.24 
(m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.23 
(m, 2H;  CH2) 
1.22 
(m, 2H;  CH2) 
1.22 
(m, 2H;  CH2) 
1.22 
(m, 2H;  CH2) 
1.24 
(m, 2H;  CH2) 
1.17 
(m, 2H;  CH2) 
1H/195Pt 9.54/543.9 9.35/564.5 9.13/572.6 9.16/544.6 9.25/551.9 9.25/531.9 8.72/539.5 8.75/543.4 8.72/536.6 8.75/540.8 
%Yield 54 43 52 48 46 57 55 47 46 49 
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2.3.8 Synthesis of 2-aminoethyldiclofenacamide (enDCF) 
 
 
 
2-(2,6-Dichloroanilino)-phenylacetic acid (DCF) was dissolved in a minimal 
amount of chloroform before 2 equivalents of 1,2-ethylenediamine (en) were added at 
room temperature. The solution was left to sit overnight after which it produced large 
clear crystals which were the filtered and washed with chloroform. Yield 95 %.1H NMR 
(400 MHz, d-DMSO) δ 7.37 (d, 2H: CH, J= 8.34 Hz), 7.20 (d, 1H: CH, J= 7.14 Hz), 7.00 (m, 
2H; CH), 6.82 (t, 1H, CH, J= 7.74 Hz), 6.37(d, 1H: CH, J= 8.19 Hz), 0.92 (m, H; NH), 4.1(m, 
H; NH). 
 
2.3.9 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane) 
(DMSO)2 ]2+ 
 
 
PHENSSCl2 (50 mg) was dissolved in 10 mL of DMSO and stirred at 40 oC overnight 
at which point the suspension had fully dissolved. The crude product was then either 
used for further synthesis or extracted using 6 washes of 25 mL Chloroform. Yield 96 
%.1H NMR (400 MHz, d-DMSO) δ 11.85 (d, 2H: CH, J=5.40 Hz), 11.58 (d, 2H: CH, J= 8.55), 
10.79 (m, 4H: CH/ CH3), 5.30 (m, 2H: CH), 4.72 (m,12H: CH3), 4.57 (m, 2H: CH), 3.96 (m, 
2H: CH), 3.83 (m, 2H: CH), 3.53 (m, 2H: CH), 195Pt -600.8 ppm. 
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2.3.10 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane) (2-aminoethyldiclofenacamide)2]2+ 
 
PHENSS(DMSO)2 (100 mg, 1 equiv) and 2.2 equivalents of 2-
Aminoethyldiclofenacamide (DCF-en) were dissolved in 30 mL water and stirred at 70 
oC for 20 min before being taken to dryness under vacuum, producing a pale yellow 
residue. Then 50 mL of absolute ethanol was added to the flask and let to stir at 40 oC 
for a further 12 hr. The grey suspension was filtered and the filtrate reduced under 
pressure to ~ 3 mL. The crude product was then precipitated with 20 mL diethyl ether. 
The precipitate was filtered and washed thrice with ether (3 mL). To remove all traces 
of solvent, the produce was taken up in ~5 mL of water and freeze dried to produce a 
plate yellow powder. Yield 85 %, 1H NMR (400 MHz,d-Acetone) δ (PHENSS peaks) 8.89 
(d, 2H: CH, J= 8.42Hz), 8.01 (dd, 2H: CH, J= 8.13, 8.41Hz), 9.11 (d, 2H: CH, J= 5.26 Hz), 
8.13 (s,2H; CH), 2.69, (m, 2H; CH2), 2.25 (d, 2H; CH2, J=12.81Hz), 1.69 (m, 2H;  CH2), 1.54 
(m, 2H;  CH2), 1.29 (m, 2H;  CH2): (enDCF peaks) 7.23 (d, 2H: CH, J= 8.08 Hz),  7.12(d, 2H: 
CH, J= 7.50 Hz), 6.91(t, 4 H: CH, J= 8.03 Hz), 6.85(t, 4 H: CH, J= 7.72 Hz), 6.70(t, 2H: CH, 
J= 7.54 Hz),6.21(d, 4 H: CH, J= 7.95 Hz), 195Pt -2820.1. 
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2.3.11 Synthesis of Pt(IV) complexes of the type 
[Pt(PL)(AL)(OH)(succinimide)]2+ 
 
 
PHENSS(OH)2 (1 equiv) was stirred in a minimal amount of water (~1 mL per 150 
mg) with succinic anhydride (5 equiv) for 1 hr at 45 oC. The product was then 
precipitated in diethyl ether, then filtered and washed with more ether (3 mL). The 
product was then dissolved in water and freeze fried to produce a pale yellow powder. 
This method was repeated for 5MESS and 56MESS with no modifications. 
 
Table 2.3.7.1. Summary of NMR data of [Pt(PL)(AL)(OH)(Succ) complexes, showing 
chemical shift (ppm), integration, multiplicity and coupling constants. Experiments were 
performed in D2O, so amine resonances were not observed. 
Complexes 
Label PHENSS(OH)(Succ) 5MESS(OH)(Succ) 56MESS(OH)(Succ) 
H4 9.07 (d, 2H: CH,k J= 8.13Hz) 9.15 (d, 1H: CH, J= 8.45 Hz) 9.08(m, 4H: CH) 
H7 - 8.93 (d, 1H: CH, J= 8.45 Hz) - 
H3 8.25 (dd, 2H: CH, J= 8.16, 8.34 Hz) 8.18 (dd, 1H: CH, J= 8.46, 8.64 
Hz) 
8.35 (dd, 2H: CH, J=8.45, 8.42 Hz) 
H8 - 8.26 (dd, 1H: CH, J= 8.69, 8.83 
Hz) 
- 
H2 9.27 (dd, 2H: CH, J= 5.71 Hz, 8.37  
Hz) 
9.26 (dd, 1H: CH, J= 5.50Hz, 
8.64Hz) 
9.31 (dd, 2H: CH, J= 5.51 Hz, 8.47  
Hz) 
H9 - 9.18 (dd, 1H: CH, J= 5.45 Hz, 
8.33 Hz ) 
- 
H5 8.33 (s,2H; CH) - - 
H6 - 8.12 (s,1H; CH) - 
CH3 - 2.89 
(s, 3H; CH3) 
8.21 (s, 6H; CH3) 
H1’/2’ 3.19  (m, 2H; CH2) 3.17 (m, 2H;  CH2) 3.15(m, 2H;  CH2) 
H3’/6’ 2.39  (m, 2H; CH2) 2.38 (m, 2H;  CH2 J=) 2.38(m, 2H;  CH2) 
H4’/5’ 1.68  (m, 2H;  CH2) 1.65 (m, 2H;  CH2) 1.66 (m, 2H;  CH2) 
H3’/6’ - - - 
H4’/5’ 1.29 (m, 2H;  CH2) 1.29 (m, 2H;  CH2) 1.29 (m, 2H;  CH2) 
H1* 2.22 (m, 2H;  CH2) 1.20 (m, 2H;  CH2) 1.22 (m, 2H;  CH2) 
H2* 2.16 (m, 2H;  CH2) 2.14 (m, 2H;  CH2) 2.13 (m, 2H;  CH2) 
1H/195Pt 9.37/542.1 9.32/543.6 9.46/ 546.5 
%Yield 85 80 86 
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2.3.12 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane) (OH)(succinatePFP) ]2+ 
 
 
This synthesis is a modified version of the method of Yuan et al.74 PHENSS(Succ)(OH) 
(1.46 mg, 1 equiv.), DCC (122.6 mg, 3 equiv.)and pentafluorophenol (PFP) (110.4 mg, 3 
equiv.) were added to 3 mL dry DMA. This solution was then stirred at room 
temperature for 14 hr after which it was filtered and washed with DMA. The product 
was then taken up in water and freeze dried to produce a yellow solid, yield 54.8 mg, 
29.5%.  1H NMR (400 MHz,D2O) δ 9.09 (d, 2H: CH,k J= 8.45 Hz), 8.31 (dd, 2H: CH, J= 
8.16, 8.34 Hz), 9.37 (dd, 2H: CH, J= 5.31 Hz, 8.37  Hz), 8.39 (s,2H; CH), 3.23  (m, 2H; 
CH2), 2.35  (m, 2H; CH2), 1.68  (m, 2H;  CH2), 1.29 (m, 2H;  CH2), 2.22 (m, 2H;  CH2), 2.16 
(m, 2H;  CH2). 
 
2.3.13 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane) (OH)(PSMA) ]2+ 
 
 
PhenSS(OH)(SuccPFP) (1 equiv) was dissolved in 4 mL of dry DMA, then 2 equiv of 
DCL was added. This solution was stirred at room temperature for 5 minutes before 
N,N-diisopropylethylamine (DIPEA) (6 equiv) was added. The solution was then dried 
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under vacuumed and purified using the Reveleris® X2 flash chromatography system 
fitted with a Reveleris® reverse phase C18 4 g column and eluted with MeOH and H2O 
(see 2.2 Instrumentation for details). The product was then taken up in water and 
freeze dried to produce a yellow solid, yield 32.4 mg, 23%.  1H NMR (400 MHz, D2O) δ 
(PHENSS peaks) 8.87 (d, 2H: CH, J= 8.30 Hz), 7.98 (dd, 2H: CH, J= 8.30, 13.80 Hz), 8.47 
(d, 2H: CH, J= 5.39 Hz), 8.11 (s,2H; CH), 2.70, (m, 2H; CH2), 2.20 (m, 2H; CH2), 1.69 (m, 
2H;  CH2), 1.22 (m, 2H;  CH2): (DCL peaks): 4.02 (dd, 1H, CH, J= 5.13 Hz), 3.98 (dd, 1H, 
CH, J= 5.23 Hz), 3.09 (t, 2H, CH2, J= 7.13 Hz), 2.91 (t, 2H, CH2, J= 7.18 Hz), 2.32 (t, 2H, 
CH2, J= 5.43 Hz), 2.16 (t, 2H, CH2, J= 5.45 Hz), 1.99 (m, 2H;  CH2), 1.82 (m, 2H;  CH2), 1.68 
(m, 2H;  CH2), 1.56 (m, 6H;  CH2), 1.43 (m, 2H;  CH2), 1.28 (m, 4H;  CH2). 
 
2.4 Cytotoxicity methodology 
Cytotoxicity assay studies were performed at Calvary Mater Newcastle Hospital, 
Waratah, NSW Australia. In vitro studies were performed according to described 
methods in literature and from Calvary Mater facility. N4-TLs were prepared in DMSO as 
stock treatment (30 mM) solutions and stored at -20 ˚C. All of the cell lines were 
cultured in a humidified atmosphere with 5 % CO2 at 37 ˚C. The cancer cell lines were 
maintained in Dulbecco’s modified eagle’s medium (DMEM; Trace Biosciences, 
Australia) supplemented with 10 % fetal bovine serum, sodium bicarbonate (10 mM), 
penicillin (100 IU mL-1), streptomycin (100 μg mL-1), and L-glutamine (4 mM). The non-
cancer MCF10A cell line was cultured in DMEM.F12 (1:1) cell culture media, 5% heat-
inactivated horse serum, supplement with penicillin (50 IU mL-1), streptomycin (50 μg 
mL-1), HEPES (20 mM), L-glutamine (2 mM), epidermal growth factor (20 ng mL-1), 
hydrocortisone (500 ng mL-1), cholera toxin (100 ng mL-1), and insulin (10 μg mL-1). 
Cytotoxicity was determined by plating cells in duplicate in 100 mL medium at a density 
of 2500-4000 cells per well in 96-well plates. On day 0, (24 hr after plating) when cells 
were in logarithmic growth, medium (100 μL) or without the test agent was added to 
each well. After 72 hr ligand exposure growth inhibitory (GI) effects were evaluated by 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, and 
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absorbance was read at 540 nm. An eight-point dose-response curve was produced, 
from which the GI50 value was calculated, representing the drug concentration at which 
cell growth is inhibited by 50% based on the difference between the optical density 
values on day 0 and those at the end of drug exposure. Cell lines MCF10A, MCF7, MIA 
PaCa-2, BE(2)-C, U-87, NCI-H460, HT-29, and DU 145 are from ATCC (American Type 
Culture Collection); A2780 and, A431 are from ECACC (European Collection of 
Authenticated Cell Cultures) and; SJ-G2 are from St Jude's childrens hospital (Australia). 
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Chapter 3 Results and Discussion 
3.1   Synthesis 
3.1.1 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)]2+ 
PHENSS was synthesised as an intermediate to form [Pt(1,10-
phenanthroline)(1S,2S-diaminocyclohexane)X2]2+ and to assess the efficiency of 
synthesis using flow. All of the optimization of the flow procedure was accomplished 
using PHENSS. When synthesised using batch chemistry, phen and [Pt(1S,2S-
diaminocyclohexane)Cl2]2+ were suspended in 50 mL of deionized water in a 1.1:1 
molar ratio and refluxed for 24 hours. During this time the chlorine ligands dissociate 
from the platinum complex and the 1,10-phenanthroline coordinates the nitrogen 
forming the soluble product PHENSS. As both starting materials are insoluble in water 
while the product is soluble, the reaction turns initially from an opaque to clear 
solution upon completion, making it an easy reaction to monitor. The volume of the 
crude solution is then reduced under pressure so that it may be purified using a Vac 
20cc (5 g) C18 Sep-Pak© column connected to a pump apparatus with UV detector (Bio-
Rad, EM-1 Econo™ UV Monitor). The column was activated with methanol (20 mL) and 
then flushed with water (~40 mL) until the UV absorbance equilibrated. Any platinum-
diaminocyclohexane impurities elute first through the column followed by the product 
which is bright yellow in colour. Phen and other impurities do no flow through the 
column when eluted with water, and remain in the top few millimetres of the column. 
The pure sample collected is reduced in volume to roughly 2 mL whereupon it is frozen 
and dried via sublimation (86.5 % yield). 
For the continuous flow synthesis of PHENSS the column was fitted sealed and 
the outlet fitted with a 100 psi pressure adaptor before being filled with water and 
heated to 140 oC. Once heated, deionized water was then eluted through the vessel at 
a flow rate 0.05 mL/min for 1.5 hrs (Figure 3.1.1.1). The volume of the crude solution is 
then reduced under pressure so that it may be filtered. The pure sample collected is 
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reduced in volume to roughly 2 mL whereupon it is frozen and dried via sublimation. 
This method relies on both starting materials being insoluble so that they do not flow 
through the glass frit fitted at the end of the column whereas the product is soluble 
and can flow through the frit into the collection vessel, avoiding a further purification 
step. Phen is moderately soluble in water at high temperatures, so at moderate 
temperatures it was hypothesised that the reagents would react while only dissolving a 
minimal amount of phen. However, this was not the case; instead the yield rose 
steadily as temperature increased, with the yield doubling every 20 oC increase until 
140 oC (Figure 3.1.1.4) at which point experiments were stopped due to safety concerns 
with the high pressure and temperature in the glass column. It is also interesting to 
note that the optimal temperature (140 oC) is significantly higher than the temperature 
used in the batch synthesis (100 oC).  
 
 
  
Figure 3.1.1.1: Set up for flow chemistry synthesis of [Pt(PL)(AL)]
2+ 
Optimization 
PhenSS was chosen as the target product for the optimization process due to its 
relative simplicity and inexpensiveness of the starting materials. The product of the 
batch synthesis of PhenSS was used to produce a standard HPLC curve so that the 
fractions off the flow apparatus (Figure 3.1.1.2) could be quantitatively analysed. The 
retention time was ~3.7 min when using gradient elution from 10% acetonitrile to 
100% over 15 minutes.  
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Figure 3.1.1.2: Standard HPLC curve for PhenSS from gradient elution of acetonitrile. 
Optimisation of Time 
Using the apparatus depicted in Figure: 3.1.1.1, deionised water was run through 
the reaction column containing [Pt(dach)Cl2] and phen (1:1.1 mole ratio) for three 
hours at a flow rate of 0.25 mL/min at 80 oC. Every 15 min a 3 mL sample was collected 
for analysis. These fractions were then assessed by HPLC and their concentration 
calculated using the standard curve. The resulting curve of concentration output over 3 
hrs (Figure 3.1.1.3) suggests that the product starts forming in between t15 and t30 and 
reaches its maximum rate at t60 before slowly declining right up until t180. 
From this it was ascertained that 1.5 hrs was the optimal reaction time, and 
consequently all subsequent optimisation reactions went for 1.5 h. Later this time was 
reconsidered after reviewing the area under the curve between t90 and t180. Another 
experiment was conducted for 2.5 hrs which resulted in an average percent yield of 
18.9% which is significantly lower than the average percent yield gained from the same 
reaction conditions run for only 1.5 hr, 28.1 %. These results appear to be contradictory 
and suggest that the use of continuous flow chemistry for the synthesis of these 
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inorganic compounds does not produce the reproducible results reported for organic 
synthesis. 
 
Figure 3.1.1.3: Concentration of fractions collected off the column containing 
[Pt(dach)Cl2] and 1,10-Phenanthroline (1:1.1 mole ratio) every 15 minutes for three 
hours at a flow rate of 0.25 mL/min at 80 oC. 
Optimisation of Temperature 
The experiment was repeated, this time running for 1.5 hrs with the temperature 
changing for each run. Experiments were run for 20, 40, 60, 80 100 and 120 oC. To 
quickly find the yield of each run, a small sample of each was analysed using the HPLC. 
The HPLC data and the standard curve for PhenSS concentration vs temperature was 
used to calculate the concentration of PhenSS in the crude product which subsequently 
allowed the yield to be calculated. When analysed by HPLC it was found that no 
significant product formation occurred until 80 oC was reached, and appeared to 
increase at higher temperatures. The experiment was repeated twice more, this time 
only with the temperatures 80, 100 and 120 oC so as not to waste reagents. The results 
revealed that the yield increased exponentially as temperature increased (Figure 
3.1.1.4). 
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Figure: 3.1.1.4: Average percentage yield of PhenSS calculated based on HPLC trace, 
synthesised at 80, 100 and 120 oC, with a flow rate of 0.25 mL/min with a [Pt(DACH)Cl2] 
to 1,10-phenanthroline more ratio of 1:1.1. 
These results were very promising and in order to confirm this trend and produce 
a higher yield, 140 oC was also assessed. To reach this temperature a pressure adapter 
was fitted to the ‘out’ tubing that brought the pressure inside the column to 100 PSI, 
which prevented the water from evaporating. The resulting yield (calculated suing the 
HPLC-standard curve method) was far above 100% and this brought the reliability of 
the yield calculation method into question. The reactions were repeated however, this 
time the crude product was purified using Vac 20cc (5 g) C18 Sep-Pak© columns and the 
product was weighed. The result of this data series (Figure 3.1.15) clearly shows that 
the yields calculated via the HPLC-standard curve method were vastly exaggerated. 
Each subsequent yield was calculated using the new method as it was more accurate 
and more appropriate to compare to the yield gained from the batch chemistry 
method. 
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Figure: 3.1.1.5: Average percentage yield of PhenSS calculated based on isolated pure 
complex, synthesised at 80, 100 and 120 oC, with a flow rate of 0.25 mL/min and a 
[Pt(dach)Cl2] to phen ratio of 1:1.1. 
To find the optimal flow rate, a single run at 0.10 mL/min was undertaken and 
the % yield was determined to be higher than that of 0.25 mL/min; a faster flow rate 
was not assessed as it was predicted that the relationship would be linear and thus 
such a run would be a waste of resources. The reaction was repeated for 0.25, 0.10, 
0.05 and 0.02 mL/min in duplicate (Table 3.3.1). It is suspected that the partial 
solubility of the phen was the reason that a reduced flow rate is beneficial; if the flow 
rate was too high, a solid white phen precipitate formed in the collection vessel. Thus it 
was concluded that the 1,10-phenanthroline had reached a high enough temperature 
to become soluble, and so could flow through the glass frit of the outlet; reducing the 
flow rate increases the chance of reaction as the 1,10-phenanthroline has more of a 
chance to react with the [Pt(dach)Cl2] before leaving the reaction vessel.  
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Table 3.3.1: Percent yield of [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane)]2+  
Flow Rate [Pt(SSDACH)Cl2] 
 (mg) 
1,10-PHEN 
 (mg) 
Predicted 
 yield 
Actual 
Yield 
Yield 
 (%) 
0.25 98.0 53.2 144.5 43.8 30.3 
0.25 108.4 54.2 159.8 41.3 25.8 
0.10 97.8 51.5 144.1 53.2 37.1 
0.10 118.2 65.3 183.9 61.5 33.4 
0.05 110.2 73.2 162.4 59.0 36.3 
0.05 118.0 78.8 183.6 91.1 49.6 
0.02 101.9 53.5 150.2 24.4 16.3 
0.02 76.7 43.4 174.2 65.7 37.7 
 
Table 3.3.1 shows that the yield increases as the flow rate drops, the yield 
reaches a maximum at 0.05 mL/min before dropping off at 0.02 mL/min. This indicated 
that the optimal flow rate is 0.05 mL/min; however, it was noticed that when the flow 
rate was 0.05 mL/min the water level within the reaction vessel dropped slightly and 
even more so when the flow rate was 0.02 mL/min. The reaction vessel was standing 
upright with the inlet at the base, and so a drop in the water level means that the 
water was leaving the vessel as a gas, preventing the product from being filtered out of 
the reaction solution into the collection vessel. Thus the drop in yield after 0.05 mL/min 
could be due to the fact that the product was unable to leave the reaction vessel rather 
than because the product was only being synthesised at a small yield. This theory is 
supported by the inconsistency of the yields calculated for flow rates of 0.05 and 0.02 
mL/min. When the materials remaining inside the vessel were prepared for NMR  it 
was revealed that only the starting products remained, there was no trace of PhenSS; 
thus the inconsistency of the results was not due to the positioning of the vessel. 
The continuous flow method is not advantageous over the traditional batch 
method. Although the flow method produced PhenSS in just one 16th of the time of 
batch method; at its best the flow method produced just half the predicted yield 
compared with 80-85% from the batch method. Continuous flow chemistry typically 
produces consistent reliable results however this was not the case when used to 
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synthesise PhenSS. Due to poor yields and inconsistent results, the continuous flow 
method development was terminated. Despite being unsuccessful, this is as far as I am 
aware, first time continuous flow chemistry has been used for the synthesis of this type 
of coordination compound, as there are no other references to such methods in the 
literature. 
 
3.1.2 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)]2+, [Pt(1,10-phenanthroline)(1R,2R-
diaminocyclohexane)]2+, [Pt(5 methyl-1,10-phenanthroline)(1S,2S-
diaminocyclohexane)]2+, [Pt(5-methyl-1,10-phenanthroline)(1R,2R-
diaminocyclohexane)]2+ [Pt(5,6 dimethyl-1,10-
phenanthroline)(1S,2S-diaminocyclohexane)]2+, [Pt(5,6 dimethyl-
1,10-phenanthroline)(1R,2R-diaminocyclohexane)]2+ 
PHENSS, PHENRR, 5MESS, 5MERR, 56MESS and 56MERR were synthesised as 
intermediates to form platinum(IV) complexes and to assess the efficiency of batch 
synthesis compared to using flow and, as a part of a series of compounds of which the 
dihydroxy and asymmetric (OH)(OAc) compleses were made. When synthesised using 
batch chemistry, phen and [Pt(SS-dach)Cl2]2+ were suspended in 50 mL of deionized 
water  in a 1.1:1 molar ratio and refluxed for 24 hours. During this time the chlorine 
ligands dissociate from the platinum complex and the PL coordinates the atomic 
nitrogen forming the soluble product [Pt(56Me2phen)(SS-dach]2+. As both starting 
materials are insoluble and the product soluble, the reaction turns initially from an 
opaque to clear solution at completion, making it an easy reaction to monitor. The 
volume of the crude solution is then reduced under pressure so that it may be filtered 
using a Vac 2Occ (5 g) C18 sep-pak column connected to a pump apparatus with UV 
detector (Bio-Rad, EM-1 Econo™ UV Monitor). The column was activated with 
methanol (20 mL) and then flushed with water (~40 mL) until the UV absorbance 
equilibrated. Any dach impurities elute first through the column followed by the 
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product which is bright yellow in colour. The 5,6-dimethyl-1,10-phenathroline and any 
other impurities do not flow through the column when eluted with water, and remain 
in the top few millimetres of the column. The pure sample collected is reduced in 
volume to roughly 2 mL whereupon it is frozen and dried via sublimation. The purity of 
these compounds was confirmed using NMR and HPLC. 
 
3.1.3 The Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)X2]2+ 
For the synthesis of [Pt(phen)(SS-dach)X2]2+ there are two reported methods, 
both of which were modified to suit this type of complex and trialled for the synthesis 
of [Pt(phen)(SS-dach)Cl2]2+. The first synthetic method was a combination of the 
procedure described in Symal A. et al102 and Yamanda M. et al.103 This procedure 
required the in situ generation of the halide gas (in this case Cl2) from the combination 
of the halide salt and a mixture of concentrated sulphuric and nitric acids. The gas 
produced was then passed through a vessel containing PHENSS dissolved in dilute HCl 
(Figure 3.1.4.1). This reaction was left until the gas ceased to form (~3 h) at which point 
the apparatus was flushed with N2 for several hours to remove any excess chlorine. The 
crude product neutralized and produced chlorine gas when the volume was reduced 
under pressure which is highly unfavourable as chlorine gas is highly toxic and cause 
severe respiratory damage. The chlorine gas produced during this reaction corroded all 
of the plastic tubing and the plastic joint clips, demonstrating that the gas was not 
sufficiently contained within the glassware. These observations provide evidence that 
the safety precautions undertaken may not be adequate and thus the N-
halogensuccinimide reaction is preferable. 
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Figure 3.1.4.1: Reaction scheme for the formation of [Pt(Phen)(SS-dach)Cl2]2+ using the 
in situ formation of Cl2 gas. 
 
The second method (NXS method) utilises the oxidating property of N-
halogensuccinimides in order to oxidise platinum whilst also binding halogens to the 
platinum centre. This method achieved oxidation in less than five minutes and is 
significantly less hazardous than the first method, whilst producing the same yield of 
product. Half of the NXS reacts with ethanol to produce HX (where X is Br, Cl, or I) 
which then reacts with the second half of NXS to produce halogen radicals which attack 
the platinum centre;104 reducing it to Pt(IV) to produce the desired product [Pt(1,10-
phenanthroline)(1S,2S-diaminocyclohexane)X2]2+ (Figure 3.1.4.2). However, the 
introduction of the succinimide resulted in the synthesis of impurities where one of the 
axial ligands is succinimide bound via the nitrogen (Figure 3.1.4.3). 
 
62 
 
 
Figure 3.1.4.2: Reaction scheme for the formation of [Pt(1,10phenanthroline)(1S,2S-
diaminocyclohexane)Cl2]2+ using NCS. 
 
 
 
Figure 3.1.4.3: Suggested impurity synthesised using the NXS method. Where X is Br, Cl, 
or I. and where R1 and R2 are either H or CH3. 
 
The presence of this impurity was confirmed both by NMR and Mass 
spectrometry. In proton NMR spectra there is a large peak at 2.7 ppm, which is very 
easily identifiable. A 1H/1H homonuclear correlation spectroscopy (COSY) spectra 
confirmed that this impurity was succinimide; the 2.7 ppm 1H peak corresponded to a 
carbon peak at 29 ppm, which is likely to be a carbon adjacent to a ketone. 
Computational models (completed using Avogadro) were made to predict how binding 
of the halogens and the succinimide were affecting the structure and consequently the 
NMR (Figure 3.1.4.3). These models suggest that the configuration of PhenSS is not 
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changed from their typical planar structure with the addition of bromine on the axial 
ligands. When a succinimide is bound in one of the axial positions there is a significant 
bend in the overall structure and this pushes the dach region toward the halide, which 
explains why there is a shift in the proton NMR peaks in the dach region when the 
impurity is present.  Analysis of mass spectra of these complexes revealed that the 
succinimide binds directly to the Pt centre via the nitrogen, and that there are no 
instances of two succinimide binding. Several attempts were made to separate the di-
halogenated product from the mono-halogenated succinimide impurity; however, it 
appeared that the two major products have the same solubilities and chromatographic 
retention times and thus cannot be separated by filtration, crystallisation, precipitation 
or by changing the counter ions. Standard crystallisation methods did not produce 
crystals or produced crystals which were in low yields and which were inappropriate of 
x-ray crystallography. 
 
 
 
Figure 3.1.4.3: Structure of PHENSSX2 and PhenSSX(succinimide), showing the 
distortion of the DACH region. 
Due to these issues with purification, the reaction conditions were revisited to 
attempt to favour the formation of one product over another. It was found that a pure 
PhenSSXsuccinimide could be synthesised by refluxing 1 mol equiv of PhenSS with 2.4 
mol equiv of NXS in a solution of 50:50 (v:v) ethanol and water at 78 oC. The purity of 
these compounds was confirmed by NMR and the structure confirmed by mass 
spectrometry. Interestingly, the addition of hydrochloric acid pushed the reaction to 
favour the dihalogen product. Presumably this is due to the interaction between the 
succinimide by-product and the acid, preventing the coordination of the succinimide. 
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Perhaps due to the high concentration of ions in the solution encouraging the halogen 
to remain bound to the Pt. This method resulted in the successful synthesis of 
PHENSSCl2, PHENSSBr2, PHENSSI2, 5MESSCl2, 5MESSBr2, 5MESSI2, 56MESSCl2, 
56MESSBr2, and 56MESSI2. 
Another hurdle that needed to be surmounted was the purification of these 
complexes. The presence of unbound succinimide remained in all samples both 
asymmetric and symmetric, which was easily seen in the NMR spectra. Again the 
products and the succinimide have almost the same solubility and could not be 
separated by filtration, precipitation or Sep-Pak C18 column. However, free succinimide 
is mildly soluble in toluene, and so if the crude complex was washed 5 times with 
toluene only a small amount of succinimide removed. It was concluded that extended 
washing could considerably improve the purity of the sample so a soxhlet apparatus 
was set up. The soxhlet needed to be run for a minimum of two weeks before the 
impurity was undetectable. In some cases the soxhlet resulted in the appearance of 
other small unidentified impurities but, these were easily removed using flash 
chromatography. The soxhlet and the flash chromatography both contributed to the 
overall loss of yield (16.3- 30.4%). The identity and purity of the compounds was 
confirmed using NMR spectra, elemental microanalysis, circular dichroism (CD), 
synchrotron radiation circular dichroism (SRCD), UV spectra and HPLC. 
 
3.1.4 Synthesis of [Pt(5,6-dimethylphenanthroline)(1S,2S-
diaminocyclohexane)X2]2+ and [Pt(5-methylphenanthroline)(1S,2S-
diaminocyclohexane)X2]2+ 
The synthesis of 56MESSX2 and 5MESSX2 was much the same as for PhenSSX2 
however; they tended to need slightly more time to react and produced more darkly 
coloured products in lower yields. The complexes were also much harder to purify in 
most cases which also contributed to a lower average yield. Some compounds 
however, such as 5MESSCl2 (yield of 52.9%), separated more cleanly in the flash 
chromatography system resulting in a significantly higher yield overall than complexes 
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that were run through the soxhlet then the flash. None of these complexes were 
completely purified during the two week soxhlet and they all had to be run through the 
flash chromatography needing a minimum of 5 runs each. Each flash chromatography 
elution resulted in approximately 5 mg of compound being lost, only some of which can 
be attributed to the removal of the impurity. The 5MESSX2 complexes were slightly 
more pure after the soxhlet and were pure after fewer runs through the flash 
chromatography system than the 56MESSX2 complexes. The number of methyl 
substituents appears to influence the ease of purification in this case. Interestingly, 
despite the succinimide impurity having a white appearance, as the purity of the 
desired complex improved, it became lighter in colour. This was particularly the case 
for the iodo complexes which turned from a dark brown crude product to pale yellow 
when pure. There may have been some traces of the halogen which would not be 
picked up in a proton NMR, which are removed by either the toluene wash or through 
flash chromatography. The yellow colour may also be due to an unidentified impurity 
that was also present during the previous synthesis of platinum(IV) dihydroxido 
complexes, which were yellow/cream coloured at first but then white after extensive 
chromatography purification.100 The extensive chromatography did not result in a white 
final product, and so these complexes may just be yellow.  The range of yields for these 
complexes was 9.16 - 52.9% due to the extensive amount of purification required. The 
identity and purity of the compounds was confirmed using NMR, microanalysis, CD, 
synchrotron CD, UV spectra and HPLC. 
 
3.1.5 Synthesis of Pt(IV) complexes of the type [Pt(PL)(AL)(OH)2]2+ 
56MESS(OH)2, 56MERR(OH)2, PHENSS(OH)2, PHENRR(OH)2, 5MESS(OH)2, 
5MERR(OH)2, 4MESS(OH)2, 4MERR(OH)2, 44BPYSS(OH)2, and 44BPYRR(OH)2 were 
synthesised as a part of a series of compounds of which the dihydroxido and 
asymmetric (hydroxide-acetato) compounds were made. To synthesise these 
complexes, the complementary Pt(II) complex was first converted to the nitrate salt. 
This was achieved through the addition of silver nitrate, which removes chloride from 
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solution as silver chloride, allowing nitrate to become the counter-ion. Once filtered, 
the Pt(II) is dried via sublimation, ready to be converted to Pt(IV). 1 equiv. of 
[Pt(PL)(AL)]NO3 was dissolved in a minimal amount of water and stirred at 70 oC with 10 
equiv. of H2O2 for 2 h, after which the solution was immediately frozen and dried via 
sublimation. Within the 2 h, the free radicals of the peroxide react with the Pt centre, 
forming a co-ordinate bond in the axial position allowing the addition of the solvent (in 
this case acetic acid) in the remaining axial position.  If the reaction is left to heat for 
too long, heated on the hot plate rather than in a water bath or, exposed to light 
before completely dry; there is a risk that some of the newly formed Pt(IV) being 
reduced to platinum(0) (Pt(0)) which appears in the form of a black precipitate. The 
complex when removed from the freeze dryer is pale yellow, fluffy and highly sensitive 
to static due to its 2+ charge. The lyophilised solid is then dissolved in a minimal 
volume of water and filtered using a Vac 2Occ (5 g) C18 sep-pak column connected to a 
pump apparatus with UV detector (Bio-Rad, EM-1 Econo™ UV Monitor). The column 
was activated with methanol (20 mL) and then flushed with water (~40 mL) until the UV 
absorbance equilibrated. Pt(0) and other impurities remain at the head of the column. 
The aquilots containing the pure sample are combined and reduced in volume to 
roughly 2 mL whereupon it is frozen and dried via sublimation again. If after one run 
through the column the sample is still quite yellow, this process was repeated but at a 
slower elution rate until the complex is almost completely white; with the exception of 
BPYSS(OH)2 and BPYRR(OH)2 which remained bright yellow after several elutions 
through a column, suggesting that this is its characteristic colour rather than evidence 
of an impurity. The purity of these compounds was confirmed using NMR and HPLC. 
 
3.1.6 Synthesis of Pt(IV) complexes of the type [Pt(PL)(AL)(OH)(C2H3O2)]2+ 
56MESS(OH)(OAc), 56MERR(OH)(OAc), PHENSS(OH)(OAc), PHENRR(OH)(OAc), 
5MESS(OH)(OAc), 5MERR(OH)(OAc), 4MESS(OH)(OAc), 4MERR(OH)(OAc), 
44BPYSS(OH)(OAc), and 44BPYRR(OH)(OAc) were synthesised as a part of a series of 
complexes of which the dihydroxy and asymmetric (OH)(OAc) compounds were made. 
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This method was adopted from that used by B. Pages to synthesise 
PHENSS(OH)(OAc).100 Although successfully synthesised, method difficulties were 
encountered when attempting to purify the final product. As a result only partial 
characterisation was achieved, and only for one complex, PHENSS. 
Although in the aforementioned paper the Pt(II) was first converted to the 
acetate salt,  the standard method on converting to the nitrate salt as described in 
Section 3.1.6, was trailed with PHENSS however the resulting complex was a mix of 
Pt(II) dihydroxy and asymmetric compounds so the remainder of the complexes were 
made by first converting to the acetate salt. To convert to the acetate salt, Pt(II) 
chloride (1 equiv)  was dissolved in a minimal amount of water with 2 equiv of silver 
acetate, and stirred overnight in the dark. As the reaction is stirred, the acetate ions 
from the silver acetate exchange with the chloride from the Pt salt, producing silver 
chloride and the nitrate salt of the Pt(II) complex. The silver chloride precipitates out as 
a very fine white precipitate which must be filtered with membrane filters with a pore 
size of 45 micrometres or less. As mentioned previously the solution must be kept in 
darkness as the silver chloride is photosensitive. Once filtered the Pt(II) is dried via 
sublimation, it is ready to be converted to Pt(IV). Due to the use of acetic acid in the 
Pt(IV) synthesis, the Pt(II) chloride was converted to the acetate salt, rather than the 
nitrate salt, prior to oxidation. To oxidise, 1 equiv. of Pt(II) acetate was stirred in the 
dark at room temperature for two days with 3.5 equiv. of hydrogen peroxide and 25 
equiv of acetic acid (as a 1.5 mL solution). The reaction was kept at room temperature 
to prevent rapid activation of the peroxide and coordination of two hydroxide ligands, 
in order to allow time for the acetardo ligands to coordinate. It was determined that 
even a mild heat (45 oC) resulted in an NMR with many impurities. The acetic acid is 
added in excess to maximise binding as the hydroxyl ligands tend to be more reactive, 
thus the peroxide volume must be kept to a minimum in order to avoid the synthesis of 
the dihydroxy product. After 48 hrs the solution was added dropwise to diethyl ether, 
resulting in a very fine precipitate formed which was then refrigerated in an attempt to 
increase the yield. After 24 hrs more precipitate formed and collected in a fluffy 
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aggregate toward the bottom of the flask. Some of the precipitation had also adhered 
to the flask. Water (2 mL) was added to increase the volume of the small immiscible 
layer that formed so that the ether could be removed (along with any Pt(II) impurities) 
via separation rather than by filtration. This was beneficial as the presence of water 
from the acetic acid solution would contribute to the low yield and, the precipitate 
adhered to the flask could also be collected. The next step was to evaporate the 
solution to obtain a NMR spectrum; however, drying resulted in the formation of Pt(II) 
and Pt(0) and an impure NMR spectra, instead the volume was reduced to 0.5 mL and 
the complexes stored in solution. In solution, the Pt(II) concentration increased slightly 
over a period of 3 months but, the majority of the solution remained as Pt(IV). It is 
hypothesised that the acetate ligands are in constant exchange with the solvent, and 
when the solvent is removed, the acetate ligands are removed along with it. Despite 
being unable to isolate the complexes for characterisation, the complexes in solution 
could still be used to build further asymmetric Pt(IV) complexes. 
 
3.1.7 Synthesis of 2-aminoethyldiclofenacamide  
Diclofenacamide (DCF) was dissolved in a minimal amount of chloroform before 2 
equivalents of 1,2-ethylenediamine (en) were added at room temperature. This 
reaction appeared to occur instantaneously in quantitative yields. The solution was left 
to sit overnight, after which large clear crystals were obtained, which were the filtered 
and washed with chloroform. The crystals were large, completely clear, and colourless; 
in some instances there was a slight beige colour to the crystals at which point they 
were recrystallised in ethanol to produce colourless crystals. (95 % yield) 
 
3.1.8 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane) 
(DMSO)2]2+  
PhenSS(DMSO)2 was synthesised as a part of a reaction scheme used to attach 
DCF to platinum, the concept being that DMSO would be such a good leaving group 
that any other potential ligands in solution would bind in preference. Based on 
69 
 
methods previously published, stirring a Pt complex solution that has chloride ligands 
with a DMSO solvent at a low temperature, will result in the synthesis of a DMSO 
ligated complex.105 PHENSSCl2 was synthesised as per the method described in Section 
2.3.5. However, the purification steps were not undertaken in order to save time and 
with the understanding that upon precipitation, the succinimide by-product from the 
synthesis of the dichlorido intermediate would be separated from the final product. 
The crude solution was instead dried under vacuum and added as is to 16 mL of DMSO. 
The reaction can be easily monitored visually as the starting reagent is not soluble in 
DMSO; thus a clear solution indicates that the chlorido ligands have exchanged with 
the solvent. In the first attempt 100 mg of PHENSS was used to synthesise the 
dichlorido intermediate, which was then dissolved in 16 mL of solvent, as per the 
literature method. In an attempt to reduce the amount of DMSO used, this volume was 
reduced to 2 mL per 100 mg starting material, this reaction did not turn clear, 
indicating that the desired product was not formed. The sample was heated 
incrementally over a period of a week to see if this would allow the ligands to exchange 
without increasing the volume of DMSO. A temperature of up to 120 oC was used 
without the observation of a clear solution, at which point the idea was scraped and 
more DMSO was added. Optimisation revealed that a minimum of 7 mL DMSO is 
required for every 100 mg of starting reagent. In the published method mentioned 
above the final product was precipitated in diethyl ether; this method was unsuccessful 
using PHENSS, which would not precipitate even when cooled to 4 oC with excess ether. 
In order to extract the product from DMSO, the solution was washed with 5 x 50 mL of 
dicloromethane (DCM). Although the DCM layer appeared to go cloudy when dried 
there was no trace of Pt complex in the NMR spectrum. Extraction with a mixture of 
briny water with DCM or ether were attempted but, when these methods could not 
remove the DMSO, elution through a flash chromatography C18 column was trailed. 
However, multiple runs were required, removing less than 1 mL of DMSO per run. 
Because continued runs through the flash would result in lost product, a chloroform 
extraction was trailed and successfully separated the Pt(IV) complex from DMSO; 
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however the 195Pt NMR signal was suspiciously similar to that of PHENSS(Cl)2, as was 
the 1H spectra. The compound was consequently made in deuterated DMSO so that the 
final product could be characterised without the axial ligand exchanging. The resulting 
solution had no trace of Pt(II) nor the dichloro starting materials. Although all the peaks 
could be assigned the amine peaks appear much further upfield then expected, 
resonating close to the phenanthroline peaks. For reaction with DCF, the crude solution 
was used and the final product precipitated out of the DMSO solution so it could be 
characterised as per usual. (96 % yield) 
 
3.1.9  Synthesis of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)(2-aminoethyldiclofenacamide)2]2+ 
As mentioned previously, the starting reagent for this method PHENSS(DMSO)2 
was not isolated from the reaction solvent before being used. 5 equiv. of en-DCF was 
added directly into the DMSO solution, at which point the colour changed from pale 
yellow to dark orange, back to almost clear before becoming dark green, all within the 
space of a minute; after several minutes the solution had turned to a purple black 
colour. The reaction was then stirred at 70 oC for 20 minutes. The 20 minute stir time 
was increased in instances where the en-DCF crystals had not fully dissolved, and this 
had no noticeable impact on the purity or quantity of the yield. Once the en-DCF had 
dissolved (or after at least 20 minutes) the DMSO was diluted by a factor of 4 with 
absolute ethanol and stirred overnight at 40 oC. The ethanol was then removed via 
evaporation and the remaining liquid was filtered before being eluted through the flash 
chromatography unit using a C18 reverse phase column using a low water to methanol 
gradient. Two peaks eluted through the column; one did not contain anything 
recognisable on a proton NMR and the other contained the final product along with 
some impurities. This fraction was reduced to a minimal volume and run through the 
same column again at a higher gradient to remove these impurities. The final product 
was an off white powder that was slightly soluble in water and very soluble in 
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methanol. The typical yield from this reaction scheme (Figure 3.1.10.1) is about 50% of 
the PHENSS starting material. (85 % yield) 
 
Figure 3.1.10.1: Reaction scheme for the synthesis of PHENSS(enDCF). 
 
3.1.10 Synthesis of of Pt(IV) complexes of the type 
[Pt(PL)(AL)(OH)(succinimide)]2+ 
This is a general method that was developed to work with all compounds 
developed in the lab of the type in order to offer new synthetic pathways. This 
unpublished method was in part developed by Krishant Deo who developed how to 
selectively synthesise the mono and di-succinate analogues.106 This process appears to 
72 
 
be time dependant which explains why preliminary testing resulted in the near pure 
synthesis of the mono succinate product. Mild conditions were used to prevent 
reduction and diethyl ether was used to wash the product clean of any Pt(II) or 
succinate impurities. 
 
3.1.11 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane) 
(OH)(succinatePFP)]2+ 
[Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane)(OH)(succinatePFP)]2+ was 
synthesised as an intermediate for PHENSS(OH)(DCL) synthesis, to facilitate the 
formation of the amide bond. DCC (dicyclohexylcarbodiimide) was used as a coupling 
agent ensuring that the addition occurred on the carboxylic acid and not the hydroxide 
ligand. The DCC temporarily bonds to the carboxylic acid, and then leaves upon 
nucleophilic substitution. During this reaction dicyclohexylcarbodiimide is transformed 
to dicyclohexylurea which is insoluble in water and can thus be removed by washing 
with organic solvents. The solvent was dried to prevent water disturbing the reaction. 
The reaction worked on the first attempt and further development was not undertaken 
as the product was produced in good yield and purity. (29.5 % yield) 
 
3.1.12 Synthesis of [Pt(1,10-phenanthroline)(1S,2S-diaminocyclohexane) 
(OH)(DCL) ]2+ 
The conjugation of DCL to the asymmetric PHENSS(IV) has been attempted 
previously.100 However, the final product was unable to be isolated in sufficient 
quantities to be characterised aside from evidence of the product in a mass spectrum. 
The method of DCL-platinum conjugation has advanced since this attempt,107 and so 
there is cause to revisit this reaction in the context of polyaromatic platinum 
complexes. DIPEA was used as a coupling reagent and when added to the solution 
resulted in near immediate precipitation. The PFP moiety is an excellent leaving group 
and was attached so that this step would have a higher yield. The reaction solution was 
filtered and washed with ether, however upon investigation the precipitate was not 
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pure and had traces of both Pt(II) and unbound DCL. The flash chromatography unit 
was employed to separate the three complexes which resulted in good separation after 
2 elations through the C18 column. The overall yield was very low, which can be 
attributed to several factors; firstly there was not full conversion with a significant 
portion of the Pt(IV) being reduced in solution to Pt(II), during filtration the filtrate was 
not passed through the filter a second time to avoid contamination however some 
product was probably lost here, and each elution through the chromatography unit 
results in approximately 5 mg of lost product. (23 % yield) 
 
 
Figure 3.1.13.1: Reaction scheme for the synthesis of PHENSS(OH)(DCL).  
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3.2   Characterisation 
NMR is a technique used to measure the energy released when the magnetic spin 
on particular atoms in a molecule returns to its ground state after being stimulated to a 
higher spin state. The energy profile of the solution is displayed in an NMR spectrum. 
When an atom is close to another that is electronegative, it becomes de-shielded and 
its magnetic spin is more easily reversed. Thus if an atom were to bind to a complex 
there would be a quantitative change in the NMR spectra and the site of binding could 
be determined by noting where on the spectrum variations occur.108 The NMR 
spectrometers can measure the spin change of different elements including 1H, 195Pt 
and, 13C. An NMR spectrum of hydrogen atoms is called a proton or 1H NMR which was 
used in this spectrum due to the relative abundance of this atom in the compounds 
being characterised and in any impurities, thus making it perfect for confirming the 
structure and determining the purity. 
UV absorbance spectroscopy is can be used to determine the characteristic 
absorbance spectra of complexes which provide structural information as well as 
information about the colour. UV spectra were recorded on a Cary 1E 
spectrophotometer at room temperature in the 200–400 nm range, using a 10 mm 
quartz cell. All samples were automatically corrected for solvent baseline. Titration of a 
stock solution into a known volume of solvent allowed the calculation of the extinction 
coefficient, a measure of the absorbance at a given wavelength per mass density. 
Circular dichroism (CD) is a technique used to measure chirality. This is achieved 
my measuring the absorption of elliptically polarised light traveling normal through the 
sample. The chirality of the compound can be determined by comparing the CD spectra 
of two enantiomers which will have spectra that are mirror images to each other: this 
occurs because one will absorb the right had polarised light whilst the other absorbs 
left-handed polarised light. CD spectra were obtained using a Jasco-810 
spectropolarimeter at room temperature. The instrument was left to equilibrate for 30 
minutes prior to use. Spectra were obtained in a 10 mm quartz cell, and were 
measured from 400–200 nm with a data pitch of 1 nm, bandwidth of 1 nm and 
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response time of 1 second. For each spectrum, 40 accumulations were collected and a 
water baseline was subtracted 
Synchrotron Radiation Circular Dichroism (SRCD) experiments were performed at 
the Centre for Storage Ring Facilities, Aarhus, Denmark (ASTRID and ASTRID2). The 
instrument was calibrated for magnitude and polarisation daily, using D-10-
camphorsulfonic acid (CSA, 7.4 mg mL−1). For all experiments the ratio of the 192.5 : 
290 nm peaks ranged between 2.07 and 2.09. Data as averaged triplicate scans were 
collected from 170-350 nm in 1 nm steps. Samples were loaded into a circular sealed 
0.1 mm pathlength quartz cuvette. A water baseline was run prior to each new 
complex run and subtracted from each data set. 
Flash Chromatography, samples were purified using the Reveleris® X2 flash 
chromatography system fitted with a Reveleris® reverse phase C18 4 g column. The 
column was equilibrated to 3% MeOH for 2.4 min at 8 mL/min, and the samples eluted 
for 9 minutes with the UV detector sensitivity on high and detecting at 230, 254 and 
280 nm. Samples between 20 and 100 mg were prepared in ~1-2 mL H2O, injected and 
eluted at a flow rate of 8 mL/min. The column was eluted with 3% MeOH for 6 minutes 
then MeOH was increased to 100% over 1 minute, kept steady for 1 minute before 
returning to 3% over another minute. Only one peak was detected and this was 
collected in 10 mL fractions. 
 
3.2.1 The characterisation of Pt(II) complexes of the type [Pt(PL)(AL)]2+ 
The characterisation of PHENSS, PHENRR, 56MESS, 56MERR, 5MESS, 5MERR, 
4MESS, 4MERR, 44BPYSS and, 44BPYRR was achieved using a combination of 1H proton 
NMR spectra and 1H 195Pt heteronuclear multiple quantum correlation (HMQC) spectra. 
These complexes have been characterised in previously published papers. 34 The NMR 
characterization of Pt(II) complexes of the type [Pt(PL)(AL)]2+ was achieved using a 
combination of 1H proton NMR spectra and 1H/195Pt heteronuclear multiple quantum 
correlation (HMQC) spectra. The HMQC peak was the same as other platinum 
complexes of the same type reported in the literature.109 An example of the HMQC 
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spectra is shown in Figure 3.3.1.1, the 195Pt chemical shift of –2823.4 ppm is 
significantly different to the two starting Pt complexes [Pt(SS-dach)Cl2] and K2PtCl4 
(−3282 and −1650 ppm, respectively). The correlation between the Pt centre and the 
aromatic resonance 8.96 ppm confirms the coordination of the 1,10-phenanthroline. 
 
Figure 3.2.1.1: The 1H–195Pt HMQC spectrum of PHENSS in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
The proton spectra were almost identical the literature with very minor chemical 
shifts which occur due to staking of the 1,10-phenanthroline ligands in solution.110 
Figure 3.2.1.2 shows the 1H spectra of PHENSS with the peaks labelled with the 
corresponding proton. The aromatic region for PHENSS was assigned as follows: the 
singlet at 8.07 ppm was assigned to H5 and H6 as the two protons will share the peak 
location due to the symmetry of the complex and there are no protons on the adjacent 
carbons. The doublet of doublets (dd) at 7.97 ppm was assigned to H3 and H8, again 
the symmetry resulted in the combining of the two peaks and the presence of the 
protons on the adjacent carbons resulting in a dd splitting pattern due to coupling. The 
remaining two doublet (d) peaks in the aromatic region were merged in the spectra; 
however, they could still be distinguished due to the larger coupling constant of H2 and 
H9 due to the proximity to the nitrogen. Thus the 8.48 ppm doublet J= 8.50 Hz was 
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assigned to H4 and H7 and the doublet at 8.87 ppm J= 5.35 Hz was assigned to H2 and 
H9. The resonances for the aliphatic region were consistent with NMR spectra reported 
in the literature with the same axillary ligands. The aliphatic peaks were assigned as 
follows: the multiplet at 2.71 ppm was assigned to H1’ and H2’ as the two protons 
closest to the amine. The remaining protons do not display symmetry due to the 
conformation of the dach ring. Consequently each of the remaining peaks corresponds 
to 2 protons and can be assigned based on their proximity to the Pt(II) centre and 
amine groups.   H3’ and H6’ are the next closed and were consequently assigned to the 
multiples at 2.21 and 1.65 ppm. The remaining two peaks  at 1.46 and 1.24 ppm were 
assigned to H4’’ and H5’ The amine proton resonances were not visible due to 
exchange with D2O. 
 
Figure 3.2.1.2: The 1H NMR spectra of PHENSS in D2O, showing proton assignment; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
The above assignment was repeated for the NMR spectra of PHENSS, PHENRR, 
56MESS, 56MERR, 5MESS, 5MERR, 4MESS, 4MERR, 44BPYSS, and 44BPYRR, the results 
are summarised in Table 2.3.4.1 (Chapter two). There were some minor differences in 
the resonances for these complexes, particularly in the aromatic region where the 
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relative concentration of each solution affects the stacking of the phenanthroline 
region and thus affects the resonance of the H2, 9 and H4,7 peaks; and the symmetry 
of the complexes changed the splitting pattern for complexes with ligands in the 4 and 
5 positions. 
3.2.2 The characterisation of complexes of the type [Pt(PL)(AL)] X2]2+ 
Each complex was characterised using a combination of NMR spectroscopy, 
HPLC, circular dichroism (CD spectroscopy), UV spectroscopy, micro analysis and ESI-
MS. The NMR spectra produced peaks consistent with those seen in the literature for 
similar compounds with little to no impurities detected.32 The compound broke down 
in the HPLC column producing 2 by-products. It was hypothesised that this was due to 
the trifluoroacetic acid (TFA) however the elution profiles did not improve when TFA 
was removed from the mobile phase or when formic acid was used. The benchtop CD 
spectra confirmed that the chirality of the starting materials was retained during 
synthesis; whilst the synchrotron spectra provided additional information about the 
structure revealing dramatic differences from similar, previously published Pt(IV) 
complexes. ESI-MS also resulted in significant fracturing of the compounds; although 
the correct mass peak could be identified in all samples, in some spectra this was not 
the main peak. 
The NMR characterization of PHENSSCl2, PHENSSBr2 and PHENSSI2 was achieved 
using a combination of 1H proton NMR spectra and 1H 195Pt heteronuclear multiple 
quantum correlation (HMQC) spectra. The HMQC peak was significantly different to 
other platinum complexes of the same type reported in the literature.109 Typically a 
Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2 will demonstrate a 195Pt resonance at 450 
ppm whereas the complexes synthesised in this work have 195Pt resonate at 
approximately -630 ppm, this confirms the presence of the halide ligands in place of 
the typical hydroxyl ligands seen in the literature.40 An example of the HMQC spectra is 
shown in Figure 3.2.2.1, the 195Pt chemical shift of -645.8 ppm is significantly different 
to the two starting Pt complexes [Pt(SS-dach)Cl2] and K2PtCl4 (−3282 and −1650 ppm, 
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respectively). The correlation between the Pt centre and the aromatic resonance 9.19 
ppm confirms the coordination of the 1,10-phenanthroline. 
 
Figure 3.2.2.1: The 1H–195Pt HMQC spectrum of PHENSSCl2 in D2O, displaying the 
correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
The proton spectra were almost identical to similar complexes in the literature with 
very minor chemical shifts which occur due to staking of the 1,10-phenanthroline 
ligands stacking in solution.110 Figure 3.3.2.2 shows the 1H spectra of PHENSSCl2 with 
the peaks labelled with the corresponding proton. The aromatic region for PHENSSCl2 
was assigned as follows: the singlet at 8.33 ppm was assigned to H5 and H6 as the two 
protons will share the peak location due to the symmetry of the complex and there are 
no protons on the adjacent carbons. The doublet of doublets (dd) at 8.27 ppm was 
assigned to H3 and H8, again the symmetry resulted in the combining of the two peaks 
and the presence of the protons on the adjacent  carbons resulting in a dd splitting 
pattern due to coupling. The remaining two doublet (d) peaks in the aromatic region 
were merged in the spectra; however, they could still be distinguished due to the 
smaller coupling constant of H2 and H9 due to the proximity to the nitrogen. Thus the 
9.03 ppm doublet J= 8.31 Hz was assigned to H4 and H7 and the doublet at 9.09 ppm J= 
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5.56 Hz was assigned to H2 and H9. The resonances for the aliphatic region were 
consistent with NMR spectra reported in the literature with the same axillary ligands. 
The peaks were almost identical with only slight variants in the ppm. The amine proton 
resonances were not visible due to exchange with D2O. 
The above was repeated for the NMR spectra of PHENSSBr2 and PHENSSI2, the 
results of which are summarised in Table 2.3.5.1 (Chapter two). There were some 
minor differences in the resonances for these complexes, particularly in the aromatic 
region where the relative concentration of each solution affects the stacking of the 
phenanthroline region and thus affects the resonance of the H2,9 and H4,7 peaks. 
 
 Figure 3.3.2.2: The 1H NMR spectra of PHENSSCl2 in D2O, showing proton assignment; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
The NMR characterization of 56MESSCl2, 56MESSBr2 and 56MESSI2 was achieved 
using a combination of 1H proton NMR spectra and 1H 195Pt heteronuclear multiple 
quantum correlation (HMQC) spectra. The spectra were analysed in the same way as 
for complexes PhenSSX2, however, in the aliphatic region for complexes had an 
additional peak due to the presence of the methyl group on the 1,10-phenanthroline, 
apart from this there were no changes in the region and peaks were assigned using the 
same rational. The results of the NMR spectra are summarised in Table 2.3.5.1 (Chapter 
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two), the 1H and 195Pt spectra of 56MESSCl2 are shown in Figures 3.2.2.3 and 3.2.2.4, 
respectively. 
 
Figure 3.2.2.3: The 1H NMR spectra of 56MESSCl2 in D2O, showing proton assignment; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
 
Figure 3.2.2.4: The 1H–195Pt HMQC spectrum of 56MESSCl2 in D2O, displaying the 
correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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The NMR characterization of 5MESSCl2, 5MESSBr2 and 5MESSI2 was achieved 
using a combination of 1H proton NMR spectra and 1H 195Pt heteronuclear multiple 
quantum correlation (HMQC) spectra. The spectra were analysed in the same way as 
above however, these complexes are split due to their asymmetry. The aliphatic region 
for complexes 4-9 had an additional peak due to the presence of the methyl group on 
the 1,10-phenanthroline but again the remaining peaked were assigned using the same 
rational described above. The results of the NMR spectra are summarised in Table 
2.3.5.1 (Chapter two), the 1H and 195Pt spectra of 56MESSCl2 are shown in Figures 
3.2.2.5 and 3.2.2.6, respectively. The relative 195Pt resonances of these complexes 
appear to be more dependent on the halide ligand than the variations in the PL. For 
example complexes with bromo ligands tended to have a much lower ppm of around -
960 ppm and those with iodo ligands tended to have the highest 195Pt peak of 
approximately -640 ppm. 
 
Figure 3.2.2.5: The 1H NMR spectra of 5MESSCl2 in D2O, showing proton assignment; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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Figure 3.2.2.6: The 1H–195Pt HMQC spectrum of 5MESSCl2 in D2O, displaying the 
correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
The UV characterisation of PHENSSCl2, PHENSSBr2 and PHENSSI2 was achieved 
titration of a stock solution into a known volume of solvent allowed the calculation of 
the extinction coefficient (ε). Figure 3.2.2.7 shows the titration curves and the 
extinction coefficient calculation of PHENSSCl2, achieved by plotting the absorbance 
against concentration change at each of the two peaks (278 and 208 nm). The UV 
spectra of each PHENSSX2 compound is compared in Figure 3.2.2.8, allowing the 
analysis of the structural change of the molecule caused by each halide ligand. The 
spectra of complexes where the axial ligands are chloro or iodo complexes are similar 
to the spectra of Pt(IV)PHENSS complexes with hydroxido axial ligands reported in the 
literature.40 Complexes with bromo axial ligands are easily distinguishable with 
distinctive board, shoulder band between 220 and 250 nm. Despite the appearance of 
this shoulder the change in axial ligand did not result in a change in absorbance i.e. the 
peaks had almost identical wavelengths. The UV data for PHENSSCl2, PHENSSBr2 and 
PHENSSI2 is summarised in Table 3.2.4.1 in Section 3.2.4. 
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Figure 3.2.2.7: Titration of a stock solution of PHENSSCl2 into a known concentration of 
H2O and the resulting extinction coefficient calculated based on the two main peaks at 
278 (red)  and 208 nm (blue). 
 
Figure 3.2.2.8: UV spectra of PHENSSCl2 (green), PHENSSBr2 (purple)and, PHENSSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
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The UV characterisation of 56MESSCl2, 56MESSBr2 and 56MESSI2 was achieved 
titration of a stock solution into a known volume of solvent allowed the calculation of ε. 
Figure 3.3.2.9 shows the titration curves and the extinction coefficient calculation of 
56MESSCl2, achieved by plotting the absorbance against concentration change at each 
of the two peaks (289 and 211 nm). The UV spectra of each 56MESSX2 compound is 
compared in Figure 3.2.2.10, allowing the analysis of the structural change of the 
molecule caused by each halide ligand. The spectra of complexes where the axial 
ligands are chloro or iodo complexes are similar to the spectra of Pt(IV)PHENSS 
complexes with hydroxido axial ligands reported in the literature.109 Complexes with 
bromo axial ligands are easily distinguishable with distinctive board, shoulder band 
between 220 and 30 nm on top of the shoulders appearing between 250 and 230 nm 
which are present in all three spectra. Despite the appearance of this shoulder the 
change in axial ligand did not result in a change in absorbance i.e. the peaks had almost 
identical wavelengths. The UV data for 56MESSCl2, 56MESSBr2 and 56MESSI2 is 
summarised in Table 3.2.4.1 in Section 3.2.4. 
 
Figure 3.2.2.9: Titration of a stock solution of 56MESSCl2 into a known concentration of 
H2O and the resulting extinction coefficient calculated based on the two main peaks at 
289 (red) and 211 nm (blue). 
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Figure 3.2.2.10: UV spectra of 56MESSCl2 (green), 56MESSBr2 (purple)and, 56MESSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
The UV characterisation of 5MESSCl2, 5MESSBr2 and 5MESSI2  was achieved 
titration of a stock solution into a known volume of solvent allowed the calculation of ε. 
Figure 3.2.2.11 shows the titration curves and the ε calculation of 5MESSCl2, achieved 
by plotting the absorbance against concentration change at each of the two peaks (283 
and 210 nm). The UV spectra of each 56MESSX2 compound is compared in Figure 
3.2.2.12, allowing the analysis of the structural change of the molecule caused by each 
halide ligand. The spectra of complexes where the axial ligands are chloro or iodo 
complexes are similar to the spectra of Pt(IV)PHENSS complexes with hydroxido axial 
ligands reported in the literature.40 Complexes with bromo axial ligands are easily 
distinguishable with distinctive board shoulder band between 220 and 250 nm. The 
bromo ligand for 5MESSX2 complexes has a hysochromic effect significant enough that 
the peak is outside of the measured wavelengths (less than 200 nm) while the other to 
5MESSX2 complexes peak at ~280 nm well within the measured wavelength. Despite 
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the appearance of this shoulder the change in axial ligand did not result in a change in 
absorbance i.e. the peaks had almost identical wavelengths. The UV data for 
56MESSCl2, 56MESSBr2 and 56MESSI2 is summarised in Table 3.2.4.1 in Section 3.2.4. 
 
 
Figure 3.2.2.11: Titration of a stock solution of 5MESSCl2 into a known concentration of 
H2O and the resulting extinction coefficient calculated based on the two main peaks at 
283 (red) and 210 nm (blue). 
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Figure 3.2.2.12: UV spectra of 5MESSCl2 (green), 5MESSBr2 (purple) and, 5MESSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
If the complexes of the type [Pt(PL)(AL)(X)2]2+ are compared in terms of the 
polypyridyl ligands another trend appears; the transitions of the phenanthroline ligand 
produce a consistent difference in the bands with the band at 280-290 nm which then 
shifts (blue) in order of the number of methyl groups (i.e. PhenSS(X)2 complexes 
followed by 5MeSS(X)2 and then 56MeSS(X)2 complexes). A similar trend is observed for 
the weak bands above 300 nm. The 56MeSS(X)2 compounds also display a shoulder at 
approximately 240 nm which is not present for 5MeSS(X)2 and PhenSS(X)2. Figure 
3.2.2.13 illustrates the effect the polypyridal ligand has on the di-chloro complexes. All 
complexes were measured at 24.7 µM and thus the decrease in absorption intensity 
from PHENSS to 56MESS followed by 5MESS can be attributed to hypochromic effect. 
Interestingly the same trend is followed for the bathochromic effect (red shift) in the 
peaks between 250 and 300 nm, where PHENSS<56MESS<5MESS. For the shoulder 
between 260 and 280 nm, 5 and 56MESSCl2  have much broader shoulders than 
PHENSSCl2. This trend continues for the shoulder between 220 and 250 nm where 
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PhenSS has the narrowest peak while 5MESS has a slight shoulder and 56MESS has a 
significant board shoulder. 
 
  
Figure 3.2.2.13: UV spectra of PHENSSCl2 (green), 5MESSCl2 (purple) and, 56MESSCl2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
Figure 3.2.2.14 illustrates the effect the polypyridal ligand has on the di-bromo 
complexes. All complexes were measured at 28.7 µM and thus the decrease in 
absorption intensity from PHENSS to 5MESS followed by 56MESS for the peak between 
260 and 300 nm can be attributed to hypochromic effect; interestingly following a 
different trend to the di-chloro complexes. Unlike the di-chlorocomplexes the 
hypochromic effect for the peak between 200 and 230 nm did not follow the same 
trend: instead 5MESS had the highest absorption intensity (had a hypercromic effect) 
followed by PHENSS and lastly 56MESS which had the lowest intensity (had a 
hypochromic effect). As with the di-chloro complexes the trend in hypochromic effect 
was the same as that for the red shift for the peak between 250 and 300 nm i.e. 
wavelength increased from PHENSS to 5MESS followed by 56MESS. The order so the 
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most t least broad shoulder for the peak between 200 and 250 nm is also different to 
that of the di-chloro complexes; PHENSS has the broadest shoulder followed by 
56MESS and lastly 5MESS which barely has a shoulder at all.  
  
Figure 3.2.2.14: UV spectra of PHENSSBr2 (green), 5MESSBr2 (purple) and, 56MESSBr2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
Figure 3.2.2.15 illustrates the effect the polypyridal ligand has on the di-iodo 
complexes. All complexes were measured at 28.7 µM and thus the decrease in 
absorption intensity from PHENSS to 5MESS followed by 56MESS for the peak between 
260 and 300 nm can be attributed to hypochromic effect; interestingly following the 
same trend as the di-bromo complexes and a different trend to the di-chloro 
complexes. Unlike the di-bromo complexes the trend in hypochromic effect is the same 
for the two main peaks. The blue shift trend 56MESS>5MESS>PHENSS is followed for 
both peaks however, the hypsochromic effect is more extreme in the peak between 
200 and 300 nm. 
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Figure 3.2.2.15: UV spectra of PHENSSI2 (green), 5MESSI2 (purple) and, 56MESSI2 (blue); 
at room temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected 
for solvent baseline (H2O). 
The benchtop CD spectra of all 9 complexes were taken first as a simple 
characterisation process. It was hypothesised that these spectra would be relatively 
basic similarly to the PHENSS(OH)2 benchtop CD spectra which showed only very small 
peaks from ~270 nm to 400 nm with a sharp drop off starting at ~270 nm  which 
continues downward until 200 nm (the lowest wavelength that can be reached with a 
standard benchtop machine).  The spectra for the PHENSSX2 complexes were very 
similar to this as seen in Figure 3.2.2.16. The CD spectra for the 56MESSX2 (Figure 
3.2.2.17) and 5MESSX2 (Figure 3.2.2.18) a similar trend occurred between 250 and 400 
nm however at wavelengths below this point  there are one or two peaks and although 
the spectra has a similar drop off, it appeared as though it might be on an upward 
trend.  
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Figure 3.2.2.16 illustrates the effect of the halogen axial ligand on PHENSS. The 
three spectra are very similar up until 320 nm at which point the spectra for PHENSSBr2 
varies significantly. Both PHENSSCl2 and PHENSSI2 have an absorption band at 226 nm 
but for PHENSSBr2 this absorption band is red shifted to 280 nm indicating a clockwise/ 
positive chirality shift. The height of the band followed by a much sharper drop off 
compared to the two other compounds also suggests that PHENSSBr2 have significantly 
different velocities due to different indices of refraction for left or right polarised light. 
It appears that all three spectra have another band that is reaching its minimum just 
before 200 nm but this cannot be relied upon due to the limitations of the benchtop 
spectrometer. 
 
Figure 3.2.2.16: CD spectra of PHENSSCl2 (green), PHENSSBr2 (purple) and, PHENSSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
 
Figure 3.2.2.17 illustrates the effect of the halogen axial ligand on 56MESS 
complexes. Interestingly these complexes do not follow the same trends as the PHENSS 
complexes for which the bromo complex showed the most deviation. For the 56MESS 
complexes the chloro ligands appear to have the most significant effect on the 
absorption of polarised light. The three spectra are very similar up until ~250 nm; at 
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which point both the 56MESSBr2 and 56MESSI2 start on an upward trend towards 
another peak at 332 nm whereas, 56MESSCl2 continues on its downward trend until 
210 nm where it reaches a minimum and begins to rise again. There appears to be a 
shoulder along this downward trend that has a similar shape to the two peaks seen in 
the other spectra, this suggests that although the indices of refraction are different 
there are still structural similarities causing similar absorption of polarised light. The 
absorption band at 210 nm is shared between the three complexes although the 
intensity is different for each. 56MESSCl2 has the most negative value followed by 
56MESSBR2 and lastly 56MESSI2. This trend follows the same trend as both the 
electronegativity and size of these ligands and thus it can be hypothesised the at one or 
both of these factors are effecting the structure of 56MESS such that their absorption 
of polarised light is effected at this wavelength. 
 
 
Figure 3.2.2.17:  CD spectra of 56MESSCl2 (green), 56MESSBr2 (purple) and, 56MESSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
Figure 3.2.2.18 illustrates the effect of the halogen axial ligands on 5MESS 
complexes. These complexes showed the least consistency in their spectra. Similarly to 
the complexes previously seen the specra are very similar and almost flat up unit ~ 230 
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nm at which point there are some major variations. The spectra of 5MESSI2 appears to 
be similar to that of the PHENSS complexes whereas, the spectra of 5MESSBr2 appears 
to be similar to those of the 56MESS complexes while 5MESSCl2 has a unique spectra. 
One of the key differences between 5MESS and both 56MESS and PHENSS is its 
asymmetry. Thus it can be hypothesised that the asymmetry of the phen is affecting 
the conformation of the molecule when the halogen ligands are coordinated. 
Interestingly the magnitude of effect cannot be correlated to the size or 
electronegativity of the halides unlike the 56MESS complexes. 
 
Figure 3.2.2.18: CD spectra of 5MESSCl2 (green), 5MESSBr2 (purple) and, 5MESSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline (H2O). 
The SRCD spectra for the dihydroxy Pt(IV) spectra were obtained to see if the 
absorbance would increase at lower nm. This was not the case and the larger nm range 
did not result in any extra characterisation data the spectra simply continued on a 
downward slope. The SRCD spectra of the [Pt(AL)(PL)X2]2+ complexes was collected as 
they showed some promise of having additional peaks below 200 nm. These 
experiments were successful in observing additional peaks for which there were some 
interesting trends when comparing based on the axial ligands or the polyaromatic 
ligand which helps to give some insight into the band systems. 
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The SRCD data was processed using OriginPro8.5, all spectra were smoothed 
using 11 point smoothing which ensured a clean line without disturbing any of the peak 
intensities or shapes (Figure 3.2.2.20). The units were then changed to molar ellipticity 
([Θ]); this normalises the data based on their concentration, molecular mass and, the 
difference between the pathlengths of the two cells used to obtain the spectra 
(difference of 0.00029 cm). Molar ellipticity makes comparison between the spectra 
more valid.  
 
Figure 3.2.2.20: SRCD spectra of PHENSSBr2 showing the raw data (black) and the 11 
point smoothed data (red) at room temperature in the 170-400 nm range, using a 0.1 
mm cell, corrected for solvent baseline (H2O). 
Figure 3.2.2.21 similarly to Figure 3.2.2.16, shows the effect of the halogen axial 
ligand on the PHENSS complexes. The spectra from 400 to 200 nm has already been 
discussed, the SRCD spectra allows us to see that the similarity in polarised light 
absorption between PHENSSCl2 and PHENSSI2 continues, with the only differential 
factor being the slightly more intense band at 216 nm for PHENSSCl2. The equivalent 
peak for PHENSSBr2 is red shifted, appearing at 226 nm and thus has a more positive 
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chirality shift. The second peak revealed by the SRCD at ~ 180 nm was similar for the 
three compounds however, PHENSSCl2 had a large shoulder at   212 nm.                                                           
 
Figure 3.2.2.21: SRCD spectra of PHENSSCl2 (black), PHENSSBr2 (red) and, PHENSSI2 
(blue); at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected 
for solvent baseline (H2O). 
Figure 3.2.2.22 similarly to Figure 3.2.2.18, shows the effect of the halogen axial 
ligand on the 5MESS complexes. The spectra from 400 to 200 nm has already been 
discussed, the SRCD spectra allows us to see the similarity in polarised light absorption 
between the three complexes more easily. At this scale the spectra appear more similar 
and a trend appears. Similarly to the PHENSS complexes the intensity of the band 
increases as the size of the ligand increases and as the electronegativity decreases, that 
is 5MESSI2 has the most intense band followed by 5MESSBr2 and then 5MESSCl2. Thus it 
can be hypothesised that either the size of the ligand or the electronegativity affect the 
conformation of the complex such that they have indices or refraction for left and/or 
right polarised light. The spectra of 5MESSI2 has by far the more intense absorption 
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band as well as the sharpest, indicating that the iodo ligands have a stronger effect on 
the structure than the other two ligands.  
 
 
Figure 3.2.2.22:  SRCD spectra of 5MESSCl2 (black), 5MESSBr2 (red) and, 5MESSI2 (blue); 
at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for 
solvent baseline (H2O). 
Figure 3.2.2.23 similarly to Figure 3.2.2.17, shows the effect of the halogen axial 
ligand on the 56MESS complexes. The spectrum from 400 to 200 nm has already been 
discussed but, the SRCD spectra reveal further differences between the three 
complexes. The red shift seen in the spectra of 56MESSBr2 continues into the lower 
wavelengths, indicating a positive chirality shift. The negative absorption band at 225 
nm for 56MESSBr2 is also much stronger than the blue shifted bands of 56MESSCl2 and 
56MESSI2. 56MESSCl2 appears to have two peaks more than that of 56MESSBr2 with 
additional peaks at 184 and 302 nm. The opposite is true of 56MESSI2 which has only 
one true peak which is blue shifted to the equivalent peaks of the bromo and chloro 
complexes. This indicates that this compound overall absorbs somewhat even amounts 
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of left and right polarised light. As noted earlier the intensity of the peaks for the 
56MESS complexes does not follow a trend that correlates to either size or 
electronegativity and thus more complex factors are at play. 
 
Figure 3.2.2.23: SRCD spectra of 56MESSCl2 (black), 56MESSBr2 (red) and, 56MESSI2 
(blue); at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected 
for solvent baseline (H2O). 
As with the UV data the SRCD spectra of complexes with the same polyaromatic 
region were also compared. Figure 3.2.2.24 illustrates the effect of the polyaromatic 
ligand on dichlorinated complexes. The spectra for PHENSSCl2 and 56MESSCl2 are quite 
similar in terms of their intensity where as 5MESSCl2 has a comparatively flat spectra. 
As mentioned previously the difference in the spectra is most likely due to the 
asymmetry of 5MePhen effecting the conformation and thus the absorption of 
polarised light. Although the spectra for 56MESSCl2 and PHENSSCl2 are very similar their 
bands between 275 and 325 nm are in opposition with PHENSSCl2 having a positive 
maxim and 56MESSCl2 having a negative maxim. For the remaining peaks 56MESSCl2 
was red shifted to the peaks of PHENSSCl2 which has almost identical peak locations to 
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5MESSCl2. Interestingly the Cl2 complexes had the least similar SRCD spectra, which is 
unexpected due to the smaller size of the chloro ligand, which strengthens the 
hypothesis that changes in spectra are due to the electronegativity of the ligands. 
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Figure 3.2.2.4: SRCD spectra of PHENSSCl2 (black), 5MESSCl2 (red) and, 56MESSCl2 
(blue); at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected 
for solvent baseline (H2O). 
 
Figure 3.2.2.25 illustrates the effect of the polyaromatic ligand on dibrominated 
complexes. Similarly to the dechlorinated complexes 5MePhen had the flattest spectra, 
providing more evidence for the hypothesis that asymmetry results in more even 
absorbance of right and left polarised light. For all three peaks visible in the spectra 
56MESSBr2 is the most red shifted followed by 5MESSBr2 and lastly PHENSSBr2. This 
suggests that the more methyl groups or the larger the polyaromatic ligand the more 
positive the chiral shift of the molecule however, the intensity of the bands is 
determined by other factors such as symmetry. 
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Figure 3.2.2.25: SRCD spectra of PHENSSBr2 (black), 5MESSBr2 (red) and, 56MESSBr2  
(blue); at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected 
for solvent baseline (H2O). 
Figure 3.2.2.26 illustrates the effect of the polyaromatic ligand on diiodo 
complexes. Unlike the dibromo and dichloro complexes 56Me2Phen has the flattest 
spectra not the 5MePhen complex. These three complexes had the most similar spectra 
out of any of the comparisons made so far, the main difference being the flatness of 
the spectra of 56MESSI2. A possible explanation for this is that the iodo ligands have a 
stronger influence on chirality than the polyaromatic ligand and thus the spectra 
emulate the changes made by the iodo ligands that they have in common with only 
minor differences due to the influence of the polyaromatic ligand. 
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Figure 3.2.2.26: SRCD spectra of PHENSSI2 (black), 5MESSI2 (red) and, 56MESSI2 (blue); 
at room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for 
solvent baseline. (H2O). 
3.2.3 The characterisation of Pt(IV) complexes of the type 
[Pt(PL)(AL)(OH)(C2H3O2)]2+ 
The NMR characterisation of 56MESS(OH)(OAc), 56MERR(OH)(OAc), 
PHENSS(OH)(OAc), PHENRR(OH)(OAc), 5MESS(OH)(OAc), 5MERR(OH)(OAc), 
4MESS(OH)(OAc), 4MERR(OH)(OAc), 44BPYSS(OH)(OAc) and, 44BPYRR(OH)(OAc); was 
achieved using a combination of 1H proton NMR spectra, 1H 195Pt heteronuclear 
multiple quantum correlation (HMQC) spectra and, 1H/ 1H COSY spectra. As mentioned 
in previous spectra, a Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2Has a 195Pt resonance 
at 450 ppm and so deviation from this trend can help to identify the coordination of 
the axial ligands. For these asymmetric complexes the 195Pt shift was hypothesised to 
be similar to the dihydroxy complexes as they have the same coordination sphere and 
one of the ligands is identical. Complexes of the type [Pt(PL)(AL)(OH)(C2H3O2)]2+ were 
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discovered to have a 195Pt resonance approximately 100 ppm higher than that of the 
dihydroxy counterpart. An example of the HMQC spectra is shown in Figure 3.2.3.1, the 
195Pt chemical shift of 543.9 ppm is significantly different to the two starting PCs [Pt(SS-
dach)Cl2] and K2PtCl4 (−3282 and −1650 ppm, respectively). The correlation between 
the Pt centre and the aromatic resonance 9.34 ppm confirms the coordination of the 
1,10-phenanthroline. 
The proton spectra were similar to the Pt(II) counterparts of these complexes in 
the literature with the presence of the axial ligands affecting the chemical shifts in both 
the aromatic and aliphatic regions. In the aromatic region the asymmetric ligands 
caused splitting of the 2/9 and 4/7 protons as these two protons are closest sterically 
to the axial ligands. In the aliphatic region the axial ligands caused the merging of the 
3’4 and 4’/5’ proton peaks, as is typically seen when complexes of this type are 
oxidised.  Figure 3.2.3.2 shows the 1H spectra of PHENSS(OH)(OAc) with the peaks 
labelled with the corresponding proton. As discussed in the synthesis chapter the 
isolation of these complexes was problematic, leading to the presence of Pt(II) in the 
final compound which is evident in the NMR spectra. The relative integration of peaks  
 
Figure 3.2.3.1: The 1H-195Pt HMQC spectrum of PHENSS(OH)(OAc) in D2O, displaying the 
correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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was used to identify which peaks belonged to the two PCs. The aromatic region for 
PHENSS(OH)(OAc)  was assigned as follows: the singlet at 8.31 ppm was assigned to H5 
and H6 as the two protons will share the peak location due to the symmetry of the 
complex and there are no protons on the adjacent carbons. The doublet of doublets 
(dd) at 8.24 ppm were assigned to H3 and H8, again the symmetry resulted in the 
combining of the two peaks and the presence of the protons on the adjacent  carbons 
resulting in a dd splitting pattern due to coupling. The remaining two peaks 
corresponding to H4/7 and H2/9 usually appear as doublets however, the asymmetry 
of these complexes caused further splitting. At first glance they appear to be doublets 
of doublets but, closer inspection reveals further splitting of these peaks. In order to 
distinguish between the two peaks the J coupling was still used as in previous 
interpretations. H4 and H7 were assigned to the peak at 9.05 ppm had a major coupling 
constant of 8.63 Hz, and a secondary coupling constant of 1.23 Hz. The smaller coupling 
constant of the peak at 9.25 ppm was assigned to H2 and H9 is due to the proximity to 
the nitrogen. The resonances for the aliphatic region were consistent with NMR spectra 
reported in the literature for Pt(IV) complexes with the same axillary ligands. The peaks 
were almost identical with only slight variants in the ppm. The amine proton 
resonances were not visible due to exchange with D2O. 
The above was repeated for the NMR spectra for the remaining (OH)(OAc) 
complexes the results of which are summarised in Table 2.3.7.1 (Chapter two). There 
were some minor differences in the resonances for 5MESS and 56MESS, due to the 
methyl groups, and greater differences were seen in the 4MESS and 44BPYSS spectra in 
the aromatic region. The RR and SS isomers had almost identical spectra however, the 
relative concentration of each solution affected the stacking of the phenanthroline 
region and thus affected the resonance of the H2,9 and H4,7 peaks. 
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Figure 3.2.3.2: The 1H NMR spectra of PHENSS(OH)(OAc) in D2O, showing proton 
assignment and Pt(II) impurity; performed on a Bruker Avance 400 MHz NMR 
spectrometer. * indicates steriocenter (SS). 
3.2.4 The characterisation 2-aminoethyldiclofenacamide  
The NMR characterisation of 2-aminoethyldiclofenacamide was achieved using a 
1H NMR. The NMR characterisation of the starting material was reported previously 
and this was used as a tool to help check the peak assignments.87 The proton 
assignment of en-DCF is shown in Figure 3.3.4.1. The C-H proton peaks were assigned 
as follows: the doublet at 7.45 ppm was assigned to H12 and H14 as the two protons 
will share the peak due to the symmetry of that portion of the complex and there is 
only one proton on the adjacent carbons. The multiplet at 7.08 ppm was assigned as 
the peaks from H4 and H13 overlapping. The triplet at 6.95 ppm was assigned to H6 
due to the single hydrogens on the two adjacent carbons and the splitting caused by 
the asymmetry of the ring. The triplet at 6.76 ppm was assigned to H5 for using the 
same rational, H5 and H6 were distinguished due to the proximity to the amine group 
which brings H6 further downfield. The doublet at 6.26 ppm was assigned to H7 as it 
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has only one neighbouring carbon bound to a proton. The two doublets were 
distinguishable firstly due to the integration which was doubled for the H12/14 peak vs 
the H7 peak, but also because the proximity of the electronegative chloro groups 
neighbouring the H12/14 peaks meant that they would be positioned further 
downfield. The multiplets at 3.01 and 2.51 ppmwere assigned to H1* and H2*, 
respectively were the H2* was assigned to the peak further downfield due to its 
proximity to the NH2 group. The N-H peaks were visible although their integrations 
could not be relied upon due to exchange with water. The peak at 9.89 ppm was 
assigned to the NH both of the ethylenediamine (en) and the DCF, whereas the peak at 
1.09 ppm was assigned to NH2.  
In order to confirm the binding of en to DCF the two proton NMRs were 
compared as shown in Figure 3.3.4.2. This was essential to the characterisation due to 
the small differences in 1H spectra, where the amine peaks were unreliable due to 
exchange with water and the C-H peaks of en could easily be confused with solvent 
peaks. The 1H spectra for en-DCF is shifted downfield and the H13 and H4 peaks are 
significantly merged where as in the DCF spectra the two individual peaks can more 
easily be discerned. This technique was useful for the quick confirmation of the 
presence and purity of en-DCF so that it could quickly be used for further synthesis. 
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Figure 3.3.4.1: The 1H NMR spectra of en-DCF in DMSO showing proton assignment; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
 
 
Figure 3.3.4.2: The 1H NMR spectra of en-DCF in DMSO (blue) in comparison to the 1H 
NMR spectra of DCF in DMSO (red) ; performed on a Bruker Avance 400 MHz NMR 
spectrometer. 
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3.2.5 The characterisation of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane) (DMSO)2]2+ 
The NMR characterisation of PHENSS(DMSO)2 was achieved through a 
combination of 1H proton NMR spectra, 1H 195Pt heteronuclear multiple quantum 
correlation (HMQC) spectra and, 1H/ 1H COSY spectra. As discussed earlier a typical 
Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2 will demonstrate a 195Pt resonance at 450 
ppm whereas the[Pt(PL)(AL)(X)2]+2 type complexes had a 195Pt resonance at 
approximately -630 ppm. This information was used to confirm the synthesis of 
PHENSSDMSO2 by ruling out that the Pt(IV) complex visible in the 1H spectra was not 
the starting reagent and that the Cl ligands had not exchanged with water or hydroxyl 
ligands. The 195Pt resonance of PHENSSDMSO2 was found to be at -600.7 ppm, similar 
to that of the halide complexes most likely because the coordination spheres are more 
similar in comparison to the coordination spheres containing oxygen. Both the 1 
dimensional 195Pt spectra and the 2 dimensional HMQC are displayed in the 
supplementary information. Figure 3.3.5.1 shows the 1H spectra of PhenSSDMSO2 with 
the peaks labelled with the corresponding proton. The aromatic region was significantly 
different from similar compounds previously reported, they were assigned as follows: 
the singlet at 10.79 ppm was assigned to H5 and H6 as the two protons will share the 
peak due to the symmetry of the complex and there are no protons on the adjacent 
carbons. The doublet of doublets (dd) at 10.78 ppm were assigned to H3 and H8, again 
the symmetry resulted in the combining of the two peaks and the presence of the 
protons on the adjacent  carbons resulting in a dd splitting pattern due to coupling. The 
remaining two doublet (d) peaks in the aromatic region were merged in the spectra; 
however, they could still be distinguished due to the smaller coupling constant of H2 
and H9 due to the proximity to the nitrogen. Thus the 11.58 ppm doublet J= 8.28 Hz 
was assigned to H2 and H9 and the doublet at 11.85 ppm J= 5.50 Hz was assigned to H4 
and H7. The resonances for the aliphatic region were consistent with NMR spectra 
reported in the literature with the same axillary ligands however, there were some 
minor differences and all peaks were shifted downfield due the solvent (DMSO). The 
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multiplet at 5.31 ppm was assigned to H1’ and H2’ due to the symmetry of the complex 
and their proximity to the amine groups. The multiplet at 4.56 ppm which presents as a 
doublet was assigned to H3’ and H6’ for similar reasoning: despite its appearance the 
signal must be a multiplet as there are a total of three protons on the adjacent carbons. 
The multiplet at 3.96 ppm was also assigned to H3’ and H6’, again the symmetry of the 
complex resulting in these protons sharing  a peak and the boat conformation resulting 
in two peaks both of an integration of 2. The multimplets at 3.84 and 3.53 ppm were 
assigned to H4’ and H5’ using the same rational. The amine proton resonances are 
usually not reported for this type of complex due to exchange with water, in DMSO 
they appear in the aromatic region. The two amine peaks are shifted far downfield; at 
11 and 12.08 ppm for the SS-Dach and phenanthroline amines, respectively. Despite 
being shifted further downfield than expected, the integration and shape of the peaks 
is good evidence that they are accurate and it is known that in hydrogen bonding 
solvents such as DMSO and acetone the peaks for amine groups are shifted 
downfield.111 
 
Figure 3.3.5.1: The 1H NMR spectra of PHENSSDMSO2 in d-DMSO, showing proton 
assignment; performed on a Bruker Avance 400 MHz NMR spectrometer. 
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3.2.6 The characterisation of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)(2-Aminoethyldiclofenacamide)2]2+ 
The NMR characterisation of PHENSSenDCF2 was achieved through a combination 
of 1H proton NMR spectra, 1H /195Pt heteronuclear multiple quantum correlation 
(HMQC) spectra and, 1H/ 1H COSY spectra. Additional confirmation was achieved 
through a combination of  1H/13C heteronuclear single quantum coherence (HSQC) 
which allows the inspection of carbon-proton single bond correlations, 1H/13C 
heteronuclear multiple bond correlation (HMBC) which allows for the inspection of 
interactions between protons up to four bond lengths away. The 195Pt peak resonates 
at – 2820.9 ppm, which is more similar to a typical Pt(II) complex of this type then any 
previously synthesised Pt(IV) compounds, this was a part of the reason additional 
spectra were inspected, to confirm the ligand was bound and the 1H NMR signals were 
not simply depicting a mixture of PHENSS and enDCF. The aromatic and aliphatic peaks 
of PHENSS and the peaks of enDCF were similar to those described above with only 
slight differences. The annotated 1H NMR spectra is illustrated in Figure 3.3.6.1. The 1H 
PHENSS aromatic peaks were assigned as follows: the doublet at 8.89 ppm was 
assigned to H4 and H7 which were combined due to the symmetry of the complex, the 
J coupling (J = 8.42Hz) was used to distinguish it from the other doublet at 9.11 ppm (J 
= 5.26 Hz) that was assigned to H2 and H9 which has a smaller J coupling value because 
of their proximity to the amine. The doublet of doublet at 8.01 ppm was assigned to H3 
and H8 which are again combined due to symmetry, the splitting pattern can be 
attributed to the non-equivalence of the two neighbouring protons (one of which is 
adjacent to the amine group) and confirmed by the J coupling vales J = 8.13, 8.41 Hz. 
The singlet at 8.13 ppm was assigned to H6 and H5. The aliphatic region was similar to 
that of similar compounds previously reported however, unlike previously reported 
Pt(IV) compounds the merging of the H3’/6’ peak with the H4’/5’ did not occur similarly 
to the dihalogen compounds discussed above. The splitting may be due to the solvent, 
which is this case was MeOH, or the electronegativity of the coordinating atom of the 
ligand.  The aliphatic groups were assigned as follows: the multiplet at 2.69 ppm was 
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assigned to H1’ and H2’, although the shape of the peak appeared to be similar to that 
of previously reported compounds the merging of the DMSO residual solvent peak 
made integration difficult. The pseudo doublet at 2.25 ppm was assigned to H3’ and 
H6’ as was the multiplet at 1.69 ppm. The two multiplets at 1.54 and 1.29 ppm were 
similarly assigned to H4’ and H5’.  The enDCF ligand peaks were similar to that 
described above however, all the intergradations were doubled and a slight downfield 
shift of all the aromatic peaks as well as a few peaks moving downstream in relation to 
the others. The enDCF peaks were assigned a follows: the doublet at 7.23 ppm was 
assigned to H12” and H14”  which  was distinguished from the other doublets due to its 
integration which is twice that of the others as they are the only two protons which 
have equivalent chemical environments.  The doublet at 7.12 ppm was assigned to H4”; 
which is distinguishable from the doublet at 7.95 ppm assigned to H7” due to the J 
couplings J = 7.50 Hz and J = 7.95 Hz respectively, due to the proximity of H7” to the 
amine which shifts it further downfield. The multiplet at ~ 6.9 ppm can be split into a 
triplet at 6.91 ppm and another triplet at 6.85 ppm  which correspond to H13” and H6” 
respectively. Again the relative couplings allowed these two peaks to be distinguished 
from one another with H13” J = 8.03 Hz and H6” J = 7.72 Hz, at 6.70 ppm where the 
larger J coupling of H13” can be attributed to its proximity to the two chloro groups.  
The triplet at 6.21 ppm was assigned to H5” which is a similar chemical environment to 
H6” as evident by their similarity although the H5” peak is further upfield due to its 
distance from the electronegative groups. The N-H peaks were visible although their 
integrations could not be relied upon even less than they could be in DMSO due to 
exchange with water and MeOH.  
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Figure 3.3.6.1: 1H NMR spectra of PHENSSenDCF2 in MeOD, showing proton assignment; performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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3.2.7 The characterisation of Pt(IV) complexes of the type 
[Pt(PL)(AL)(OH)(succinimide)]2+  
The NMR characterization of PHENSS(OH)(Succ), 5MESS(OH)(Succ), and 
56MESS(OH)(Succ) was achieved using a combination of 1H proton NMR spectra and 1H 
195Pt heteronuclear multiple quantum correlation (HMQC) spectra. The HMQC peak 
was significantly different to other platinum complexes of the same type reported in 
the literature.109 Typically a Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2 will 
demonstrate a 195Pt resonance at 450 ppm whereas the complexes synthesised in this 
work have 195Pt resonate at approximately -550 ppm, this confirms the presence of the 
succinate ligand in place of one of the hydroxyl.40 An example of the HMQC spectra is 
shown in Figure 3.2.7.1, the 195Pt chemical shift of 542.1  ppm is significantly different 
to the two starting Pt(II) complexes [Pt(SS-dach)Cl2] and K2PtCl4 (−3282 and −1650 ppm, 
respectively). The correlation between the Pt centre and the aromatic resonance 9.37 
ppm confirms the coordination of the 1,10-phenanthroline.  
 
Figure 3.2.7.1: The 1H–195Pt HMQC spectrum of PHENSS(OH)(Succ) in D2O, displaying 
the correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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The proton spectra were almost identical to similar complexes in the literature 
with very minor chemical shifts which occur due to staking of the 1,10-phenanthroline 
ligands stacking in solution.110 Figure 3.3.7.2 shows the 1H spectra of PHENSS(OH)(Succ) 
with the peaks labelled with the corresponding proton. The aromatic region for 
PHENSS(OH)(Succ) was assigned as follows: the singlet at 8.32 ppm was assigned to H5 
and H6 as the two protons will share the peak location due to the symmetry of the 
complex and there are no protons on the adjacent carbons. The doublet of doublets 
(dd) at 8.25 ppm was assigned to H3 and H8, again the symmetry resulted in the 
combining of the two peaks and the presence of the protons on the adjacent carbons 
resulting in a dd splitting pattern due to coupling. The remaining two doublet (d) peaks 
in the aromatic region, merged in the spectra; however, they could still be 
distinguished due to the smaller coupling constant of H2 and H9 due to the proximity 
to the nitrogen. Thus the 9.07 ppm doublet J= 8.13 Hz was assigned to H4 and H7 and 
the doublet at 9.27 ppm J= 5.77 Hz was assigned to H2 and H9. The resonances for the 
aliphatic region were consistent with NMR spectra reported in the literature with the 
same axillary ligands. The peaks were almost identical with only slight variants in the 
ppm. The amine proton resonances were not visible due to exchange with D2O. 
The above was repeated for the NMR spectra of 5MESS(OH)(Succ), and 
56MESS(OH)(Succ), the results of which are summarised in Table 2.3.11.1 (Chapter 
two). There were some minor differences in the resonances for these complexes, 
particularly in the aromatic region where the relative concentration of each solution 
affects the stacking of the phenanthroline region and thus affects the resonance of the 
H2, 9 and H4,7 peaks. 
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Figure 3.2.7.2: 1H NMR spectra of PHENSSenDCF2 in MeOD, showing proton 
assignment; performed on a Bruker Avance 400 MHz NMR spectrometer. 
3.2.8  The characterisation of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane) (OH)(succinatePFP) ]2+ 
The NMR characterisation of PHENSS(succinatePFP) was achieved using a 
combination of 1H proton NMR spectra, 1H 195Pt heteronuclear multiple quantum 
correlation (HMQC) spectra and, 1H/ 1H COSY spectra. As mentioned in previous 
characterisation analysis, a Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2 has a 195Pt 
resonance at 450 ppm and so deviation from this trend can help to identify the 
coordination of the axial ligands. An example of the HMQC spectra is shown in Figure 
3.2.5.1, the 195Pt chemical shift of 531.5 ppm (Figure 3.2.8.1) is significantly different to 
the two starting PCs [Pt(SS-dach)Cl2] and K2PtCl4 (−3282 and −1650 ppm, respectively). 
The correlation between the Pt centre and the aromatic resonance 9.34 ppm confirms 
the coordination of the 1,10-phenanthroline. The addition of the PFP moiety did not 
significantly alter the 1H NMR spectra thus the protons were assigned in using the same 
justification as in Section 3.2.8, the proton assignment is shown in Figure 3.2.8.2. 
115 
 
 
Figure 3.2.8.1: The 1H–195Pt HMQC spectrum of PHENSS(OH)(SuccPFP) in D2O, 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
 
Figure 3.2.8.1: The 1H spectrum of PHENSS(OH)(SuccPFP) in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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3.2.9 The characterisation of [Pt(1,10-phenanthroline)(1S,2S-
diaminocyclohexane)(OH)(PSMA) ]2+ 
The NMR characterisation of PHENSS(OH)(PSMA) was achieved using a 
combination of 1H proton NMR spectra, 1H 195Pt heteronuclear multiple quantum 
correlation (HMQC) spectra and, 1H/ 1H COSY spectra. As mentioned in previous 
characterisation analysis, a Pt(IV) complex of the type [Pt(PL)(AL)(OH)2]+2Has a 195Pt 
resonance at 450 ppm and so deviation from this trend can help to identify the 
coordination of the axial ligands. For these asymmetric complexes the 195Pt shift was 
hypothesised to be similar to the dihydroxy complexes as they have the same 
coordination sphere and one of the ligands is identical. Complexes of the type 
[Pt(PL)(AL)(OH)(PSMA)]2+ were discovered to have a 195Pt resonance at 537.1 ppm. An 
example of the HMQC spectra is shown in Figure 3.3.9.1, the 195Pt chemical shift of 
543.9 ppm is significantly different to the two starting PCs [Pt(SS-dach)Cl2] and K2PtCl4 
(−3282 and −1650 ppm, respectively). The correlation between the Pt centre and the 
aromatic resonance 9.34 ppm confirms the coordination of the phen. 
 
Figure 3.3.9.1: The 1H–195Pt HMQC spectrum of PHENSS(OH)(PSMA) in D2O, displaying 
the correlations between the platinum centre and the protons from each ligand; 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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The 1H analysis was significantly more difficult to analyse than the complexes 
previously mentioned as the DCL peaks resonate in the same region as DACH. An 
overview of the literature around DCL did not identify an annotated NMR spectra, so in 
order to fully characterise PHENSS bound DCL the peaks in the spectra of the DCL 
starting reagent were first analysed (Figure 3.3.9.2) 
 
Figure 3.3.9.2: 1H NMR spectra of DCF in D2O, showing proton assignment; performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
Figure 3.3.9.3 shows the proton assignment of PHENSS(OH)(PSMA), the analysis 
of which was confirmed by comparison with PHENSS and DCL spectra (Figure 3.3.9.4). 
The PHENSS aromatic peaks were assigned as follows: the doublet at 8.87 ppm was 
assigned to H4 and H7 which were combined due to the symmetry of the complex, the 
J coupling (J = 8.30 Hz) was used to distinguish it from the other doublet at 8.47 ppm (J 
= 5.39 Hz) that was assigned to H2 and H9 which has a smaller J coupling value due to  
their proximity to the amine. The doublet of doublet at 7.98 ppm was assigned to H3 
and H8 which are again combined due to symmetry, the splitting pattern can be 
attributed to the non-equivalence of the two neighbouring protons (one of which is 
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adjacent to the amine group) and confirmed by the J coupling vales J = 8.30, 13.80 Hz. 
The singlet at 8.11 ppm was assigned to H6 and H5 which was easily identifiable as the 
only singlet and the only peak with an integration of 6. The aliphatic region for the 
PHENSS peaks was similar to that of similar compounds previously reported however 
the DCL peaks hid some of the peaks which usually resonate at ~1.5 ppm. The PHENSS 
aliphatic peaks that are visible were assigned as follows: the multiplet at 2.70 ppm was 
assigned to H1’ and H2’, although the shape of the peak appeared to be similar to that 
of previously reported compounds the merging of the DMSO residual solvent peak 
made integration difficult. The pseudo doublet at 2.20 ppm was assigned to H3’ and 
H6’ and the multiplet 1.22 ppm were similarly assigned to H4’ and H5’. These 4 protons 
typically share an additional peak at ~1.5 ppm which was merged with DCL peaks such 
that an accurate ppm could not be obtained. The DCL peaks were identified in the 
aromatic region, protons bound to O or N were not visible due to exchange with the 
protic solvent (D2O). The DCL peaks were assigned as follows: the dds at 4.02 and 3.98 
ppm were assigned to H12” and H16” as these protons have very similar environments 
and would be expected to have the furthest downfield shifts due to their proximity to 
the ammine and carboxylic acid groups. The triplet of doublets at 3.09 ppm was 
assigned to H2* while the triplet at 2.91 was assigned to H1* because the trace Pt 
peaks around the peak at 2.91 ppm indicating that it is interacting with the platinum 
and thus must be assigned to the peaks closest to the Pt centre.  The triplets at 2.32 
and 2.16 ppm were assigned to H1” and H8”, respectively. Both protons have similar 
chemical environments however H1” has a closer proximity to the Pt centre and thus 
resonates further downfield. The multiplets at 1.99, 1.82 and, 1.68 ppm were assigned 
to H17”, H18” and H11”, respectively they have similar shifts as they are all located 
adjacent to a carboxylic acid. H17” is the most down field due to its proximity to both 
the amine and an additional carboxylic acid whilst H11” is in a chemically similar 
environment except for the additional carbocyclic acid group.  The remaining peaks are 
merged with each other and the DACH peaks meaning that only approximate ppm 
values can be assigned and protons are grouped together despite having slightly 
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different chemical environments which would have resulted in individual peaks if the 
spectra had not been so crowded. The multiplet at 1.56 ppm was assigned to H3”, H4’ 
and H10” from the DCL ligand as well as H3’and H6’ from the DACH ligand. These 
protons were assigned to this multiplet based on the comparison illustrated in Figure 
3.2.10.4. The multiplets at 1.43 and 1.28 ppm were assigned to H5” and H2’/9”, 
respectively for the same reason. 
 
 
 
Figure 3.3.9.3: 1H NMR spectra of PHENSS(OH)(PSMA) in D2O, showing proton 
assignment; performed on a Bruker Avance 400 MHz NMR spectrometer. 
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Figure 3.3.9.4: The aliphatic region of the 1H NMR spectra of PHENSS(OH)(PSMA)  in 
D2O (blue) in comparison to the 1H NMR spectra of PHENSS in D2O (red) and DCL in D2O 
(green); performed on a Bruker Avance 400 MHz NMR spectrometer. 
3.3    Summary of characterisation: 195Pt(IV) NMR trends  
For complexes such as those synthesised in this thesis, the 195Pt NMR spectra can 
be key to the elucidation of the structure. For Pt(II) complexes the 195Pt shift is well 
understood and as such it is possible to predict where a peak will appear. This is not the 
case for polyaromatic Pt(IV) complexes, which means that several spectra need to be 
taken in order to find the Pt(IV) peak. As our lab synthesise and characterise more of 
these complexes trends are starting to appear which help speed the elucidation of the 
structure. For example monosubstituted complexes tend to have higher ppm values 
than their disubstituted counterparts. Most of the compounds that have been 
synthesised have an N4O2 coordination sphere, new compounds with different 
coordination spheres appear at different locations. Table 3.3.1 shows the ppm values 
of the complexes synthesised in this thesis in an attempt to elucidate a trend between 
the ligand and the location of the 195Pt chemical shift. In general there appears to be a   
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Table 3.3.1: 195Pt chemical shift for all PHENSS Pt(IV) complexes syntesised during candidature, illustrating the effect 
of the axial ligand in the determination of the ppm. 
  ppm Coordination 
sphere 
Complex 
543 N4O2 
 
537 N4O2 
524 N4O2 
450 N4O2 
-600 N4S2 
-635 N4I2 
-645 N4Cl2 
-964 N4Br2 
-2820 N6 
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trend between soft ligands having negative ppm values while hard ligands tend to have 
positive values. PHENSSS(enDCL)2 was the exception to this rule with the most negative 
value of all the compounds synthesised, this could mean that only complexes with N4O2 
coordination spheres have positive values or that having a coordination sphere 
containing only one type of atom results in a more negative coordination sphere. 
Interestingly the ppm value of the halogenated compounds does not correlate to the 
atomic size or the electronegativity.  
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3.4 Cytotoxicity 
3.4.1 Cytotoxicity of [Pt(PL)(AL)(X)2]2+ type complexes 
 
The cytotoxicity of these complexes was determined and compared to the 
traditional platinum anticancer drugs, cisplatin carboplatin and oxaliplatin; as well as 
the Pt(II) and Pt(IV) dihydroxide of the most promising candidate designed in our lab 
56MESS. Figure 3.5.1.1 shows the relative cytotoxicity of 56MESS, 56MESS(OH)2, 
cisplatin carboplatin and oxaliplatin. The GI50 values of 56MESS and 56MESS(OH)2 are 
so low (within the µM range) that comparison between them and the traditional 
anticancer drugs is difficult. 
Clearly 56MESS and 56MESS(OH)2 exhibit promising cytotoxic results with the 
potential to lower dosage in patients. [Pt(PL)(AL)(X)2]2+ had results similar to that of 
56MESS and 56MESS(OH)2 and thus they will be used in place of cisplatin to evaluate 
the cytotoxicity results. Both the polyaromatic and axial ligands affected the 
cytotoxicity results. When comparing by polyaromatic ligand the general trend is 
phen>5Mephen>56Me2phen. There are several exceptions to this trend; for 
[Pt(PL)(AL)(Cl)2]2+ complexes the trend for the A2780 Ovarian cell line was 
5Mephen>phen>56Me2phen, for [Pt(PL)(AL)(Br)2]2+ complexes the trend for MCF-7 
Breast and BE2-C Neuroblastoma cell lines the trend was phen>56Me2phen >5Mephen, 
there was no deviation from the general trend for the [Pt(PL)(AL)(I)2]2+ complexes. The 
axial ligand appears to have a less consistent effect on the relative cytotoxicity. There is 
no general order to be allocated to all three polyaromatic ligands; PHENSSX2 complexes 
have the general trend Br>Cl>I while both 5MESSX2 and 56MESSX2 have the general 
trend Cl>Br>I. the exceptions for these rules are: for PHENSSX2 complexes the trend 
changes to Br>I>Cl for both ovarian cancer cell lines, for 56MESSX2 the trend is Br>Cl>I 
for both MCF-7 Breast and BE2-C Neuroblastoma cell lines. For the 5MESSX2 complexes 
there were many exceptions to the rule; for Du145 prostate cell line it was I>Cl>Br, for 
HT29 colon Br>Cl>I for A2780 ovarian, MCF-7 breast, and BE2-C neuroblastoma it was 
Br>I>Cl. Figures and tables for all data can be found in the supplementary information. 
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Figure 3.4.1.1: Cytotoxicity of 56MESS, 56MESS(OH)2, cisplatin carboplatin and 
oxaliplatin over multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 
ovarian, H460 lung, A431 skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 
glioblastoma, and MIA pancreas; incubated for 72 hr. 
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Figure 3.5.1.2 shows the GI50  values of 56MESSCl2, 56MESSBr2, and 56MESSI2 in 
comparison to 56MESS (Pt(II)) and 56MESSOH2. These complexes have been selected as 
they show an interesting trend between the Pt(II) and Pt(IV) results. In most cell lines 
56MESS has a much lower GI50 than 56MESSOH2 (all cell lines bar HT29 colon). This is 
disappointing as the Pt(IV) variant should allow oral administration and improved 
extracellular stability without affecting the mechanism of action within the cell. The 
56MESSX2 series offers a new perspective on the relationship between oxidation sate 
and cytotoxicity, with the vast majority of compounds having a lower value than that of 
56MESSOH2 and even lower than 56MESS in some cell lines. These results suggest that 
although reduction may play a role in the cytotoxicity it is not necessarily a negative 
effect. Perhaps the fast reduction off the halides contributed to their toxicity or 
perhaps the prodrug was preserved for longer as unlike OH the halides are soft bases 
and thus Pt(IV) as a soft acid is more stable when bound to them. 
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Figure 3.4.1.2: GI50 values of 56MESSCl2, 56MESSBr2, 56MESSI2  56MESS, and 
56MESSOH2 in multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 
ovarian, H460 lung, A431 skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 
glioblastoma, MIA pancreas, MCF10A breast (normal), and SMA glioblastoma (murine); 
incubated for 72 hr. 
All nine complexes show remarkable results in comparison to cisplatin in terms of 
their GI50 values. Further testing will need to be undertaken to compare the ability of 
these complexes to target cancer cells in comparison to cisplatin. Comparing the results 
for the normal and cancerous breast cell lines (MCF-7 and MC10A respectively) 
obtained in this study provides hope that these results may be positive, but again 
further testing is required for confirmation (Figure 3.4.1.3). 
 
Figure 3.4.1.3: : IC50 values of 56MESSCl2, 56MESSBr2, 56MESSI2, 56MESS, and 
56MESS(OH)2 in human breast cell lines, MCF-7 (normal) and MCF10A; incubated for 72 
hr. 
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Chapter 4 Conclusions 
In this work, 55 complexes were synthesised of which 23 were novel. All Pt(II) 
complexes were of the type [Pt(PL)(AL)]2+ and Pt(IV) complexes were of the type 
[Pt(PL)(AL)(X)2]2+; were PL was either Phen, 4Mephen, 5Mephen, 56Me2phen or BPY, AL 
was either SS-dach or RR-dach, and X was either, OH, succinimide, Br, I, Cl, en-DCF, DCL 
or OAc. The synthesis of Pt(II) complexes was achieved using methods in previously 
published papers, although PHENSS was also synthesised via a novel method developed 
in this work which utilised flow chemistry techniques. Pt(IV) complexes were 
synthesised via methods designed and optimised in this work aside from the 
[Pt(PL)(AL)(OH)2]2+ complexes which were synthesised via previously published 
methods. 
A series of Pt(IV) polyaromatic complexes with halogenated axial ligands made up 
for 9 of the novel complexes. These complexes were characterised using ESIMS, UV 
spectroscopy, CD spectroscopy, SRCD spectroscopy, microanalysis, NMR and HPLC and 
the cytotoxicity was analysed. For this series only the SS-dach isomer was synthesised, 
the PL was restricted to Phen, 5Mephen, and 56Me2phen and the halogens used were 
Cl, Br and I. This resulted in a family of complexes that could be compared either by 
their polyaromatic ligand or the halogen of the axial ligand. In general, the halogen 
axial ligands tended to have a significant impact on the UV absorbance, CD spectra, 
mass and cytotoxicity of the complexes whilst having a small impact on the NMR 
spectra. The polyaromatic ligand tended to have more of an effect on the NMR spectra 
and cytotoxicity, while only some impact on the UV absorbance and CD spectra. The 
cytotoxicity of these complexes was much better than cisplatin and its derivatives, was 
comparable to the Pt(II) precursors to these complexes, and more cytotoxic than the 
dihydroxy analogues. These compounds allow the development of new synthetic 
methods which were previously closed to these complexes, allowing the synthesis of 
targeted complexes that have the potential to improve prognosis. The developed 
method is much less time consuming than the current oxidation methods, reducing 
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time spent on synthesising intermediates which will maximise outcomes for the 
synthesis of derivatives. 
[Pt(PL)(AL)(OH)2]2+ type complexes were synthesised as per previously published 
methods to be used as a point of comparison for the [Pt(PL)(AL)(OH)(OAc)]2+ type 
complexes, whose method was designed as a part of this work. These complexes were 
found to be highly susceptible to reduction and as a result only NMR characterisation 
was undertaken. Despite these difficulties with the characterisation it could still be 
confirmed that the desired complexes were synthesised in good yields and they 
account for another 10 of the novel complexes synthesised in this work. Further 
investigation is required to asses if these complexes will make good intermediates for 
the synthesis of new asymmetric complexes. 
The synthesis of Pt(IV) complexes with additional biological design resulted in the 
synthesis of the remaining four novel complexes for which new methods were 
designed. The synthesis of PHENSS-enDCF required the synthesis of two Pt(IV) 
intermediates and the addition on a linker (en) to the ligand (DCF). The addition of an 
amide to a Pt centre has been achieved previously in the literature however only 
through substitution of a DMSO ligand, thus the PHENSSDMSO2 ligand was required. 
Both PHENSSenDCF and PHENSS(DMSO)2 were characterised by NMR, confirming the 
attachment of the ligands. PHENSSenDCF was then sent to our collaborators for 
biological testing. The attachment of the PSMA targeting ligand DCL also required the 
synthesis of several Pt(IV) intermediates one of which (PHENSS(OH)(SuccPFP)) was 
novel. Both the intermediates PHENSS(OH)(Succ) and PHENSS(OH)(SuccPFP) were 
characterised using NMR along with the final product PHENSS(OH)(DCL). The final 
product was then sent to our collaborator for further testing and biological analysis. 
The PHENSS derivatives were sent as for biological assessment with plans to make 
further derivatives if the biological results are promising.  
This project has provided opportunities for future work and further development 
of methods. The NXS oxidation method has the potential to be used to synthesise 
intermediates for future complexes, with targeting ligands or bioactive ligands similarly 
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to how it was used in the development of PHENSS(enDCF)2 and PHENSS(OH)(DCL). The 
method for the synthesis of PHENSS(X)(Succinamide) (which was a by-product) could 
also be developed further to be used as an intermediate and also to test its biological 
activity to compare to the dihalogenated equivalent. The asymmetric (OH)(OAc) type 
complexes need similar method development for use as intermediates and also require 
further characterisation and isolation so that the GI50 value can be determined. Further 
investigation of the influence of axial ligands on the 195Pt NMR shift would be very 
interesting with the potential elucidate an equation, with which the chemical shift 
could be determined computationally prior to the synthesis of the complex. The 
mechanism of action for these complexes is still not completely understood and the 
design and synthesis of florescent molecules may enable the elucidation of the 
mechanism. Reduction studies on the Pt(IV) complexes would also provide additional 
information on the mechanism of action; and the influence of redox potential on the 
GI50 results would be valuable in the design of future potential anticancer complexes. 
Other avenues this research could take is looking at the mechanism of action for 
56MESS and its analogues, synthesis of quadruplex DNA (QDNA) binding complexes 
and synthesis of multination dinuclear Pt(IV) complexes. One potential way to further 
the investigation into the mechanism of action is the synthesis of cyclometallated 
analogues of 56MESS. These analogues have cyclometallation as the nitrogen of the 
56MePhen is replaces by a carbon this typically results in luminescence of PCs. It is 
hypothesised that the mechanism of action would be the same as they are very 
structurally similar non-cyclometallated complexes. Thus biological testing of the 
florescent molecules may help to elucidate the mechanism of action. Cyclometallated 
complexes with QDNA binding potential is another area of interest. It is thought that 
binding to QDNA may be a good strategy for a new class of anticancer complexes and 
cyclometalated Pt(II) complexes have been made successfully by other groups. 112 
Lastly 56MESS dinuclear complexes can be synthesised with multiple targeting and 
bioactive ligands as mentioned in Section 1.3.5. There are many promising bioactive 
linkers and ligands that can be attached to such a complex, many of which are already 
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used in clinics. Figure 4.1 shows some of the complexes that will be potentially 
synthesised in future works. 
 
 
Figure 4.1: Potential complexes to be synthesised in future works. 
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NMR Data    
   PHENSS(Cl)2 195Pt NMR spectra  
 
Figure A1: The 1H–195Pt HMQC spectrum of PHENSSCl2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
  PHENSS(Cl)2 1H NMR spectra         
           
Figure A2: The 1H spectrum of PHENSSCl2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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PHENSS(Br)2 195Pt NMR spectra 
   
Figure A3: The 1H–195Pt HMQC spectrum of PHENSSBr2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer.          
 PHENSS(Br)2 1H NMR spectra 
                                                      
         
Figure A4: The 1H spectrum of PHENSSBr2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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PHENSS(I)2 195Pt NMR spectra 
                      
Figure A5: The 1H–195Pt HMQC spectrum of PHENSSl2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
 
 PHENSS(I)2 1H NMR spectra           
        
Figure A6: The 1H spectrum of PHENSSBr2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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  5MESS(Cl)2 195Pt NMR spectra                                        
 
Figure A7: The 1H–195Pt HMQC spectrum of 5MESSCl2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
5MESS(Cl)2 1H NMR spectra         
              
Figure A8: The 1H spectrum of 5MESSCl2 in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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           5MESS(Br)2 195Pt NMR spectra                                                         
 
Figure A7: The 1H–195Pt HMQC spectrum of 5MESSBr2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
  5MESS(Br)2 1H  NMR spectra        
 
Figure A8: The 1H spectrum of 5MESSBr2 in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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          5MESS(I)2 195Pt NMR spectra                                                         
 
Figure A9: The 1H–195Pt HMQC spectrum of 5MESSl2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
  5MESS(I)2 1H  NMR spectra        
 
 
Figure A10: The 1H spectrum of 5MESSl2 in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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56MESS(Cl)2 195Pt NMR spectra                                                         
 
Figure A11: The 1H–195Pt HMQC spectrum of 56MESSCl2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
  56MESS(Cl)2 1H NMR spectra        
 
Figure A12: The 1H spectrum of 56MESSCl2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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56MESS(Br)2 195Pt NMR spectra                                                         
 
Figure A13: The 1H–195Pt HMQC spectrum of 56MESSBr2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
  
56MESS(Br)2 1H NMR spectra        
 
 
Figure A14: The 1H spectrum of 56MESSBr2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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56MESS(l)2 195Pt NMR spectra                                                         
 
 
Figure A15: The 1H–195Pt HMQC spectrum of 56MESSl2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
  56MESS(l)2 1H NMR spectra        
 
 
Figure A16: The 1H spectrum of 56MESSl2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
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PHENSS(OH)(DCL) 1H NMR spectra        
 
Figure A17: The 1H spectrum of PHENSS(OH)(DCL) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
DCL 1H NMR spectra        
 
Figure A18: The 1H spectrum of DCL in MeOD, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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PHENSS(OH)(PSMA) 195Pt NMR spectra                                                         
 
Figure A19: The 1H–195Pt HMQC spectrum of PHENSS(OH)(DCL) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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Figure A20: The 1H  spectrum of PHENSS(enDCF) in D2O, performed on a Bruker Avance 400 MHz NMR spectrometer. 
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PHENSSenDCF2 195Pt NMR spectra     
    
Figure A21: The 195Pt spectrum of PHENSS(enDCF) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
PHENSS(DMSO)2 (in DMSO) 1H NMR spectra 
 
Figure A22: The 1H spectrum of PHENSS(DMSO)2 in d-DMSO, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
 
21 
 
PHENSS(DMSO)2 (in DMSO) 195Pt NMR spectra        
 
Figure A23: The 195Pt spectrum of PHENSS(DMSO)2 in d-DMSO, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
en-DCF 1H NMR spectra 
 
Figure A24: The 1H spectrum of en-DCF in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
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PHENSS 1H NMR spectra
 
Figure A25: The 1H spectrum of PHENSS in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
PHENSS 195Pt NMR spectra      
 
Figure A26: The 1H–195Pt HMQC spectrum of PHENSS in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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PHENRR 1H NMR spectra
 
Figure A27: The 1H spectrum of PHENRR in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
PHENRR 195Pt NMR spectra       
 
Figure A28: The 1H–195Pt HMQC spectrum of PHENRR in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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5MESS 1H NMR spectra
 
Figure A29: The 1H spectrum of 5MESS in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
5MESS 195Pt NMR spectra     
Figure A30: The 1H–195Pt HMQC spectrum of 5MESS in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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5MERR 1H NMR spectra
 
Figure A31: The 1H spectrum of 5MERR in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
5MERR 195Pt NMR spectra       
 
Figure A32: The 1H–195Pt HMQC spectrum of 5MERR in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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56MESS 1H NMR spectra
 
Figure A33: The 1H spectrum of 56MESS in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
56MESS 195Pt NMR spectra    
Figure A34: The 1H–195Pt HMQC spectrum of 56MESS in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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56MERR 1H NMR spectra
Figure A35: The 1H spectrum of 56MERR in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
56MERR 195Pt NMR spectra       
 
Figure A36: The 1H–195Pt HMQC spectrum of 56MERR in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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4MESS 1H NMR spectra
 
Figure A37: The 1H spectrum of 4MESS in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
4MESS 195Pt NMR spectra    
 Figure A38: The 1H–195Pt HMQC spectrum of 4MESS in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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4MERR 1H NMR spectra 
 
Figure A39: The 1H spectrum of 4MERR in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
4MERR 195Pt NMR spectra    
     
Figure A40: The 1H–195Pt HMQC spectrum of 4MERR in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
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44BPYSS 1H NMR spectra 
 
Figure A41: The 1H spectrum of 44BPYSS in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
44BPYSS 195Pt NMR spectra    
     
Figure A42: The 1H–195Pt HMQC spectrum of 44BPYSS in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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44BPYRR 1H NMR spectra 
 
Figure A43: The 1H spectrum of 44BPYRR in D2O, performed on a Bruker Avance 400 
MHz NMR spectrometer. 
BPYRR 195Pt NMR spectra   
 
Figure A44: The 1H–195Pt HMQC spectrum of 44BPYRR in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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PHENSS(OH)(OAc) 1H NMR spectra 
 
Figure A45: The 1H spectrum of PHENSS(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
PHENSS(OH)(OAc) 195Pt NMR spectra     
Figure A46: The 1H–195Pt HMQC spectrum of PHENSS(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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PHENRR(OH)(OAc) 1H NMR spectra 
 
Figure A47: The 1H spectrum of PHENRR(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
PHENRR(OH)(OAc) 195Pt NMR spectra     
 
Figure A48: The 1H–195Pt HMQC spectrum of PHENRR(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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5MESS(OH)(OAc) 1H NMR spectra 
 
Figure A49: The 1H spectrum of 5MESS(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
5MESS(OH)(OAc) 195Pt NMR spectra        
 
Figure A50: The 1H–195Pt HMQC spectrum of 5MESS(OH)(OAc) in D2O, performed on 
a Bruker Avance 400 MHz NMR spectrometer. 
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5MERR(OH)(OAc) 1H NMR spectra 
 
Figure A51: The 1H spectrum of 5MERR(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
5MERR(OH)(OAc) 195Pt NMR spectra 
 
Figure A52: The 1H–195Pt HMQC spectrum of 5MERR(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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56MESS(OH)(OAc) 1H NMR spectra 
 
Figure A53: The 1H spectrum of 56MESS(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
56MESS(OH)(OAc) 195Pt NMR spectra   
     
Figure A54: The 1H–195Pt HMQC spectrum of 56MESS(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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56MERR(OH)(OAc) 1H NMR spectra 
 
Figure A55: The 1H spectrum of 56MERR(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
56MERR(OH)(OAc) 195Pt NMR spectra  
      
Figure A56: The 1H–195Pt HMQC spectrum of 56MERR(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
 
38 
 
4MESS(OH)(OAc) 1H NMR spectra 
 
Figure A57: The 1H spectrum of 4MESS(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
4MESS(OH)(OAc) 195Pt NMR spectra   
 
Figure A58: The 1H–195Pt HMQC spectrum of 4MESS(OH)(OAc) in D2O, performed on 
a Bruker Avance 400 MHz NMR spectrometer.  
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4MERR(OH)(OAc) 1H NMR spectra 
 
Figure A59: The 1H spectrum of 4MERR(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
4MERR(OH)(OAc) 195Pt NMR spectra        
 
Figure A60: The 1H–195Pt HMQC spectrum of 4MERR(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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44BPYSS(OH)(OAc) 1H NMR spectra 
 
Figure A61: The spectrum of 44BPYSS(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
BPYSS(OH)(OAc) 195Pt NMR spectra        
 
Figure A62: The 1H–195Pt HMQC spectrum of 44BPYSS(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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44BPYRR(OH)(OAc) 1H NMR spectra
 
Figure A63: The 1H spectrum of 44BPYRR(OH)(OAc) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
44BPYRR(OH)(OAc) 195Pt NMR spectra        
 
Figure A64: The 1H–195Pt HMQC spectrum of 44BPYRR(OH)(OAc) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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PHENSS(OH)2 1H NMR spectra 
 
Figure A65: The 1H spectrum of PHENSS(OH)2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
PHENSS(OH)2 195Pt NMR spectra     
 
Figure A66: The 1H–195Pt HMQC spectrum of PHENSS(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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PHENRR(OH)2 1H NMR spectra 
 
Figure A67: The 1H spectrum of PHENRR(OH)2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer.    
PHENRR(OH)2 195Pt NMR spectra     
 
Figure A68: The 1H–195Pt HMQC spectrum of PHENRR(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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5MESS(OH)2 1H NMR spectra 
 
Figure A69: The 1H spectrum of 5MESS(OH)2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
5MESS(OH)2 195Pt NMR spectra        
 
Figure A70: The 1H–195Pt HMQC spectrum of 5MESS(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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5MERR(OH)2 1H NMR spectra 
 
Figure A71: The 1H spectrum of 5MERR(OH)2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
5MERR(OH)2 195Pt NMR spectra   
Figure A72: The 1H–195Pt HMQC spectrum of 5MERR(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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56MESS(OH)2 1H NMR spectra
 
Figure A73: The 1H spectrum of 56MESS(OH)2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
56MESS(OH)2 195Pt NMR spectra      
   
Figure A74: The 1H–195Pt HMQC spectrum of 56MESS(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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56MERR(OH)2 1H NMR spectra
 
Figure A75: The 1H spectrum of 56MERR(OH)2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
56MERR(OH)2 195Pt NMR spectra       
 
Figure A76: The 1H–195Pt HMQC spectrum of 56MERR(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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4MESS(OH)2 1H NMR spectra
 
Figure A77: The 1H spectrum of 4MESS(OH)2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
4MESS(OH)2 195Pt NMR spectra        
 
Figure A78: The 1H–195Pt HMQC spectrum of 4MESS(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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4MERR(OH)2 1H NMR spectra 
 Figure A79: The 1H spectrum of 4MERR(OH)2 in D2O, performed on a Bruker Avance 
400 MHz NMR spectrometer. 
4MERR(OH)2 195Pt NMR spectra        
 
Figure A80: The 1H–195Pt HMQC spectrum of 4MERR(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
 
50 
 
44BPYSS(OH)2 1H NMR spectra 
 
Figure A81: The 1H spectrum of 44BPYSS(OH)2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
44BPYSS(OH)2 195Pt NMR spectra  
       
Figure A82: The 1H–195Pt HMQC spectrum of 44BPYSS(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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44BPYRR(OH)2 1H NMR spectra 
 
Figure A83: The 1H spectrum of 44BPYRR(OH)2 in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
44BPYRR(OH)2 195Pt NMR spectra     
 
Figure A84: The 1H–195Pt HMQC spectrum of 44BPYRR(OH)2 in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
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PHENSS(OH)(Succ) 1H NMR spectra
 
Figure A85: The 1H spectrum of PHENSS(OH)(Succ) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
PHENSS(OH)(Succ) 195Pt NMR spectra    
 
Figure A86: The 1H–195Pt HMQC spectrum of PHENSS(OH)(Succ) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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5MESS(OH)(Succ) 1H NMR spectra 
 
Figure A87: The 1H spectrum of 5MESS(OH)(Succ) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
5MESS(OH)(Succ) 195Pt NMR spectra 
 
Figure A88: The 1H–195Pt HMQC spectrum of 5MESS(OH)(Succ) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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 56MESS(OH)(Succ) 1H NMR spectra 
 
Figure A89: The 1H spectrum of 56MESS(OH)(Succ) in D2O, performed on a Bruker 
Avance 400 MHz NMR spectrometer. 
56MESS(OH)(Succ) 195Pt NMR spectra     
 
Figure A90: The 1H–195Pt HMQC spectrum of 56MESS(OH)(Succ) in D2O, performed 
on a Bruker Avance 400 MHz NMR spectrometer. 
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PHENSS(OH)(SuccPFP) 1H NMR spectra 
 
Figure A91: The 1H spectrum of PHENSS(OH)(SuccPFP) in D2O, performed on a 
Bruker Avance 400 MHz NMR spectrometer. 
PHENSS(OH)(SuccPFP) 195Pt NMR spectra     
 
Figure A92: The 1H–195Pt HMQC spectrum of PHENSS(OH)(SuccPFP) in D2O, 
performed on a Bruker Avance 400 MHz NMR spectrometer. 
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UV Data  
Spectra by Polypyridyl Ligand 
UV Spectra of PHENSS(X)2 complexes 
 
Figure B1: UV spectra of PHENSSCl2 (green), PHENSSBr2 (purple)and, PHENSSI2 
(blue); at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline, measured in H2O at 28.7 µM. 
UV Spectra of 5MESS(X)2 complexes 
 
Figure B2: UV spectra of 5MESSCl2 (green), 5MESSBr2 (purple)and, 5MESSI2 (blue); 
at room temperature in the 200–350 nm range, using a 10 mm quartz cell, 
corrected for solvent baseline, measured in H2O at 28.7 µM. 
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UV Spectra of 56MESS(X)2 complexes 
 
Figure B3: UV spectra of 56MESSCl2 (green), 56MESSBr2 (purple)and, 56MESSI2 (blue); at 
room temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for 
solvent baseline, measured in H2O at 28.7 µM. 
Spectra by Axial Ligand 
UV Spectra of Chloro complexes 
 
Figure B4: UV spectra of PHENSSCl2 (green), 5MESSCl2 (purple) and, 56MESSCl2 (blue); at 
room temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for 
solvent baseline, measured in H2O at 28.7 µM. 
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UV Spectra of Bromo complexes 
 
Figure B5: UV spectra of PHENSSBr2 (green), 5MESSBr2 (purple)and, 56MESSBr2 (blue); at 
room temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for 
solvent baseline, measured in H2O at 28.7 µM. 
UV Spectra of Iodo complexes 
 
Figure B6: UV spectra of PHENSSI2 (green), 5MESSI2 (purple) and, 56MESSI2 (blue); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
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UV Spectra PhenSS(Cl)2 
 
Figure B7: Titration of a stock solution of PHENSSCl2 into a known concentration in H2O and 
the resulting extinction coefficient calculated based on the two main peaks at 278 (red)  
and 208 nm (blue). 
UV Spectra PhenSS(Br)2 
 
Figure B8: Titration of a stock solution of PHENSSBr2 into a known concentration in H2O and 
the resulting extinction coefficient calculated based on the two main peaks at 277 (red)  
and 207 nm (blue). 
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UV Spectra PhenSS(I)2 
 
Figure B9: Titration of a stock solution of PHENSSI2 into a known concentration in H2O and 
the resulting extinction coefficient calculated based on the two main peaks at 277 (red)  
and 208 nm (blue). 
UV Spectra 5MeSS(Cl)2 
 
Figure B10: Titration of a stock solution of 5MESSCl2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 283 (red) and 210 nm (blue). 
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UV Spectra 5MeSS(Br)2 
 
Figure B11: Titration of a stock solution of 5MESSBr2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 282 (red) and 228nm (blue). 
UV Spectra 5MeSS(I)2 
 
Figure B12: Titration of a stock solution of 5MESSl2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 282 (red) and 209 nm (blue). 
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UV Spectra 56MeSS(Cl)2 
 
Figure B13: Titration of a stock solution of 56MESSCL2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 289 (red) and 211 nm (blue). 
UV Spectra 56MeSS(Br)2 
 
Figure B14: Titration of a stock solution of 56MESSBr2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 289 (red) and 211 nm (blue). 
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UV Spectra 56MeSS(I)2 
 
Figure B15: Titration of a stock solution of 56MESSCL2 into a known concentration in 
H2O and the resulting extinction coefficient calculated based on the two main peaks 
at 289 (red) and 211 nm (blue). 
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CD Data 
Spectra by Polypyridyl Ligand 
CD Spectra of PHENSS(X)2  
 
 
Figure C1: CD spectra of PHENSSCl2 (blue), PHENSSBr2 (red) and, PHENSSI2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
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CD Spectra of 5MESS(X)2  
 
Figure C2: CD spectra of 5MESSCl2 (blue), 5MESSBr2 (red) and, 5MESSI2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
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CD Spectra of 56MESS(X)2  
 
Figure C3: CD spectra of 56MESSCl2 (blue), 56MESSBr2 (red) and, 56MESSI2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
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Spectra by Axial Ligand 
CD Spectra of Chloro complexes 
 
Figure C4: CD spectra of PHENSSCl2 (blue), 5MESSCl2 (red) and, 56MESSCI2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
CD Spectra of Bromo complexes 
 
Figure C5: CD spectra of PHENSSBr2 (blue), 5MESSBr2 (red) and, 56MESSBr2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
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CD Spectra of Iodo complexes 
 
Figure C6: CD spectra of PHENSSl2 (blue), 5MESSl2 (red) and, 56MESSI2 (green); at room 
temperature in the 200–350 nm range, using a 10 mm quartz cell, corrected for solvent 
baseline, measured in H2O at 28.7 µM. 
Smoothed individual spectra: 
CD Spectra PHENSS(Cl)2 
 
Figure C7: CD spectra of PHENSSCl2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
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CD Spectra PHENSS(Br)2 
 
Figure C8: CD spectra of PHENSSBr2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
CD Spectra PHENSS(I)2 
 
Figure C9: CD spectra of PHENSSl2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
-3
-2
-1
0
1
2
3
200 250 300 350 400
C
D
 (
m
d
eg
) 
Wavelength (nm) 
-3
-2
-1
0
1
2
3
200 250 300 350 400
C
D
 (
m
d
eg
) 
Wavelength (nm) 
70 
 
 
CD Spectra 5MESS(Cl)2 
 
Figure C10: CD spectra of 5MESSCl2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
CD Spectra 5MESS(Br)2 
 
Figure C11: CD spectra of 5MESSBr2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
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CD Spectra 5MESS(I)2 
 
Figure C12: CD spectra of 5MESSI2 at room temperature in the 200–400 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
CD Spectra 56MESS(Cl)2 
 
Figure C13: CD spectra of 56MESSCl2 at room temperature in the 200–400 nm range, using 
a 10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
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CD Spectra 56MESS(Br)2 
 
Figure C14: CD spectra of 56MESSBr2 at room temperature in the 200–350 nm range, using 
a 10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
CD Spectra 56MeSS(I)2 
 
Figure C15: CD spectra of 56MESSI2 at room temperature in the 200–350 nm range, using a 
10 mm quartz cell, corrected for solvent baseline, measured in H2O at 28.7 µM. 
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SRCD Data 
All SRCD data smoothed using 11 points, spectra for PHENSSBr2 shown here as an example 
to show that smoothing does not affect the peak shape or size. 
 
Figure D1: SRCD spectra of PHENSSBr2 showing the raw data (black) and the 11 point 
smoothed data (red) , measured in H2O at 2.74 µM. 
Spectra by Polypyridyl Ligand 
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SRCD Spectra of PHENSS(X)2 
 
Figure D2: SRCD spectra of PHENSSCl2 (black), PHENSSBr2 (red) and, PHENSSI2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSCl2 1.77 µM, PHENSSSBr2 28.7 µM and PHENSSI2 2.74 µM. 
 
Figure D3: SRCD spectra of PHENSSCl2 (black), PHENSSBr2 (red) and, PHENSSI2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSCl2 1.77 µM, PHENSSSBr2 28.7 µM and PHENSSI2 2.74 µM. 
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SRCD Spectra of 5MESS(X)2
 
Figure D4:  SRCD spectra of 5MESSCL2 (black), 5MESSBr2 (red) and, 5MESSI2 (blue); at room 
temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent baseline. 
Samples were measured in H2O Concentrations were varied due to absorbance: 5MESSCl2 
4.97 µM, 5MESSSBr2 2.22 µM and 5MESSI2 2.75 µM. 
 
Figure D5:  SRCD spectra of 5MESSCl2 (black), 5MESSBr2 (red) and, 5MESSI2 (blue); at room 
temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent baseline. 
Samples were measured in H2O Concentrations were varied due to absorbance: 5MESSCl2 
4.97 µM, 5MESSSBr2 2.22 µM and 5MESSI2 2.75 µM. 
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SRCD Spectra of 56MESS(X)2 
 
Figure D6:  SRCD spectra of 56MESSCl2 (black), 56MESSBr2 (red) and, 56MESSI2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
56MESSCl2 4.18 µM, 56MESSSBr2 3.27 µM and 56MESSI2 3.98 µM. 
 
Figure D7:  SRCD spectra of 56MESSCl2 (black), 56MESSBr2 (red) and, 56MESSI2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
56MESSCl2 4.18 µM, 56MESSSBr2 3.27 µM and 56MESSI2 3.98 µM.  
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Spectra by Axial Ligand 
SRCD Spectra of Chloro compounds  
 
Figure D8: SRCD spectra of PHENSSCL2 (black), 5MESSCL2 (red) and, 56MESSCL2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSCl2 1.77 µM, 5MESSSCl2 4.97 µM and 56MESSCI2 4.18 µM. 
 
Figure D9: SRCD spectra of PHENSSCL2 (black), 5MESSCL2 (red) and, 56MESSCL2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSCl2 1.77 µM, 5MESSSCl2 4.97 µM and 56MESSCI2 4.18 µM. 
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SRCD Spectra of Bromo compounds  
 
Figure D10: SRCD spectra of PHENSSBr2 (black), 5MESSBr2 (red) and, 56MESSBr2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSBr2 2.74 µM, 5MESSSBr2 2.22 µM and 56MESSBr2 3.27 µM. 
 
Figure D11: SRCD spectra of PHENSSBr2 (black), 5MESSBr2 (red) and, 56MESSBr2 (blue); at 
room temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent 
baseline. Samples were measured in H2O Concentrations were varied due to absorbance: 
PHENSSBr2 2.74 µM, 5MESSSBr2 2.22 µM and 56MESSBr2 3.27 µM. 
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SRCD Spectra of Iodo compounds  
 
Figure D12: SRCD spectra of PHENSSI2 (black), 5MESSI2 (red) and, 56MESSI2 (blue); at room 
temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent baseline. 
Samples were measured in H2O Concentrations were varied due to absorbance: PHENSSl2 
2.74 µM, 5MESSSl2 2.75 µM and 56MESSI2 3.98 µM. 
 
Figure D13: SRCD spectra of PHENSSI2 (black), 5MESSI2 (red) and, 56MESSI2 (blue); at room 
temperature in the 170-400 nm range, using a 0.1 mm cell, corrected for solvent baseline. 
Samples were measured in H2O Concentrations were varied due to absorbance: PHENSSl2 
2.74 µM, 5MESSSl2 2.75 µM and 56MESSI2 3.98 µM. 
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SRCD Spectra PHENSS(Cl)2 
 
Figure D14: SRCD spectra of PHENSSCI2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 1.77 µM. 
SRCD Spectra PHENSS(Br)2 
 
Figure D15: SRCD spectra of PHENSSBr2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 2.74 µM. 
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SRCD Spectra PHENSS(I)2 
 
Figure D15: SRCD spectra of PHENSSI2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 2.74 µM. 
SRCD Spectra 5MESS(Cl)2 
 
Figure D16: SRCD spectra of 5MESSCI2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 4.97 µM. 
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SRCD Spectra 5MESS(Br)2 
 
Figure D17: SRCD spectra of 5MESSBr2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline. , measured in H2O at 2.22 µM. 
SRCD Spectra 5MESS(I)2 
 
Figure D18: SRCD spectra of 5MESSI2 at room temperature in the 170-400 nm range, using 
a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 2.75 µM. 
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SRCD Spectra 56MESS(Cl)2 
 
Figure D19: SRCD spectra of 56MESSCI2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 4.18 µM. 
SRCD Spectra 56MESS(Br)2 
 
Figure D20: SRCD spectra of 56MESSBr2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 3.27 µM. 
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SRCD Spectra 56MeSS(I)2 
 
Figure D21: SRCD spectra of 56MESSI2 at room temperature in the 170-400 nm range, 
using a 0.1 mm cell, corrected for solvent baseline, measured in H2O at 3.98 µM. 
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Cytotoxicity 
Tables 
DOSE SCREEN:  
Table E1: Percentage (%) Cell Growth Inhibition in response to 25 µM of Drug (The higher the value the greater the growth inhibition) 
COMPOUND NAME 
AND TUBE NUMBER: 
HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10
A 
ADDP 
Colon Glioblas
toma 
Breast Ovarian Lung Skin Prostate Neurobl
astoma 
Glioblas
toma 
Pancrea
s 
Breast 
(Normal) 
Ovarian 
n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 n=3-6 
B16
1 
1 BM01 - 
PhenSS(IV)Cl2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
2 BM02 - 
PhenSS(IV)Br2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
3 BM03 - 
PhenSS(IV)I2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
4 BM04 - 
5MeSS(IV)Cl2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
5 BM05 - 
5MeSS(IV)Br2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
6 BM06 - 
5MeSS(IV)I2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
7 BM07 - 
56MeSS(IV)Cl2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
8 BM08 - 
56MeSS(IV)Br2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
B16
1 
9 BM09 - 
56MeSS(IV)I2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
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DOSE RESPONONSE: 
 Table E1: GI50 = Concentration (µM) that inhibits cell growth by 50% (The higher the value the greater the growth inhibition) 
COMPOUND NAME 
AND TUBE 
NUMBER: 
HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10
A 
ADDP 
Colon Glioblast
oma 
Breast Ovarian Lung Skin Prostate Neurobl
astoma 
Glioblast
oma 
Pancrea
s 
Breast 
(Normal) 
Ovarian 
n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 n=3-4 
B1
61 
1 BM01 - 
PhenSS(IV)Cl2 
0.11 
±0.028 
0.81 
±0.15 
0.46 
±0.069 
0.23 
±0.0058 
0.33 ± 
0.0088 
0.44 ± 
0.045 
0.11 
±0.033 
0.44 
±0.050 
0.34 ± 
0.063 
0.21 ± 
0.029 
0.30 ± 
.0033 
0.23 
±0.026 
B1
61 
2 BM02 - 
PhenSS(IV)Br
2 
0.16 
±0.015 
0.82 
±0.090 
0.53 
±0.10 
0.27 
±0.023 
0.36 
±0.029 
0.68 
±0.023 
0.18 
±0.010 
0.52 
±0.025 
0.42 
±0.071 
0.25 
±0.010 
0.36 
±0.032 
0.28 
±0.017 
B1
61 
3 BM03 - 
PhenSS(IV)I2 
0.10 
±0.0033 
0.70 
±0.055 
0.46 
±0.10 
0.24 
±0.059 
0.32 
±0.031 
0.44 
±0.021 
0.11 
±0.0033 
0.37 
±0.0000
0 
0.31 
±0.031 
0.20 
±0.013 
0.29 
±0.032 
0.25 
±0.020 
B1
61 
4 BM04 - 
5MeSS(IV)Cl2 
0.032 
±0.0036 
0.23 
±0.033 
0.22 
±0.13 
0.25 
±0.18 
0.089 
±0.018 
0.13 
±0.028 
0.023 
±0.0030 
0.25 
±0.060 
0.18 
±0.034 
0.044 
±0.0045 
0.094 
±0.024 
0.056 
±0.0032 
B1
61 
5 BM05 -
5MeSS(IV)Br2 
0.035 
±0.0058 
0.20 
±0.029 
0.087 
±0.032 
0.044 
±0.012 
0.070 
±0.0091 
0.11 
±0.015 
0.025 
±0.0053 
0.20 
±0.010 
0.16 
±0.044 
0.037 
±0.0046 
0.062 
±0.0083 
0.048 
±0.0046 
B1
61 
6 BM06 - 
5MeSS(IV)I2 
0.032 
±0.0035 
0.22 
±0.030 
0.091 
±0.026 
0.046 
±0.010 
0.065 
±0.0061 
0.10 
±0.0123 
0.027 
±0.0027 
0.20 
±0.0000
0 
0.16 ± 
.040 
0.032 
±0.0022 
0.061 
±0.0082 
0.044 
±0.0058 
B1
61 
7 BM07 - 
56MeSS(IV)Cl
2 
0.025 
±0.0020 
0.12 
±0.018 
0.060 
±0.010 
0.037 
±0.0067 
0.048 
±0.012 
0.062 
±0.013 
0.012 
±0.0017 
0.12 
±0.0000
0 
0.092 
±0.039 
0.028 
±0.0021 
0.044 
±0.0062 
0.036 
±0.0041 
B1
61 
8 BM08 - 
56MeSS(IV)B
r2 
0.021 
±0.0023 
0.090 
±0.012 
0.11 
±0.056 
0.035 
±0.013 
0.032 
±0.0020 
0.061 
±0.011 
0.011 
±0.0031 
0.34 
±0.18 
0.074 
±0.033 
0.024 
±0.0026 
0.034 
±0.0038 
0.033 
±0.0023 
B1
61 
9 BM09 - 
56MeSS(IV)I2 
0.019 
±0.0032 
0.074 
±0.014 
0.033 
±0.0068 
0.032 
±0.017 
0.027 
±0.0032 
0.037 
±0.0054 
0.025 
±0.017 
0.087 
±0.063 
0.067 
±0.028 
0.022 
±0.0022 
0.030 
±0.0039 
0.027 
±0.0007 
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Figures 
Spectra by axial ligand 
IC50 values of [Pt(PL)(AL)(Cl)2]2+ type complexes 
Figure E1: IC50 values of PHENSSCl2, 5MESSCl2, 56MESSCI2  56MESS, and 56MESSOH2 in multiple cell 
lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 
prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and 
SMA glioblastoma (murine). 
 
Figure E2: IC50 values of PHENSSCl2, 5MESSCl2, 56MESSCI2  56MESS, 56MESSOH2, and cisplatin in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 
skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast 
(normal), and SMA glioblastoma (murine). 
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IC50 values of [Pt(PL)(AL)(Br)2]2+ type complexes 
 
Figure E3: IC50 values of PHENSSBr2, 5MESSBr2, 56MESSBr2  56MESS, and 56MESSOH2 in multiple cell 
lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 
prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and 
SMA glioblastoma (murine). 
Compared to cisplatin: 
 
Figure E3: IC50 values of PHENSSBr2, 5MESSBr2, 56MESSBr2  56MESS, 56MESSOH2, and cisplatin in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 
skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast 
(normal), and SMA glioblastoma (murine). 
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 IC50 values of [Pt(PL)(AL)(I)2]2+ type complexes 
 
Figure E5: IC50 values of PHENSSI2, 5MESSI2, 56MESSI2  56MESS, and 56MESSOH2 in multiple cell lines: 
HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 prostate, 
BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and SMA 
glioblastoma (murine). 
Compared to cisplatin: 
 
Figure E8: IC50 values of PHENSSI2, 5MESSI2, 56MESSI2  56MESS, 56MESSOH2, and cisplatin in multiple 
cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 
prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and 
SMA glioblastoma (murine). 
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Spectra by polyaromatic ligand 
IC50 values of PHENSSX2 type complexes 
 
Figure E7: IC50 values of PHENSSCl2, PHENSSBr2, PHENSSI2  56MESS, and 56MESSOH2 in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, 
A431 skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, 
MCF10A breast (normal), and SMA glioblastoma (murine). 
Compared to cisplatin: 
 
Figure E8: IC50 values of PHENSSCl2, PHENSSBr2, PHENSSI2  56MESS, 56MESSOH2, and cisplatin  in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 
skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast 
(normal), and SMA glioblastoma (murine). 
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IC50 values of 5MESSX2 type complexes 
 
Figure E9: IC50 values of 5MESSCl2, 5MENSSBr2, 5MENSSI2  56MESS, and 56MESSOH2 in multiple cell 
lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 
prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and 
SMA glioblastoma (murine). 
Compared to cisplatin 
 
Figure E10: IC50 values of 5MESSCl2, 5MESSBr2, 5MESSI2  56MESS, 56MESSOH2, and cisplatin  in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 
skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast 
(normal), and SMA glioblastoma (murine). 
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IC50 values of 56MESSX2 type complexes 
 
Figure E11: IC50 values of 56MESSCl2, 56MESSBr2, 56MESSI2  56MESS, and 56MESSOH2 in multiple cell 
lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 skin, Du145 
prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast (normal), and 
SMA glioblastoma (murine). 
Compared to cisplatin: 
 
Figure E11: IC50 values of 56MESSCl2, 56MESSBr2, 56MESSI2  56MESS, 56MESSOH2, and cisplatin  in 
multiple cell lines: HT29 colon, U87 glioblastoma, MCF-7 breast, A2780 ovarian, H460 lung, A431 
skin, Du145 prostate, BE2-C neuroblastoma, SJ-G2 glioblastoma, MIA pancreas, MCF10A breast 
(normal), and SMA glioblastoma (murine). 
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ESIMS Data 
PHENSSCl2 
 
Figure F1: ESIMS spectrum of PHENSSCl2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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PHENSSBr2 
 
Figure F2: ESIMS spectrum of PHENSSBr2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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PHENSSI2 
 
Figure F3: ESIMS spectrum of PHENSSI2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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5MESSCl2 
 
Figure F4: ESIMS spectrum of 5MESSCl2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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5MESSBr2
 
Figure F5: ESIMS spectrum of 5MESSBr2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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5MESSI2
 
Figure F6: ESIMS spectrum of 5MESSl2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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56MESSCl2 
 
Figure F7: ESIMS spectrum of 56MESSCl2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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56MESSBr2 
 
Figure F8: ESIMS spectrum of 56MESSBr2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
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56MESSI2 
 
Figure F9: ESIMS spectrum of 56MESSl2 measured on a Waters TQ-MS triple quadrupole mass spectrometer. Sample solutions were made up to 0.5 mM in 
H2O and flowed at 0.1 mL/min. 
 
